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The function of the skeleton is to give structure to the body and provide protection 
to vital organs such as the heart, lungs and brain. Bones also serve as a reservoir for 
calcium, phosphorus and magnesium and as an environment for the bone marrow 
where blood cells are produced. In addition, they provide attachment points for 
muscles and thereby facilitate movement. While bone appears to be a static tissue, 
it is actually constantly formed, resorbed and reformed by the different cells in the 
bone to adapt to changes in metabolic and mechanical requirements. This process is 
known as remodeling. 
There are three main cell types in bone tissue involved in the remodeling of 
bone: the osteoclasts, osteoblasts and osteocytes (Figure 1). During remodeling, 
bone is resorbed by osteoclasts. Osteoclasts are large multinucleated cells that are 
derived from the hematopoietic cell lineage, like monocytes and macrophages. They 
attach to the mineralized matrix and release protons and proteolytic enzymes, which 
demineralize and degrade the matrix, into the space between the cell membrane and 
the bone. After resorption, osteoblasts are recruited to the resorbed surface to form 
new bone matrix. Osteoblasts originate from mesenchymal stromal cells that also 

















Figure 1. Bone remodeling. Osteoclasts (red) are derived from hematopoietic stem cells and resorb bone. 
Osteoblasts from the mesenchymal lineage (green) then fill the bone resorption pit with new bone matrix. Some 
osteoblasts are trapped inside the newly formed matrix and differentiate further into osteocytes (yellow).
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and adipocytes (fat). During their differentiation, osteoblasts express different 
genes in a set order, starting with alkaline phosphatase (ALP). Later the osteoblasts 
synthesize proteins that form the organic matrix of bone mainly consisting of collagen 
type  I [1]. Osteoblasts are directly involved in the mineralization of bone matrix, 
secreting vesicles that are rich in calcium, phosphate, alkaline phosphatase and 
calcium binding molecules. In these vesicles the initial production of hydroxyapatite 
crystals begins, and when they are released, these crystals support propagation of 
mineralization on the prepared matrix [2-4]. 
During bone formation, osteoblasts can become trapped in the matrix and 
differentiate further into osteocytes. Alternatively, they become quiescent bone lining 
cells or undergo apoptosis. Osteocytes are the most abundant cell type in bone. They 
are enclosed in the matrix and communicate with each other and the lining cells on 
the surface with long cellular processes. Because of this cellular network, osteocytes 
are implicated as important players in the orchestration of bone remodeling, as they 
are in a perfect location for sensing mechanical stress on the bone and secrete factors 
and transfer signals to many other bone cells. 
Regulation of bone metabolism
In healthy adults, bone formation and resorption are coupled and balanced so that 
the total bone mass is maintained. This is tightly regulated by systemic and local 
factors. Systemic factors such as hormones play an important role in the regulation 
of bone metabolism. They meet needs of the body for calcium and phosphate by 
influencing both bone formation and resorption. Factors that are produced locally 
can affect bone cells independent from systemic hormones. Local factors control 
changes in metabolism to adapt to the specific requirements of the local environment. 
In addition, many systemic hormones have been shown to act via the production 
and/or activation of local factors. 
Local factors
Locally produced receptor activator of nuclear factor κB ligand (RANKL) and 
macrophage colony stimulating factor (M-CSF) are essential for osteoclast 
differentiation [5]. M-CSF promotes the survival, proliferation and differentiation 




osteoblasts, binds to its receptor RANK on osteoclast precursor cells and stimulates 
the commitment of differentiation to osteoclasts (Figure 2) [6, 7]. Osteoblasts also 
produce osteoprotegerin (OPG) a soluble protein that acts as a decoy receptor for 
RANKL and, as the name implies, protects the bone by reducing bone resorption 
through inhibition of osteoclast formation [8]. The ratio between RANKL and OPG 
determines the effect on osteoclasts. RANKL is not only essential to osteoclast 
differentiation and survival, it contributes to activation of mature osteoclast function 
as well [9]. The importance of the RANK/RANKL/OPG system was demonstrated 
by the effects of deletion and overexpression of these genes in animal and in vitro 
models [10]. For example, Rank -/- as well as Rankl -/- mice have a complete absence 
of osteoclasts with consequent shortened limbs and poorly remodeled structures 
blocking the marrow cavities [11, 12]. In contrast, OPG -/- mice showed a progressive 
decrease in Bone Mineral Density (BMD) and excessive osteoclast activity [13, 14]. 
Calcium-regulating hormones such as sex hormones, parathyroid hormone (PTH) 
and Vitamin D regulate expression of both RANKL and OPG and thereby control 
osteoclast activity [10, 15]. 
Different cytokines produced by cells of the immune system have an effect 
on both osteoblasts and osteoclasts, explaining bone effects of inflammation like 
the bone erosion seen in inflammatory joint disease. Activated T-cells have been 













Figure 2. The RANK/RANKL/OPG system. RANKL produced by osteoblasts binds to RANK receptors on the 
surface of osteoclast precursors, which are then activated to differentiate and mature into osteoclasts. OPG is 




In addition to direct stimulation, T-cells produce many cytokines that stimulate 
(Tumor Necrosis Factor α (TNF-α), Interleukin (IL) 6 and IL-17) or inhibit (IL-4, 
IL-13 and IL-10) osteoclast activity and production [18]. 
Bone morphogenetic proteins (BMPs) were originally identified as proteins 
capable of induction of ectopic bone formation [19]. BMPs activate the type I and 
type II receptor complex, leading to initiation of signaling via phosphorylation 
of intracellular Smad proteins [20]. This can be inhibited by several extracellular 
inhibitors such as Noggin, Gremlin, Chordin and Cerberus or inhibitory Smads 6 
and 7 [21]. BMP signaling has been shown to regulate the differentiation of various 
cells implicated in cartilage and bone formation during skeletal development and 
fracture repair [22-24]. Over 20 different BMPs have been identified and of these 
BMP2, -4, -5, -6 and -7 have been shown to induce osteoblast differentiation. In 
addition, BMP signaling in bone is closely linked to Wnt signaling, and many reports 
have shown interactions between these two pathways [25-32]. 
WNTs are a family of secreted proteins that regulate many developmental 
processes, for example body axis formation, chondrogenesis and limb development 
[33, 34] and have an important role in the regulation of osteoblast differentiation 
[35]. In the absence of Wnt activation, β-catenin is phosphorylated by glycogen 
synthase kinase 3 beta (GSK3β) in a complex with axin and adenomatous polyposis 
coli (APC) and is subsequently degraded. When WNTs bind to the Frizzled receptor 
and Low-density lipoprotein receptor-related protein 5/6 (LRP5/6) co-receptor, axin 
is recruited to the membrane. This leads to the disruption of the destruction complex 
and subsequent inhibition of β-catenin phosphorylation by GSK3β. Consequently, 
β-catenin accumulates in the cytoplasm, translocates to the nucleus and activates 
the transcription of the Wnt target genes with the TCF/LEF transcription factors 
(Figure 3) [36, 37]. Specific deletion of β-catenin in osteocytes in vivo gave rise to 
dramatically reduced cortical bone thickness and almost absent cancellous bone, 
indicating the important role of Wnt/β-catenin signaling in bone formation [38]. 
Dickkopf-1 (DKK1) and sclerostin inhibit Wnt signaling by binding to the LRP5/6 
co-receptor and thereby preventing the interaction with WNTs and the Frizzled 
receptor [39, 40]. Animal models have emphasized the importance of these Wnt 
inhibitors in regulation of bone formation. Knockout animals of both Dkk1 and Sost 
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Figure 3. Wnt signaling pathway. In the absence of Wnt, GSK3β forms a complex with axin and APC to 
phosphorylate β-catenin, which is subsequently degraded. When Wnts are present, they bind to the Frizzled (Fz) 
receptor and LRP5/6 co-receptor. Axin is recruited to the membrane and the destruction complex is disrupted. 
β-catenin is no longer degraded and accumulates in the cytoplasm. It then translocates to the nucleus where it 
activates transcription of the Wnt target genes by binding to TCF/LEF transcription factors.
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models showed very low bone mass [43, 44]. In humans, mutations have been found 
in different components of the Wnt signaling pathway. Inactivating mutations of 
LRP5 result in low bone mass and visual impairment (osteoporosis-pseudoglioma 
syndrome), while a mutation that prevents binding of the Wnt inhibitors sclerostin 
and DKK1 results in activation of Wnt signaling and a high bone mass phenotype 
[45-48]. Mutations in sclerostin or the surrounding regulatory region lead to bone 
overgrowth as seen in sclerosteosis and Van Buchem disease [49, 50]. 
Finally, bone is remodeled in response to mechanical stimuli to adapt to local 
loading conditions. Bone mass is lost with disuse e.g. in bedrest or microgravity, and 
gained with increasing levels of activity [51-54]. Osteocytes are thought to regulate 
this process by altering the production of signaling molecules after mechanical 
stimulation. The importance of osteocytes was demonstrated by Tatsumi et al. [55] 
who showed that loss of bone mass after hind limb unloading of mice was prevented 
when the majority (~80%) of osteocytes was ablated. Precisely how osteocytes 
sense mechanical stimuli is unknown. The current consensus is that mechanical 
loading induces fluid movements and shear stress in the canaliculi that surround 
the osteocyte processes, and this leads to changes in cytoskeleton conformation or 
activates stretch-activated ion channels [56]. 
The signaling pathways that act in osteocytes upon loading have been 
thoroughly investigated. Wnt/β-catenin signaling appears to play an important role 
as β-catenin activation is increased and SOST expression is decreased in bone by 
mechanical stimulation [57-59]. In addition, deletion of the Wnt co-receptor LRP5 
reduced, while a gain-of-function mutation of LRP5 increased the response to 
mechanical stimulation [60, 61]. Similarly, sclerostin knockout mice are insensitive 
to unloading-induced bone loss [62]. PTH enhances the effect of mechanical loading, 
evidenced by a synergistically increased cortical bone volume in adult female mice 
when loading was combined with intermittent PTH(1-34) [63]. As described below, 
PTH may also function through modulation of sclerostin expression.
Importantly, a Wnt/LRP5 independent mechanism involving the estrogen 
receptor α (ERα) has also been observed [64]. The ERα was shown to be important for 
the response to in vivo loading in a study comparing expression of genes in wildtype 
and ERα knockout mouse bones after loading [65]. In this study, 642 genes were 




the expression of only 26 genes was altered in the tibiae of the ERα knockout mice. 
The ERα was proposed to act together with the insulin growth factor-1 receptor 
(IGF-1R) to activate protein kinase B (PKB or AKT), which inhibits GSK3β and 
causes accumulation of β-catenin [66, 67]. 
Systemic factors
Parathyroid hormone (PTH) is produced in the parathyroid in response to low 
serum calcium concentrations sensed by calcium sensing receptors. It increases the 
reabsorption of calcium in the distal tubules in the kidney and increases production 
of  active vitamin D leading to increased absorption of calcium in the intestine 
[68]. Interestingly, PTH can have both catabolic and anabolic actions on bone 
depending on dosage and frequency of administration. Continuous high levels of 
PTH in the body stimulate the PTH receptors on osteoblasts, leading to increased 
expression of RANKL and reduced expression of OPG [69-71]. The change in the 
RANKL/OPG ratio in favor of RANKL leads to increased osteoclast differentiation 
and bone resorption. As a result, hyperparathyroidism is a cause of secondary 
osteoporosis [72]. In contrast, when PTH is administered intermittently, it inhibits 
osteoblast apoptosis extending their matrix-synthesizing function [73]. In addition, 
expression of SOST is decreased [74-76] and this response is blunted in mice lacking 
the co-receptor LRP5 and in Sost overexpressing or deficient mice [77] suggesting an 
important role for sclerostin in the effect of PTH. 
Loss of estrogen has long been implicated as the causative factor for the 
accelerated bone loss in women after menopause [78]. In women, circulating 
sclerostin levels are influenced by estrogen [79, 80] and estrogen has been shown 
to downregulate sclerostin expression in osteocyte-like cells in vitro [81]. The 
fundamental effects of estrogen on bone are to decrease bone turnover by inhibiting 
the initiation of remodeling and inhibit differentiation and promote apoptosis of 
osteoclasts. In addition, estrogen promotes osteoblast precursor commitment and 
differentiation and prevents osteoblast apoptosis. With estrogen withdrawal, this 
leads to an increase in bone remodeling and a disbalance between formation and 
resorption [82, 83]. 
Calcium is required for many functions in the body, including neuromuscular 
activity, membrane function, hormone secretion, enzyme activity, coagulation of 
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the blood and skeletal mineralization [84]. It is therefore not surprising that calcium 
concentrations in the blood are tightly controlled. Bone serves as a calcium store 
from which minerals can be drawn to maintain calcium levels when calcium 
intake is not sufficient to compensate for losses in urine and digestive juices [85]. 
Recommended daily doses differ between experts and countries, leading to wide-
ranging results from 15% up to 90% of women that do not meet recommended 
calcium intake [86, 87]. As calcium uptake in the gut as well as food intake decrease 
with age, calcium supplementation in combination with vitamin D is recommended 
for postmenopausal women and elderly men at risk for osteoporis [88, 89]. Vitamin D 
is produced in the skin upon exposure to sunlight, which also accounts for shortage 
in the elderly and less mobile population. It increases calcium uptake in the intestine 
and also directly stimulates mineralization of bone matrix [90]. In addition, due to 
its important role in muscle function vitamin D deficiency leads to a higher risk of 
falling [91, 92]. 
A relatively new concept was presented by Gerard Karsenty and collegues 
in 2008 [93]. They proposed a model in which LRP5 has no direct role in bone 
metabolism but regulates the production of serotonin in the duodenum, and 
circulating serotonin inhibits bone formation. This model is actively debated as the 
significance of LRP5 and Wnt signaling in bone cells has been investigated in detail 
using (cell specific) knockout models [38, 94-100]. Cui et al. [101] could not replicate 
the results presented by Yadav et al. and found no relation between serotonin and 
bone mass. This discrepancy may be explained by differences in the mouse models 
that were used. At this point a definitive answer has not been found, and further 
research may establish whether both models can be integrated.
Osteoporosis 
Disregulation of the balance between bone formation and resorption leads to an 
increase or reduction in bone mass, and subsequent diseases such as osteoporosis. 
Osteoporosis is the most common skeletal disease and is characterized by low bone 
mass and the loss of connectivity in the trabecular bone. This leads to decreased bone 
strength and increased risk of fracture, particularly in the spine, hip and wrist [102]. 
Osteoporosis is defined on the basis of bone mineral density (BMD) assessment of 




World Health Organisation criteria, osteoporosis is defined as a BMD of 2.5 standard 
deviations or more below the average value for young healthy women (a T-score of 
< -2.5 SD) [103, 104]. There are several factors that can lead to osteoporosis: low peak 
bone mass, accelerated bone loss, impaired bone formation during remodeling, and 
secondary causes like glucocorticoid use and genetic, inflammatory or nutritional 
disorders [105]. Peak bone mass is largely determined by genetic background, as 
evidenced by the large number of genetic loci associated with BMD [106, 107], but 
can also be influenced by lifestyle [108, 109]. Bone loss due to increased resorption 
is accelerated after menopause due to the loss of estrogen production and this is 
the main cause for development of osteoporosis in large groups of elderly females 
[78]. Changes in bone formation rate are inherent to ageing and may begin shortly 
after reaching peak bone mass [110]. The lower formation rate is probably due to 
changes in growth factor production and an increase in reactive oxygen species, 
but the precise mechanisms are unclear. In addition, inadequate calcium intake or 
vitamin D production decreases the bone formation rate [90]. 
An estimated 75 million people in Europe, the United States and Japan have 
osteoporosis. The disease mostly becomes apparent at a later age so due to increases 
in life expectancy and changing demographics this number is expected to increase 
worldwide, and especially in developing countries [111, 112]. In the United States, the 
incidence of osteoporotic fractures is higher than 1.5 million per year [113] and costs 
related to these fractures were estimated at 17 billion US dollars [114]. Osteoporosis 
mainly affects females, with only 30% of fractures occurring in males [114]. The 
lifetime risk for a wrist, hip, or vertebral fracture in women in the US is estimated 
to be 30-40% [104]. 
Osteoporotic fractures are most common in the hip, wrist and vertebral bones. 
Vertebral fractures often occur unnoticed but cause pain, deformity and long-term 
debility [102]. Many individuals will not regain mobility and independence after a 
fracture, and approximately 20% of patients will require long-term care [111, 115]. 
Hip fractures are known to have a high morbidity and mortality, and 5-25% of 
patients die within 1 year of the fracture event [102, 115, 116]. 
Treatment of osteoporosis
There are several established pharmacological approaches for treatment of 
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osteoporosis, as well as new therapies that have just been approved or are in advanced 
stages of clinical trials. Bisphosphonates are considered a first-line treatment for 
osteoporosis, and this is the most common drug class for this purpose [117]. These 
compounds bind strongly to hydroxyapatite in bone and have two side chains; one 
that participates in binding of the drug to bone and one that determines the potency 
and biological properties [118, 119]. During bone resorption bisphosphonates 
that were bound to the bone are taken up by osteoclasts and inhibit their action. 
Depending on the side chain the bisphosphonates have a direct toxic effect or 
disturb the osteoclast cytoskeleton [120, 121]. Because of their high affinity to bone, 
bisphosphonates are quickly bound and gradually released. They have a long half-
life and can be found in plasma and urine for months or even years after the last 
dose [122, 123]. Most bisphosphonates are administered orally with daily or weekly 
dosing schedules. Oral formulations are poorly absorbed and adversely affected if 
taken with food or drinks. In addition they often lead to side effects like esophageal 
and gastric irritation [111, 117]. 
Bisphosphonate treatment results in decreased resorption which, through 
coupling mechanisms, also leads to decreased formation. The overall balance however 
is positive because of several reasons: 1) bone loss due to reduced bone formation is 
slowed in a state of decreased remodeling, 2) Slower turnover allows more time for 
remodeling units to finish the process of bone formation and mineralization before 
the site is remodeled again, 3) bone formation itself is not affected, only as a result 
of decreased resorption. Resorption pits that have already been formed will first 
be filled, leading to a transient netto increase in bone formation. 4) a decrease in 
resorption depth at individual remodeling sites is not matched by a decrease in local 
formation, and formation exceeds resorption at that location [119]. 
As loss of estrogen production is implicated as an important causative factor 
in development of osteoporosis, it seems logical to use estrogen or estrogen receptor 
modulators as a therapy. Indeed, hormone replacement therapy and the estrogen 
receptor agonist/antagonist raloxifen decreased fracture risk at both vertebral and 
non-vertebral sites. However, the Women’s Health Initiative reported increased risk 
of myocardial infarction, stroke, breast cancer and deep vein thrombosis after use of 
these drugs. Even though a protective effect was found on endometrial cancer, these 




The bioactive N-terminal 34-amino acid fragment of PTH (rhPTH 1-34, 
teriparatide) is the only bone anabolic drug currently on the market. As described 
above, intermittent doses of PTH stimulate osteoblast function and therefore lead 
to increased bone formation. The intermittent nature of administration seems to 
limit the effects of PTH on RANKL expression and bone resorption [126]. rhPTH 
affects trabecular bone more than cortical bone and therefore reduces the fracture 
risk of the spine much greater than that of nonvertebral bones [127]. However, it 
can only be used for a maximum of 2 years as after that, bone resorption catches 
up with formation and the drug is no longer effective. In addition, teriparatide is 
administered in daily subcutaneous injections and is therefore reserved for severe 
osteoporosis [126]. 
Recently, a human monoclonal antibody against RANKL (denosumab, Amgen) 
was approved for treatment of osteoporosis and bone destruction by bone metastases 
or rheumatoid arthritis [128]. Binding to RANKL, denosumab inhibits the 
formation, function and survival of osteoclasts and thereby inhibits bone resorption. 
Preclinical studies comparing denosumab to the bisphosphonate alendronate in 
ovariectomized mice showed that denosumab was more effective in preserving 
trabecular architecture and cortical thickness [129]. Clinical trials revealed marked 
reduction of bone turnover markers and a BMD gain at all measured sites after 1 
year of treatment and a reduction in fracture risk after 3 years similar to that of the 
most common bisphosphonates [130]. Few specific side-effects have been reported 
even though RANK/RANKL also has functions in the immune system and vascular 
system [131]. Other than bisphosphonates, which are usually prescribed in daily 
or weekly tablets, denosumab is administered every 6 months by subcutaneous 
injections and is therefore less sensitive to adherence problems.
Neutralizing antibodies against sclerostin have been developed and are 
currently in phase III clinical trials (AMG 785, NCT01575834 and NCT01631214 
on www.clinicaltrials.gov). Due to the restricted expression pattern of sclerostin 
and the good quality bone and absence of extra-skeletal complications in patients 
with sclerostin deficiency, sclerostin is considered a good target for bone anabolic 
therapy [126, 132]. Preclinical studies showed great promise increasing bone mass 
and strength in animal models of ovariectomized and aging animals as well as in 
secondary causes of osteoporosis [133-137]. In a phase I randomized double-blind 
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placebo-controlled study in healthy volunteers substantial and dose-dependent 
increases in bone formation markers and reduction of bone resorption markers were 
found [138]. Results from the phase II clinical trial have recently been published 
and reported significant increases in lumbar spine BMD at 12 months compared 
to placebo and, importantly, compared to the other active drugs teriparatide and 
alendronate [139]. 
Compliance is a major issue in all osteoporosis treatments. Up to 75% of 
patients have been reported non-compliant, and this significantly decreased therapy 
effectiveness [140, 141]. Determinants of compliance appear to be concerns about 
adverse side effects, belief in the need for medication, the relationship with the 
prescribing physician, administration requirements, dosing schedules and follow-
up or feedback on effectiveness [142, 143]. 
In addition to pharmacological therapies, patients are advised to stop smoking 
to increase overall health, and regularly exercise to increase mechanical loading on 
the bones and improve muscle strength, posture and balance. This will help reduce 
the risk of falling and consequently fractures. Supplementation of calcium and 
vitamin D is also advised to achieve adequate serum levels to maintain the skeletal 
homeostasis [125]. 
Antisense oligonucleotides
Antisense oligonucleotides (AONs) are small (usually 13-25 nucleotides) RNA or 
DNA molecules that hybridize to a target sequence on the messenger RNA (mRNA) 
or pre-mRNA. AONs are well-known for their ability to induce RNAse H cleavage 
of the target RNA [144]. RNAse H is a ubiquitous enzyme that hydrolyzes the RNA 
strand of an RNA:DNA duplex. This method has been used to knock down gene 
expression in both experimental and clinical applications [145-148]. A 5-bp stretch 
of homology appears to be sufficient to induce RNAse H acitivity, and is therefore 
sensitive to off-target effects in longer AONs [149-151]. The only AON-based therapy 
currently approved is fomivirsen (Isis Pharmaceuticals), an RNAse H-inducing AON 
for treatment of cytomegaloviral-induced retinitis [152]. In addition, mipomersen 
(Genzyme) reduces APOB100 in familial hypercholesterolaemia and is under review 
by the European and American authorities, but there are significant side effects 




in cancer cells and is currently in phase III clinical trials [154]. 
While RNAse H cleavage and knockdown of genes was already a known effect 
of AONs in the 1980s, certain classes of AONs can have non-RNAse H mediated 
effects as well. For example, modulation of pre-mRNA splicing using 2’-O-methyl 
AONs was pioneered by Ryszard Kole in the 1990s [155]. His goal was to block a 
mutation that introduced a ‘cryptic’ splice site in the β-globin (HBB) and cystic 
fibrosis transmembrane conductance regulator (CFTR) genes and thereby restore 
normal splicing in patients with β-thalassemia and cystic fibrosis [155-157]. Splicing 
is a process in which non-coding regions (introns) are removed from the pre-mRNA 
to generate the messenger RNA (mRNA) with the coding regions (exons) before an 
RNA transcript can be translated into protein (Figure 4) [158]. Depending on for 
example developmental state, type of tissue or activation of cells, different (parts 
of) exons can be included or excluded, producing different proteins from the same 
gene (alternative splicing) [159, 160]. This process is controlled by sequence motifs in 
introns and exons that are recognized by splicing factors and can be modulated by 
blocking these motifs with antisense oligonucleotides (AONs). 














1st Exon 2nd ExonIntron
Translation Discard
Figure 4. The process of splicing. The pre-mRNA consists of exons and introns. The end of an exon is called the 
donor splice site, and the beginning the acceptor splice site. A branch point sequence is located inside the intron. 
During splicing the branch point reacts with the donor splice site, splicing off the intron. Secondly, the donor 
splice site binds to the acceptor splice site and the intron is discarded. Exonic splicing enhancers (ESEs) are exon-
internal sequences where proteins can bind to induce or facilitate splicing.
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modulate splicing of different genes for different diseases has quickly expanded. 
Depending on the target, exon skipping has now also been shown to induce isoform 
switching, secretion of a membrane-bound protein by skipping of the membrane 
anchor or inactivation of a protein by removal of the active domain or disruption of 
the reading frame (reviewed in [161] and [148]). In addition, another class of AONs 
can arrest translation by steric hindrance of the ribosomal complex and consequently 
inhibit expression of a protein [162].
Unmodified AONs are rapidly degraded by intracellular endonucleases and 
exonucleases and have a short half-life [163]. Therefore, several backbone modifications 
have been designed to increase stability and specificity (Figure 5). The most widely 
used modifications for non-RNAse H mediated approaches are 1) the 2’-O-methyl 
RNA phosphorothioate (2OMePS) backbone, in which a methyl group is added to 
the 2’-O position in the ribose and one of the nonbridging oxygens is replaced by 
sulfur in the phosphate backbone of the oligonucleotide chain [144, 164] and 2) the 
phosphorodiamidate molpholino oligomers (PMOs), containing a mopholine ring 
and a nitrogen-based backbone [161, 165]. Phosphorothioate AONs are resistant to 
nucleases, easily synthesized and capable of inducing RNAse H activity for gene 
knockdown. The 2’-O-methyl modification eliminates the latter property, but further 








Figure 5. Frequently used AON modifications. Unmodified AONs are quickly degraded by nucleases in 
biological fluids. To decrease nuclease action different modifications have been developed. The 2’-O-Methyl 
phosphorothioate modification consists of a methyl group at the 2’-O location of the ribose, and a oxygen to 
sulphur substitution in the phosphate backbone. Phosphoroamidate morpholino’s consist of a backbone without 




increases stability and improves affinity for the target sequence [164]. PMOs are 
extremely stable, do not induce RNAse H cleavage and are thus suitable for splicing 
modulation. Because they are uncharged molecules, delivery of PMOs into cells in in 
vitro experiments is more difficult than 2OMePS [166]. Chimeric AONs that consist 
of a central region with phophorothioate backbone and a 2’-O-methyl backbone at 
the 3’ and 5’ ends (gapmers) can be used to induce RNAse H cleavage while retaining 
the favorable characteristics of the 2OMePS AONs [150, 167]. 
One of the most clinically advanced applications of exon skipping is practiced 
in treatment for boys with the severe progressive muscular disorder Duchenne 
muscular dystrophy (DMD). Patients are usually wheelchair-bound by the age 
of twelve, often require assisted ventilation later in life and generally die in their 
twenties [168]. The disease is caused by mutations or deletions in the DMD gene 
that lead to disruption of the reading frame, truncation, and loss of function of 
dystrophin (Figure 6) [169]. Dystrophin is required for muscle fibre stability and 
anchors the cytoskeleton to the extracellular matrix with two functional domains 
linked by a central rod domain [170, 171]. It has been demonstrated in patient cell 
cultures that exon skipping can be used to skip the mutated or an adjacent exon 
to restore the reading frame (Figure 6) [172-175]. This allows the production of 
dystrophins for which the central domain is shortened but both anchor domains 
are present, leaving it largely functional and resembling the dystrophin protein 
found in patients with the much milder Becker muscular dystrophy [172]. After 
local administration and successful dose-escalation and safety studies [176, 177], a 
2OMePS AON targeted to exon 51 of DMD (GlaxoSmithKline; originally developed 
by the Dutch company Prosensa) is currently in Phase III clinical trials [178] 
(www.clinicaltrials.gov NCT01480245, NCT01462292, NCT01254019). A competing 
PMO AON (Sarepta (previously AVI BioPharma)) is following closely [179, 180]. 
Other applications of splicing-modulating AONs in early pre-clinical stages include 
frontotemporal dementia [181], prostate cancer [182], spinal muscular atrophy [183] 
and inflammatory diseases such as rheumatoid arthritis [184, 185].
Because of sequence-specificity AONs have to be designed for each new 
target. The first places to target for the induction of exon skipping are the donor 
and acceptor splice sites. However, these sites consist of consensus sequences that 
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Figure 6. Exon skipping in Duchenne muscular dystrophy (DMD). Dystrophin is a large protein that contains 
two binding domains to link the actin in the cytoskeleton to the extracellular matrix in muscle cells and is thereby 
essential for muscle function (A). In DMD patients, the reading frame of the RNA is disrupted by a mutation 
(B). This results in a premature stop codon and loss of the linker function. In Becker dystrophy, the protein is 
shortened, but contains both binding domains and can partly fulfill its function. The reading frame of dystrophin 
in DMD patients can be restored by using AONs to induce skipping of an exon (in this case exon 51), allowing the 
production of Becker-like dystrophin instead of a non-functional protein (C). Figure adapted from Aartsma-Rus 




[161, 186]. In addition to the splice site sequences, many exons contain splicing 
regulatory sequences such as exonic splicing enhancers (ESEs), which facilitate the 
inclusion of exons [187]. A subfamily of splicing factors, the serine and arginine rich 
proteins (SR proteins), bind to these ESEs and recruit other splicing factors to the 
splice sites [188]. ESE motifs are loosely defined because the main task of the exon is 
encoding protein information, and strict motifs would interfere with this. Putative 
ESE sites can be predicted with software packages like RESCUE-ESE (http://genes.
mit.edu/burgelab/rescue-ese/) or ESEfinder (http://rulai.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi?process=home), to help in choosing favorable sites. Based on 
analysis of 156 AONs that were designed for the DMD gene, several characteristics 
have been revealed that increase the likelihood of designing effective AONs to 65-
70% [189, 190]. Around 20 nucleotides appears to be an optimal length for 2OMePS 
AONs, although some longer AONs can be more effective [191]. A high percentage of 
guanines (Gs) and cytosines (Cs) increases affinity of the AON to the target sequence, 
and therefore this percentage should preferable not be below 40%. However, stretches 
of three or more Gs or Cs or a GC percentage of >60% should be avoided as this 
makes self-hybridization of the AON by dimerization or folding more likely. The 
Tm should be above 48°C as this greatly increased efficacy in the tested DMD AONs 
[190]. In addition, the secondary structure of the targeted RNA sequence should be 
accessible for hybridization with the AON [192]. Possible secondary structures can 
be predicted by m-fold (http://mfold.rna.albany.edu/?q=mfold [193]). This program 
can also calculate the SS count for each nucleotide, indicating in how many of the 
predicted structures the nucleotide is single stranded. The AON should then be 
designed to cover partly open and partly closed structures to allow for binding to 
the target sequence and disruption of the secondary structure [189]. 
Outline of this thesis
This thesis describes different aspects of bone metabolism, mainly focused on 
sclerostin, Wnt signaling and bone formation. In Chapter 2, the current knowledge 
on sclerostin is reviewed and its potential as a therapeutic target for osteoporosis is 
highlighted. The discovery of sclerostin in patients with sclerosteosis and related 
mutations in Van Buchem disease have greatly improved insight in the function of 
sclerostin in regulation of bone metabolism. In Chapter 3 Dkk1 levels were measured 
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in patients with sclerosteosis and Van Buchem disease. As this inhitibor has a similar 
action to sclerostin, there may be a mechanism by which Dkk1 compensates for lack 
of sclerostin. Further advancing knowledge is the discovery of new mutations that 
result in bone phenotypes. Chapter 4 describes a novel mutation in sclerostin that 
results in impaired folding and secretion of the protein, and a phenotype that closely 
resembles sclerosteosis. 
The characteristics of patients with sclerosteosis or Van Buchem disease 
and carriers of these diseases indicate that sclerostin would be a good target for 
increasing bone formation in future osteoporosis therapies. For this, sclerostin 
levels in osteoporosis patients will need to be persistently decreased, for example by 
interfering with endogenous regulatory pathways. Chapter 5 therefore investigates 
the regulation of SOST, the gene that codes for sclerostin, and the role of GSK3β. In 
Chapter 6 AONs are investigated as a method for inhibition of sclerostin expression 
and consequently stimulation of bone formation. In addition, bone resorption is 
targeted by using AONs to interfere with the function of RANK. 
Further research into new therapies for osteoporosis would be aided by suitable 
high-throughput research methods. Since mineralization is the last and therefore 
a very important step in osteoblast differentiation, this is a relevant read-out. 
Chapter 7 describes a new method to quantify mineralization in bone cell cultures 
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Sclerostin: current knowledge and future perspectives
Abstract
In recent years study of rare human bone disorders led to the identification of 
important signaling pathways that regulate bone formation. Such diseases include 
the bone sclerosing dysplasias sclerosteosis and Van Buchem disease, which are due to 
deficiency of sclerostin, a protein secreted by osteocytes that inhibits bone formation 
by osteoblasts. The restricted expression pattern of sclerostin in the skeleton and 
the exclusive bone phenotype of good quality of patients with sclerosteosis and Van 
Buchem disease provide the basis for the design of therapeutics that stimulate bone 
formation. We review here current knowledge of the regulation of the expression and 
formation of sclerostin, its mechanism of action and its potential as a bone building 




Osteoporosis is characterized by low bone mass and microarchitectural deterioration 
of bone tissue with a consequent increase in bone fragility and susceptibility to 
fractures [1]. The balance between bone resorption and bone formation determines 
the mass and structural integrity of the skeleton and is disturbed in osteoporosis. 
Current therapies of osteoporosis, with the exception of parathyroid hormone 
(PTH), decrease the risk of osteoporotic fractures by reducing bone resorption and 
preserving its architecture but cannot stimulate bone formation. Elucidating the 
mechanisms regulating bone formation may lead to the development of therapeutics 
able to rebuild bone mass and architecture.
In recent years, study of rare human bone disorders and of genetically 
manipulated animal models has led to the identification of signaling pathways 
that regulate bone formation which provide potential targets for the development 
of novel therapeutics. Fundamental for this progress have been studies of two rare 
bone sclerosing dysplasias, sclerosteosis and Van Buchem disease, that led to the 
identification of sclerostin, an important negative regulator of bone formation. 
Sclerosteosis and Van Buchem disease
Sclerosteosis (OMIM 269500) and Van Buchem disease (OMIM 239100) are two rare 
sclerosing bone disorders, first described in the 1950’s as distinct clinical entities, 
with closely related phenotypes [2]. Sclerosteosis has been mainly diagnosed among 
Afrikaners of Dutch descent in South Africa, while most patients diagnosed with 
Van Buchem disease come from a small fishing village in The Netherlands. A 
few individuals and families with sclerosteosis or Van Buchem disease have been 
reported in other parts of the world, including Spain, Brazil, USA, Germany, Japan, 
Switzerland, and Senegal [3].
The skeletal manifestations of sclerosteosis and Van Buchem disease are the 
result of endosteal hyperostosis and are characterized by progressive generalized 
osteosclerosis [3-8]. The manifestations are most pronounced in mandible and 
skull, with characteristic enlargement of the jaw and facial bones leading to facial 
distortion, increased intracranial pressure and entrapment of cranial nerves, often 
associated with facial palsy, hearing loss and/or loss of smell (Figure 1). Patients with 
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sclerosteosis have a more severe phenotype compared to patients with Van Buchem 
disease and usually have syndactyly. In a limited number of bone biopsies of affected 
individuals there is evidence of increased bone formation including predominance of 
cuboidal active osteoblasts, increased double tetracycline label spacing and increased 
osteoid that mineralizes normally, while no consistent alteration of osteclast 
numbers or activity has been reported [9-13]. Information about markers of bone 
turnover in such patients is also limited. Beighton’s group reported elevated serum 
alkaline phosphatase (AP) activity in the majority of patients with sclerosteosis [14, 
15] while Wergedal et al. [16] found significantly higher levels of bone formation (AP, 
procollagen type 1 amino-terminal propeptide [P1NP], osteocalcin) and resorption 
(urinary amino-terminal type I collagen telopeptide [NTX]) markers in six patients 
with Van Buchem disease compared to carriers of the disease. 
The genetic defect that leads to sclerosteosis was identified in a newly cloned gene 
called SOST, which is located on chromosome 17q12-21 and encodes for the protein 
Figure 1. Chronological portraits of a patient with sclerosteosis from the age of 3 years onwards. She was born with 
syndactyly at both hands and developed facial palsy, deafness, facial distortion, and maxillary overgrowth during 
childhood. By the age of 30, she had developed proptosis and elevated intracranial pressure due to overgrowth of 
the calvarium. Craniectomy was performed, but she died nevertheless because of elevated intracranial pressure at 
the age of 54 years (description of this case was previously published by Epstein et al. [14]).
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sclerostin. Five mutations have so far been identified in patients with sclerosteosis, of 
which three introduce a premature termination codon and the others interfere with 
splicing of the gene [17-20]. No mutations within this gene could be found in patients 
with Van Buchem disease, but instead a 52kb deletion 35kb downstream of the SOST 
gene was identified [21, 22]. The deleted region was later found to contain regulatory 
elements for SOST transcription explaining its ability to induce a phenotype closely 
resembling that of patients with sclerosteosis [23]. The different defects of the SOST 
gene cannot readily explain the differences in clinical phenotypes between the two 
diseases. However, serum sclerostin was severely decreased in patients with Van 
Buchem disease compared to controls, but could not be detected in patients with 
sclerosteosis [13, 24]. This difference may give rise to differences in disease severity. 
A gene-dose effect is also indicated by the fact that serum sclerostin concentrations 
in carriers of both diseases were significantly higher than in affected individuals, 
but lower than in controls. With regard to the digit malformations present only 
in sclerosteosis it may be that the genomic region deleted in Van Buchem disease 
does not contain regulatory elements required for sclerostin expression during digit 
formation. This could be the reason for the absence of syndactyly (or other digit 
malformations) in these patients as opposed to patients with sclerosteosis. 
SOST/sclerostin expression
SOST mRNA is, especially during embryogenesis, expressed in many tissues, 
whereas sclerostin protein expression has only been reported postnatally in 
terminally differentiated cells embedded within a mineralized matrix, i.e. 
osteocytes, mineralized hypertrophic chondrocytes and cementocytes [11, 12, 25, 
26]. SOST mRNA expression in unmineralized tissues has been detected during 
mouse embryogenesis in the otic vesicle and peridigital or interdigital regions of the 
limb buds, of which the latter may be implicated in the pathogenesis of syndactyly 
in patients with sclerosteosis [27]. In humans, SOST mRNA is expressed in heart, 
aorta, liver and at high levels in the kidney [17, 18, 28, 29], but no sclerostin protein 
has been detected in these organs. Accordingly, patients with sclerosteosis or Van 
Buchem disease do not have renal or cardiovascular abnormalities [3].
In adult murine and human bone, sclerostin expression is restricted to osteocytes 
with diffuse staining representing dendrites in osteocytic canaliculi [11, 25, 26, 
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30]. Osteoclasts, osteoblasts and bone lining cells do not express sclerostin. Due to 
the difficulties with isolating and culturing osteocytes from mammalian bone, in 
vitro studies of SOST/sclerostin expression are technically difficult. Osteogenic cell 
cultures that form mineralized bone nodules are one of the few available methods for 
generating osteocyte-like cells in vitro [31]. In mouse primary osteogenic bone marrow 
and mouse mesenchymal KS483 cell cultures, SOST mRNA expression is induced at 
low levels after onset of bone nodule mineralization [11, 32]. Similar to the induction 
of SOST mRNA in vitro, newly embedded osteocytes within unmineralized osteoid 
in humans in vivo do not express sclerostin, but become positive for the protein 
at, or shortly after primary mineralization [26]. When mineralization of osteoid 
is inhibited by administration of the bisphosphonate etidronate in rats, osteocytes 
within the unmineralized matrix remain immature and do not express sclerostin 
[33]. However, SOST mRNA is expressed by some osteoblast-like osteosarcoma cell 
lines [34].
As expected, sclerostin is not expressed by osteocytes in bone biopsies of 
patients with sclerosteosis [11]. In addition, no sclerostin expression was found in 
bone biopsies from patients with Van Buchem disease, supporting the function of 
the genomic region deleted in these patients in the regulation of sclerostin expression 
in bone [12]. 
Sclerostin mechanism of action
In patients with sclerosteosis, the combination of high bone mass due to increased 
bone formation with premature termination codons in the SOST gene suggested an 
inhibitory effect of the gene product sclerostin on bone formation. This is supported 
by the observation that addition of exogenous sclerostin to osteogenic cultures 
inhibited proliferation and differentiation of mouse and human osteoblastic cells 
[11, 25, 35]. In addition, sclerostin was shown to decrease the lifespan of osteoblasts 
by stimulating their apoptosis [35]. In vivo, overexpression of sclerostin using either 
the osteocalcin promoter or BAC recombination induced osteopenia in mice [23, 
25]. Bone formation in these animals was decreased, while bone resorption was 
unaffected. Furthermore, analysis of Sost knockout mice showed significant increases 
in radiodensity, bone mineral density (BMD), cortical and trabecular bone volume, 
bone formation rate, and bone strength [36]. Together these data support a negative 
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effect of sclerostin on bone formation.
Two processes are responsible for construction and reconstruction of the 
skeleton throughout life, bone remodeling and modeling. Bone remodeling enables 
constant renewal of the skeleton. In this process, bone resorption by osteoclasts and 
formation by osteoblasts are tightly coupled within a basic multicellular unit (BMU) 
and bone resorption always precedes bone formation. Sclerostin expression by 
newly embedded osteocytes at the onset of mineralization of osteoid may serve as a 





































Figure 2. Schematic model of the mechanism of action of sclerostin in bone remodeling and modeling. In 
remodeling (A), sclerostin produced and secreted by newly embedded osteocytes may be transported to the 
bone surface where it inhibits osteoblastic bone formation and prevents overfilling of the basic multicellular 
unit (BMU). In modeling (B), sclerostin may serve two actions. First, it may keep bone lining cells in a state 
of quiescence and prevent, thereby, initiation of de novo bone formation. In addition, sclerostin produced and 
secreted by newly embedded osteocytes may inhibit osteoblastic bone formation similar as in a BMU (reproduced 
from van Bezooijen et al. [8]).
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[11, 26]. Data on the effect of sclerostin on osteoclastic bone resorption in humans 
are scarce and inconsistent, reporting unaffected, low or increased bone resorption 
in patients with sclerosteosis and Van Buchem disease [9, 10, 16]. In addition, during 
bone modeling sclerostin may keep bone lining cells in a quiescent state [26] and 
may thereby prevent activation of osteoblasts and bone formation without previous 
bone resorption (Figure 2b) [8]. Sclerostin expression by osteocytes embedded in 
newly formed bone by modeling may serve a similar negative feedback mechanism 
on bone formation as in a BMU.
On the basis of its amino acid sequence, which indicates a cystine knot structure, 
sclerostin was classified as a member of the DAN (Differential screening-selected 
gene aberrant in neuroblastoma) family of glycoproteins [6, 17, 18, 37]. This family 
consists of a group of secreted proteins that share the ability to antagonize bone 
morphogenetic protein (BMP) activity. The currently available data, however, suggest 
that sclerostin is not a classical BMP antagonist [11]. Some DAN family members 
have also been reported to antagonize canonical Wnt signaling, among which Wise 
is the most closely related to sclerostin [38]. Wnts are secreted glycoproteins that bind 
to seven transmembrane-spanning receptors of the Frizzled family. Stimulation of 
these receptors causes the intracellular signaling molecule β-catenin to accumulate 
and translocate into the nucleus, where it initiates transcription of target genes via 
complex formation with TCF/Lef1 transcription factors. Conversely, in the absence 
of Wnt, β-catenin forms a complex with the tumor suppressor proteins APC and 
Axin, and the kinases glycogen synthase kinase 3 (GSK3) and casein kinase I (CK1), 
which facilitates phosphorylation and proteosomal degradation of β-catenin [39].
The identification of gain-of-function mutations in the first β-propeller of 
the low-density lipoprotein receptor-related protein LRP5, an essential membrane 
bound co-factor in canonical Wnt signaling, in patients with high bone mass (HBM)-
phenotype [40, 41] and loss-of-function mutations in LRP5 in patients with the 
osteoporosis pseudoglioma syndrome (OPPG) [42] demonstrated the importance of 
LRP5-mediated canonical Wnt signaling in regulating bone formation. Sclerostin 
has been shown to bind LRP5 and its closely related co-receptor LRP6 and, thereby, 
inhibit the canonical Wnt signaling via LRP5/6 (Figure 3) [43-45]. However, although 
sclerostin binds LRP5/6 to antagonize Wnt signaling, sclerostin and Wnts do not 
appear to compete for binding of this co-receptor [43], and may antagonize different 
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Wnts depending on the conformation of LRP5 or 6 [46]. It may be that sclerostin 
exerts its effect through binding to a co-receptor and inducing internalization of 
LRP5/6 as has been shown for Dkk1, another Wnt antagonist. Characterization of 
the structure of sclerostin showed that sclerostin indeed consists out of a cystine knot 
and three loops [47, 48]. One of these loops is high in positively charged residues, 
showing a possible site of interaction with the predicted binding site on the first of 6 
β-propellers of LRP5, which is negatively charged. The binding site of a neutralizing 
antibody to sclerostin was mapped to this loop, suggesting a functional role of this 
region in the inhibition of Wnt signaling. In addition, the loop contains a highly 
conserved sequence with an NXI motif (in the sequence PNAIG). This motif was also 
found  in the closely related protein WISE, in DKK proteins, and in the interaction 
between laminin with nidogen, another six-bladed β-propeller containing protein. 
Mutation of the amino acids in this motif destroyed the ability of sclerostin and 
















Figure 3. Schematic model of antagonized canonical Wnt signaling. Canonical Wnt signaling involves the 
formation of complexes of Wnts with Frizzled receptors and LRP5/6 co-receptors, resulting in the accumulation 
of β-catenin in the cytoplasm and translocation into the nucleus. The antagonist Dkk1 inhibits canonical Wnt 
signaling by the formation of complexes with LRP5/6 and Kremen, resulting in the removal of LRP5/6 from the 
membrane. Dkk1 binds to the first and third β-propeller of LRP5/6. The antagonist sclerostin inhibits canonical 
Wnt signaling by binding to probably the first β-propeller of LRP5/6. Whether sclerostin requires a co-factor like 
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also found within sclerostin, which may mediate localization of sclerostin at the cell 
surface of target cells and possibly facilitate inhibition of Wnt signaling.
The precise mechanism by which sclerostin secreted by osteocytes inhibits Wnt-
mediated bone formation is still unclear. It may be transported to the bone surface 
via the canaliculi or it may induce another signal in osteocytes that is transported to 
osteoblasts to inhibit bone formation. In support of the latter, Wnt signaling has been 
found in osteocytes [50, 51]. Another mechanism was proposed by Krause et al. [52]. 
They found that, even though sclerostin is not a classical BMP antagonist, it could 
inhibit BMP7-induced responses when both proteins were expressed in the same cell. 
Sclerostin then bound to BMP7, leading to intracellular retention and proteasomal 
degradation. The effect of sclerostin may therefore be different in osteocytes that 
produce the protein, and osteoblasts or sclerostin-negative osteocytes. 
Several ELISA methods have become available for the measurement of 
sclerostin in serum or plasma samples, showing that sclerostin also circulates in the 
bloodstream. Over the past few years many reports have been published on sclerostin 
serum concentrations in humans, showing variations in healthy adults [53, 54] and 
associations between sclerostin and a variety of diseases and conditions. Increased 
sclerostin concentrations have been found in hypercortisolism [55], type 2 diabetes 
mellitus (T2DM) [56], atherosclerosis in T2DM [57], immobilization [58], fracture 
healing [59], thalassemia-associated osteoporosis [60], and high bone turnover as 
in Paget’s disease [61], while sclerostin was decreased in hyperparathyroidism [62], 
idiopathic osteoporosis in men [63] and ankylosing spondylitis [64, 65]. However, 
not much is known about the importance of sclerostin in the serum; whether it has 
a function in circulation, whether serum concentrations reflect changes in the bone, 
and the temporal resolution of changes in serum concentrations. It is important to 
elucidate these mechanisms before sclerostin measurements can be routinely used as 
diagnostic tools in the clinic.
Recently, the role of bone expressed LRP5 in the regulation of bone formation 
was questioned, since targeted deletion of LRP5 in osteoblasts using the collagen 
type 1 promoter failed to induce osteopenia and targeted knock-in of LRP5 with 
a HBM mutation (G171V) using the same promoter did not increase bone mass in 
mice [66]. It was shown that LRP5-mediated signaling in the duodenum inhibited the 
expression of Tph1, the rate-limiting enzyme for serotonin production outside the 
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brain, and, thereby, decreased  serum levels of serotonin. Conversely, LRP5 knockout 
mice that have low bone mass had high serum serotonin levels. In addition, reduction 
of these elevated serotonin levels by administration of parachlorophenylalanine or a 
low tryptophan diet normalized bone formation parameters and bone mass. Cui et 
al. [67] could not replicate the results presented by Yadav et al. and found no relation 
between serotonin and bone mass. This discrepancy may be explained by differences 
in the mouse models that were used. At this point a definitive answer has not been 
found, and further research may prove if both models can be integrated. 
Regulation of SOST/sclerostin expression
Due to their location and morphology, osteocytes have been long implicated in 
mechanosensing and initiation of the bone anabolic response to mechanical load [68, 
69]. In support of this, specific ablation of osteocytes in mice resulted in fragile bone 
and these mice did not respond with bone loss to unloading [70]. Wnt signaling may 
play an important role in the anabolic response to deformation and loading, since 
increased Wnt signaling has been found after loading of osteoblastic cells in vitro 
and of tibiae in vivo [50, 71, 72]. Wnt signaling and the co-receptor LRP5 were found 
to be essential for the increase in bone mass after loading [73, 74]. Since sclerostin 
is produced by osteocytes in bone and inhibits bone formation by antagonizing 
canonical Wnt signaling, it may play a role in regulating Wnt-signaling in response 
to mechanical loading. Consistent with this hypothesis, loading decreased SOST 
mRNA and sclerostin levels, while unloading increased Sost mRNA expression in 
vivo (Figure 4) [72, 75, 76]. Interestingly, reduction of sclerostin staining intensity 
was most pronounced in areas with the highest strain, indicating a response to local 
loading conditions. Furthermore, Sost knock-out mice do not exhibit bone loss 
after unloading [72], and constitutive over-expression of Sost severely reduced bone 
formation after loading [74].
Several systemic and local factors have been suggested as possible regulators 
of SOST/sclerostin expression by osteocytes and the SOST promoter region includes 
Runx2, E-box and C/EBP binding motives [77]. Recombinant human PTH and active 
fragments of this protein are used in the treatment of osteoporosis [78]. In contrast to 
the bone resorption stimulating effect of continuous elevation of endogenous PTH as 
is seen in patients with hyperparathyroidism, intermittent increases of PTH provided 
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by daily injections are associated with distinct anabolic effects. The mechanisms by 
which PTH mediates this bone anabolic effect are not completely understood. Part 
of it may be mediated via sclerostin, as PTH has been shown to inhibit its expression 
both in vitro and in vivo (Figure 4). In vitro, PTH decreased SOST transcription by 
osteoblastic and osteocytic cells within 4 hours. This was not affected by the protein 
synthesis inhibitor cyclohexamide, but decreased by the cAMP inducer forskolin 
[30, 34]. These observations suggest a direct and cAMP dependent regulatory effect 
of PTH on the expression of SOST. Within the 52kb genomic region deleted in 
Van Buchem disease, a MEF2 response element (ECR5) has been identified that is 
essential for the PTH-induced downregulation of SOST expression [79, 80]. In vivo, 
PTH administration resulted in a decrease in SOST mRNA and sclerostin expression 
in mice and rats [23, 30, 79, 81]. In addition, a constitutively active PTH receptor 1 
(caPTHR1) exclusively expressed in osteocytes resulted in increased remodeling 












Figure 4. Schematic model for the regulation of the control of bone formation by sclerostin. Sclerostin may exert 
its inhibitory effect on bone formation by preventing the activation of lining cells as well as the inactivation of 
active osteoblasts. Glucocorticoids stimulate sclerostin expression and, thereby, inhibit bone formation, whereas 
intermittent PTH and loading inhibit sclerostin expression in osteocytes and, thereby, stimulate bone formation.
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effect was blunted in mice lacking LRP5, suggesting that the effect of caPTHR1 was 
mediated by increased Wnt signaling due to suppression of SOST. The importance of 
SOST regulation by PTH is further supported by the observations that the anabolic 
effect of PTH is blunted in Sost deficient mice as well as in mice overexpressing Sost 
using a constitutive active promoter [83].
Two other systemic factors have also been shown to affect SOST/sclerostin 
expression. 1,25-Dihydroxyvitamin D3 alone or in combination with retinoic 
acid increased SOST expression in human osteoblastic cells in vitro [32, 77]. The 
specific effect of glucocorticoids on SOST expression depends on the experimental 
conditions. In vitro, dexamethason suppressed SOST expression in osteoblastic cells 
[32], while in vivo treatment of mice with prednisolone increased Sost expression in 
tibiae, suggesting that suppression of Wnt signaling by the upregulation of sclerostin 
may account for the glucocorticoid-induced suppression in bone formation (Figure 
4) [84].
BMP2, 4, and 6 are local growth factors shown to stimulate SOST expression in 
osteoblastic cells in vitro [27, 32], probably by an indirect mechanism [85]. Decreased 
BMP signaling due to osteoblast specific knockout of Bmpr1a decreased Sost mRNA 
and sclerostin protein expression in embryonic mice calvariae and was associated 
with increased bone mass [86]. In these mice, however, both bone formation and 
resorption were inhibited. The authors proposed that the decrease in bone formation 
was independent of sclerostin expression and a direct result of decreased BMP 
signaling. The decrease in bone resorption, however, may be an effect of increased 
Wnt signaling due to the decrease in sclerostin expression. This in turn may be due 
to upregulation of osteoprotegerin in mature osteoblasts by Wnts and, thereby, 
inhibition of RANKL-induced osteoclastogenesis [87].
 Despite the rapid progress in our understanding of the regulation of the 
production and function of sclerostin, there are still important questions that need 
to be addressed in future research. These include the identification of factors that 
regulate sclerostin/SOST expression and determine its highly restricted expression 
pattern. Furthermore, the mechanism by which sclerostin binding to LRP5/6 
interferes with canonical Wnt signaling as well as potential additional functions of 
sclerostin, besides antagonizing canonical Wnt signaling, should be further explored. 
While sclerostin measurements in serum revealed some interesting associations 
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with disease, the precise function and relevance of circulating sclerostin need to be 
elucidated. More detailed and structured analysis of bone metabolism in patients 
with sclerosteosis and Van Buchem disease, sclerostin expression in pathological 
conditions, and a genotype-phenotype characterization of SOST are required to 
better understand its function and regulation in humans.
Therapeutic potential
The identification of sclerostin deficiency as the cause of sclerosteosis and Van 
Buchem disease and the progress in our understanding of the action of sclerostin 
on bone formation has opened a new area in bone therapeutics. The restricted 
expression pattern of sclerostin and the exclusive bone phenotype of good quality of 
patients with sclerosteosis and Van Buchem disease provide the basis for the design 
of therapeutics that specifically stimulate bone formation, an action relevant to the 
treatment of osteoporosis. As sclerostin is a secreted protein, one approach to achieve 
this is to develop antibodies capable of inhibiting the biological activity of sclerostin, 
mimicking, thus, its absence in sclerosteosis. Such antibodies have already been 
shown to increase BMD, bone volume and bone strength in ovariectomized rats 
[88] and primates [89] and to reverse bone loss in a model of colitis [90] and are 
currently in Phase III clinical trials (AMG 785, NCT01575834 and NCT01631214 
on www.clinicaltrials.gov). Placebo-controlled studies and a recent phase II study 
comparing sclerostin antibody to alendronate and teriperatide demonstrated 
a markedly increased BMD at spine, hip and femoral neck that was significantly 
higher than in patients that were treated with other drugs [91, 92]. Bone formation 
markers were rapidly increased and bone resorption markers were decreased. 
While the increase in bone formation markers was transitory, the changes in bone 
resorption was sustained over the 12-month study period and resulted in a large 
anabolic window which has not been observed in other osteoporosis therapies.
Other approaches to inhibit sclerostin production or activity are also feasible. 
However, given the availability of efficacious treatments, any novel treatment for 
osteoporosis should not only be effective but also devoid of adverse effects. The 
absence of any extraskeletal complications of patients with sclerosteosis and Van 
Buchem disease are reassuring. Furthermore, the finding of consistently higher 
BMD values in carriers of sclerosteosis with no skeletal complications [6] suggests 
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that the sclerostin inhibition can be titrated and can lead to the desired outcome 
without any side effects, but safety margins need to be determined. However, there 
have been concerns that stimulation of bone formation by increasing Wnt signaling 
may lead to unwanted skeletal effects [93, 94]. The Wnt inhibitor factor 1 (WIF1), 
for example, has been identified as a candidate tumor suppressor gene in human 
osteosarcoma, suggesting that the susceptibility to osteosarcoma may be increased 
in patients receiving novel anabolic treatments targeting Wnt antagonists [95]. This 
is another issue that needs to be further investigated.
Study of the molecular defects of rare bone disorders such as sclerosteosis 
and Van Buchem disease can, thus, lead to the development of new bone forming 
agents allowing to tailor pharmacotherapy to the needs of the individual patient 
with osteoporosis. In addition, they may help in the management of the small group 
of patients with sclerosteosis or Van Buchem disease, for whom the only currently 
available treatment is the technically difficult and often risky removal of excess bone 
tissue from the skull.
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Abstract
Context: Sclerostin and DKK1 are antagonists of the canonical Wnt signaling 
pathway, both binding to the same LRP5/6 receptor on osteoblasts, thereby inhibiting 
bone formation. It is not known whether there is an interaction between sclerostin 
and DKK1. 
Objective: We examined whether a lack of sclerostin is compensated by 
increased DKK1 levels.  
Design, setting and patients: We measured DKK1 levels in serum samples 
of patients and carriers of sclerosteosis (19 patients, 24 carriers) and Van Buchem 
disease (VBD) (13 patients, 22 carriers), and 25 healthy controls. Sclerosteosis and 
VBD are caused by deficient sclerostin synthesis and are characterised by increased 
bone formation and hyperostotic phenotypes. 
Main outcome measures: DKK1 levels were compared between patients and 
carriers, and between patients and healthy controls. We also examined associations 
between levels of DKK1 and bone turnover markers P1NP and CTX. 
Results: We found that DKK1 levels were significantly higher in patients with 
both sclerosteosis [4.28ng/ml (95%CI: 3.46-5.11ng/ml)] and VBD [5.28 ng/ml (95%CI: 
3.84-6.71ng/ml)] compared to levels in carriers of the two diseases [sclerosteosis: 
2.03ng/ml (95%CI: 1.78-2.29ng/ml) p<0.001, VBD: 3.47ng/ml (95%CI: 2.97-3.97ng/
ml) p=0.017] and to levels in healthy controls [2.77ng/ml (95%CI: 2.45-3.08ng/ml), 
p=0.004 and p<0.001 respectively]. Serum DKK1 levels were positively associated 
with levels of P1NP and CTX in both disorders. 
Conclusions: These results suggest that increased DKK1 levels observed in 
patients with sclerosteosis and VBD represent an adaptive response to the increased 
bone formation characterizing these diseases, although these increased levels do not 





Sclerosteosis and Van Buchem disease (VBD) are two rare bone sclerosing dysplasias 
with closely related phenotypes, characterized by progressive bone overgrowth and 
very high bone mass [1]. Sclerosteosis is caused by loss-of-function mutations in the 
SOST gene, while patients with VBD lack a regulatory element for the SOST gene 
caused by a 52 kb deletion of genomic DNA 35 kb downstream of the SOST gene [1]. 
In both disorders, these genetic defects lead to impaired synthesis of sclerostin. 
Sclerostin is a protein, predominantly synthesized in the skeleton by osteocytes, 
which decreases bone formation by inhibiting the terminal differentiation of 
osteoblasts and by promoting their apoptosis. Sclerostin binds to the low density 
lipoprotein receptor-related protein (LRP) 5/6 receptors and antagonizes the 
canonical Wnt-signaling pathway in osteoblasts [2]. The binding of sclerostin to 
LRP5/6 is facilitated by LRP4, a negative regulator of LRP5/6 signaling that augments 
the inhibitory activity of sclerostin on the Wnt signaling pathway [3].  Dickkopf 1 
(DKK1) is a structurally unrelated Wnt antagonist, which similar to sclerostin, 
blocks the signaling cascade by binding to LRP5/6, a process facilitated by its co-
receptor Kremen [4, 5], and inhibits bone formation by acting at different stages of 
osteoblast development [6]. A direct interaction between sclerostin and DKK1 has 
not been identified but it has been reported that sclerostin and DKK1 act through 
a common mechanism involving binding to the first ß-propeller of LRP6 with a 
conserved amino acid motif present in both proteins, suggesting an interaction 
between them [7].
Because both sclerostin and DKK1 bind to the same receptors and both proteins 
inhibit bone formation, we hypothesized that the lack of sclerostin in sclerosteosis 
and VBD might affect the production of DKK1. In the present study we tested this 
hypothesis by measuring serum DKK1 levels in patients with sclerosteosis and VBD 
and in respective heterozygous carriers of these diseases.
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Subjects and methods
Subjects
Previously collected serum samples from 19 patients with sclerosteosis and 24 
carriers of the disease, and from 13 patients with Van Buchem disease (VBD) and 22 
carriers of the disease were available for analysis. Detailed clinical characteristics of 
the subjects have been previously reported [8, 9]. In brief, patients and disease carriers 
of sclerosteosis were all Afrikaners from South Africa. Patients with sclerosteosis 
had the characteristic clinical manifestations of the disease, including syndactyly, 
facial distortion, facial palsy, hearing loss and increased intracranial pressure. 
None of the disease carriers had any symptoms or complications associated with 
sclerosteosis. The diagnosis was genetically confirmed in all subjects by the presence 
of homozygous or heterozygous mutations within the first exon of the SOST gene 
(C69T) in patients and carriers respectively. All patients and disease carriers of 
VBD were Dutch. Patients with VBD had clinical characteristics and complications 
similar, but of a milder degree than those of patients with sclerosteosis. In all patients 
and carriers with VBD the diagnosis was confirmed by presence of homozygous or 
heterozygous 52kb deletions downstream of the SOST gene in patients and carriers 
respectively. 
Informed consent was obtained from all subjects and the study was approved 
by the Medical Ethical Committee of Leiden University Medical Center. 
Serum biochemistry
Serum samples were measured for sclerostin using the MSD® 96-well MULTI-
ARRAY® Human Sclerostin Assay (Meso-Scale Discoveries, Gaithersburg, USA), 
as previously described [8]. Serum was also measured for calcium adjusted for 
albumin, phosphate and creatinine using semi automated techniques. Serum 
procollagen type 1 amino-terminal propeptide (P1NP) and carboxy-terminal cross-
linking telopeptide (CTX) levels were determined by the E-170 system (Roche, Basel, 
Switzerland), 25-hydroxyvitamin D (25OHD) by the LIAISON 25-OH-Vitamin D 
TOTAL assay (DiaSorine S.A./N.V., Brussels, Belgium) and 1,25-dihydroxyvitamin 
D (1,25-DHD) concentrations by the LIAISON 1,25-(OH)2 Vitamin D TOTAL 
assay (DiaSorine S.A./N.V., Brussels, Belgium). Serum DKK1 was measured by 
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the Quantikine® Human DKK-1 Immunoassay R&D systems (R&D systems Inc., 
Minneapolis, USA). In our hands the inter-assay and intra-assay precision were 
5.8% and 10.4%, respectively. In 25 healthy men and women aged 20 to 63 years, 
with normal renal function and serum calcium concentrations, and serum P1NP 
concentration below 65 ng/ml, the mean serum DKK1 level was 2.77 ng/ml (95%CI: 
2.45-3.08 ng/ml) range 1.40 to 4.83 ng/ml. These serum DKK1 values are very similar 
to those reported by the manufacturer of the assay (mean 2.5 ng/ml range 1.4 to 5.2 
ng/ml) and by other investigators [10] with this assay (mean 2.4 ng/ml range 1.0 to 3.0 
ng/ml). Fibroblast Growth Factor 23 (FGF23) levels were measured using the Kainos 
Intact Human FGF23 Elisa (Kainos Laboratories Inc., Tokyo, Japan).  Intra-assay 
and inter-assay precisions were 9% and 11%, respectively.  In 30 healthy controls 
with normal renal function, normal calcium and phosphate metabolism and normal 
serum P1NP levels, mean serum FGF23 was 28.7 pg/ml (95% CI:25.9-31.5 pg/ml). 
Statistical analysis 
Differences between patients and carriers of sclerosteosis and VBD were assessed 
using the  Student’s t-test. Pearson correlation test was used to assess the relationships 
between DKK1, biochemical markers of bone turnover and age. The SPSS 17.0 
program (SPSS Inc., Chicago, USA) was used for the statistical analysis.
Results
Characteristics and biochemical measurements of all studied subjects are 
summarized in Table 1. Subjects were aged between 5 and 82 years. Patients with 
sclerosteosis were significantly younger than carriers of the disease, although there 
was no difference in mean age between patients with VBD and carriers.
All studied subjects had normal biochemical indices of mineral metabolism, 
and normal renal function. As previously reported, serum sclerostin levels were 
undetectable in patients with sclerosteosis and were very low in patients with VBD. 
Sclerostin levels were higher in the respective carriers of the two diseases, although 
still significantly lower than levels measured in healthy subjects [8, 9]. Serum 1,25-
DHD concentrations were higher in patients with sclerosteosis compared to carriers 
of the disease. Serum FGF23 levels were within the normal reference range and not 
different between patients and carriers of both diseases.
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Serum DKK1 levels ranged between 1.19 ng/ml and 10.02 ng/ml and children 
with sclerosteosis or VBD had the highest measured values. Patients with sclerosteosis 
had significantly higher DKK1 levels than carriers of the disease [4.28 ng/ml (95%CI: 
3.46-5.11 ng/ml) vs 2.03 ng/ml (95%CI: 1.78-2.29 ng/ml), p<0.001]. Similarly, patients 
with VBD had significantly higher serum DKK1 levels [5.28 ng/ml (95%CI: 3.84-6.71 
ng/ml)] than carriers of the disease [3.47 ng/ml (95%CI: 2.97-3.97 ng/ml), p=0.017] 
(Figure 1). These differences between patients with sclerostin deficiency and carriers 
remained significant after removal of the higher values of the children included in 
the analysis from the calculations [patients 3.90 ng/ml (95%CI: 3.32-4.48 ng/ml), 
carriers 2.7 ng/ml (95%CI: 2.39-3.07 ng/ml),  p<0.001]. Compared to controls [2.77 
ng/ml (95%CI: 2.45-3.08 ng/ml)], patients had significantly higher serum DKK1 
values [sclerosteosis p=0.004, VBD p<0.001].
In patients and carriers of both diseases serum DKK1 levels were negatively 
correlated with age (sclerosteosis: r=-0.64, p<0.001; VBD: r=-0.33, p=0.050).  DKK1 
levels were positively correlated with serum P1NP levels (sclerosteosis: r=0.78, p<0.001; 
VBD: r=0.69, p<0.001) and serum CTX levels (sclerosteosis: r=0.74, p<0.001; VBD: 
r=0.64, p<0.001). These relationships remained significant after adjustment for age. 
Figure 1. Mean  serum DKK1 levels in patients and carriers of sclerosteosis (A) and VBD (B). Bars represent SEM.
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Discussion
Our study shows that sclerostin deficiency, as occurs in patients with sclerosteosis 
or Van Buchem disease, is associated with higher circulating DKK1 levels compared 
to those of heterozygous carriers of either disease and of healthy subjects. Serum 
DKK1 concentrations have not been previously reported in sclerostin deficiency, 
but increased DKK1 expression has been observed in Sost knock-out mice (Dr. M. 
Kneissel, unpublished observations). These findings suggest an interaction between 
sclerostin and DKK1, two of the known inhibitors of the Wnt-signaling pathway in 
osteoblasts.
Previously reported measurements of both serum sclerostin and DKK1 in 
humans have provided variable results not allowing any conclusion to be drawn 
about a potential functional relationship between the two proteins. For example, 
serum DKK1 levels were found to be normal in patients with the high bone mass 
phenotype and high serum sclerostin levels, [11] as was also the case in women 
with osteoporosis treated with a bisphosphonate [12]. In patients with multiple 
myeloma and osteolytic bone disease, the levels of both inhibitors were found to 
be increased [13], whereas DKK1 levels were found to be increased in women with 
osteoporosis treated with teriparatide, which is associated with a decrease in serum 
sclerostin levels [14], also consistent with recent findings in patients with primary 
hyperparathyroidism [15]. Conversely, treatment with denosumab was associated 
with decreases  in serum DKK1 and increases in serum sclerostin levels [16].
The increased serum DKK1 levels in patients with sclerostin deficiency we 
found in the present study may be related to the higher rate of bone formation and 
turnover observed in these patients, as illustrated by the positive correlation between 
DKK1 and the bone turnover markers P1NP, and CTX. Alternatively or in addition 
to this potential explanation, the higher serum DKK1 levels found in sclerostin 
deficiency may be an adaptive response to the lack of sclerostin, in an attempt to 
protect the skeleton from unrestrained bone formation. This notion is supported by 
the finding of the highest DKK1 values in children in whom the effect of sclerostin 
deficiency is most pronounced [8, 9]. Previous studies have shown no association 
between DKK1 values and age in either healthy adults [17-19] or children (Dr. P. 
Dimitri, personal communication). In sclerosteosis and VBD, bone overgrowth is 
progressive mainly during childhood, and both diseases stabilize during adulthood, 
as shown by a decline in serum levels of PINP with age [8, 9]. The finding of the 
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highest DKK1 levels in children is, therefore, in keeping with the natural course of 
the two sclerosing disorders and with the potential compensatory role of DKK1 for 
the underlying sclerostin deficiency. The hyperostotic phenotypes of sclerosteosis 
and VBD indicate, however, that the increased DKK1 synthesis is not able to fully 
compensate for the lack of sclerostin in these patients. Whereas both Wnt antagonists 
act by binding to the same LRP5/6 receptor, they have different mechanisms of 
action and expression pattern (sclerostin is expressed in bone by osteocytes while 
DKK1 by osteoblasts and osteocytes and outside bone) and they act on osteoblasts 
at different developmental stages. This might explain therefore why the functions of 
these two proteins are not fully compensatory, although sclerostin and DKK1 are 
both antagonists of the Wnt signaling pathway in osteoblasts.
Despite the profound changes in bone metabolism observed in patients with 
sclerostin deficiency, mineral metabolism is not generally affected in these patients. 
A recent study in Sost knock-out mice reported increased serum concentrations of 
1,25-DHD and decreased levels of FGF-23 in these mice, suggesting that sclerostin 
deficiency may also affect mineral metabolism [20]. In contrast to patients with VBD, 
in whom there was no difference in 1,25-DHD levels between patients and carriers, 
we found higher serum 1,25-DHD concentrations in patients with sclerosteosis 
compared to carriers of the disease. Serum 1,25-DHD concentrations bore, however, 
no relationship to serum FGF-23 levels, which were within the normal range in all 
subjects whether patient or carrier, with no difference between patients and carriers 
of both diseases or healthy controls. Our results in humans do not, therefore, support 
the findings from the animal study. 
In conclusion, we hypothesize that the higher levels of DKK1 we found 
in patients with sclerosteosis and Van Buchem disease and their carriers are a 
compensatory response to the prevalent sclerostin deficiency found in both diseases. 
This response is however insufficient to protect against the excessive bone formation 
characteristic of these disorders. 
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Abstract 
Sclerosteosis is a rare bone dysplasia characterized by greatly increased bone mass, 
especially of the long bones and the skull. Patients are tall, show facial asymmetry 
and often have syndactyly. Clinical complications are due to entrapment of cranial 
nerves. The disease is thought to be due to loss-of-function mutations in the SOST 
gene. The SOST gene product, sclerostin, is secreted by osteocytes and transported 
to the bone surface where it inhibits osteoblastic bone formation by antagonizing 
Wnt signaling. In a small Turkish family with sclerosteosis, we identified a missense 
mutation (c.499T>C; p.Cys167Arg) in exon 2 of the SOST gene. This type of mutation 
has not been previously reported and using different functional approaches, we 
show that it has a devastating effect on the biological function of sclerostin. The 
affected cysteine is the last cysteine residue of the cystine-knot motif and loss of this 
residue leads to retention of the mutant protein in the ER, possibly as a consequence 
of impaired folding. Together with a significant reduced ability to bind to LRP5 and 
inhibit Wnt signaling, the p.Cys167Arg mutation leads to a complete loss of function 




Bone mineral density (BMD) in humans is a quantitative trait determined to a great 
extent by genetic factors [1, 2]. The involvement of genes has been clearly demonstrated 
in patients with sclerosing bone dysplasias, a heterogeneous group of 40 different 
monogenetic diseases associated with increased BMD. One subgroup comprises the 
craniotubular hyperostoses, mainly characterized by increased cortical thickness 
of the long bones and the skull [3, 4]. Sclerosteosis (SCL; MIM# 269500) and Van 
Buchem disease (VBD; MIM# 239100) are two closely related, rare craniotubular 
hyperostoses with an autosomal recessive mode of inheritance. 
Patients with SCL show progressive bone overgrowth and thickening, 
especially of the skull, the mandible and the tubular bones. Patients are tall and 
have facial distortion due to enlargement of the mandible and forehead. Entrapment 
of cranial nerves often results in facial nerve palsy, hearing loss, and loss of smell. 
Calvarial overgrowth leads to elevated intracranial pressure causing headache and 
occasionally sudden death. The majority of patients with SCL have some degree of 
hand malformations, mainly syndactyly. These features are not present in patients 
with VBD and together with tall stature, may allow the clinical differentiation of the 
two conditions [5-8]. Sclerosteosis has a high prevalence in the Afrikaner population 
in South-Africa. In addition, it has been reported in isolated individuals or families 
from Spain, Brazil, the USA, Germany, Japan and Senegal [9-16]. Apart from an 
isolated family in Scotland, patients with VBD are Dutch, originating from an 
isolated community in The Netherlands [17]. Because the Africaner population is 
of Dutch origin, it was assumed that SCL and VBD were caused by the same genetic 
defect. The mapping of SCL to locus 17q12-21, the region that was also shown to 
contain the gene responsible for VBD, further supported this hypothesis [18, 19]. 
However, genetic analysis revealed that the two conditions have a different genetic 
defect. Through positional cloning, Balemans et al. identified two homozygous 
nonsense mutations (c.372G>A (p.Trp124X); c.376C>T (p.Arg126X)) in a Brazilian 
and an American SCL family, respectively, and a splice site mutation (c.220+3A>T) in 
a Senegalese patient with SCL in the previously unknown SOST gene (MIM# 605740) 
[20]. Simultaneously, Brunkow et al. identified a homozygous nonsense mutation 
(c.70C>T (p.Gln24X)) in affected individuals from South Africa. The nonsense 
mutations lead to premature termination of the protein, while the c.220+3A>T 
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mutation was shown to alter splicing of the SOST gene [21]. In 2005, another splice-
site mutation (c.220+1G>C) in the SOST gene was reported in two affected siblings 
of German origin, putatively disease-causing in the same way as the c.220+3A>T 
mutation [22]. In the Dutch patients diagnosed with VBD no SOST mutation was 
present, but a 52kb deletion downstream of the SOST gene was identified. This deleted 
region harbours an enhancer element that drives the expression of the SOST gene 
explaining the similarities between the two conditions [23, 24]. All of the reported 
mutations in SOST as well as the deletion found in patients with VBD, result in the 
absence of expression of the SOST gene product sclerostin by osteocytes [25, 26]. 
In patients with SCL and VBD, the increase in BMD is due to increased bone 
formation [14, 26-28]. In addition, mouse models with deletion or overexpression of 
the SOST gene as well as in vitro studies of osteoblast proliferation and differentiation, 
matrix mineralization and apoptosis demonstrated that sclerostin has an inhibitory 
action on bone formation [26, 29-32]. Although the precise molecular mechanism of 
action of sclerostin still needs to be elucidated, it has been shown that it antagonizes 
Wingless-Int (Wnt) signaling and binds directly to the first two ß-propellers of low 
density lipoprotein receptor related protein (LRP) 5, but does not compete with the 
binding of Wnt proteins to LRP5/6 receptors [31, 33, 34]. LRP5 is required for the 
transduction of Wnt signals and the first ß-propeller domain of LRP5 is known 
to harbour mutations causing a High Bone Mass (HBM) phenotype [35-37]. This 
condition is also classified among the craniotubular hyperostoses and has an 
autosomal dominant mode of inheritance. For all these LRP5 mutants, binding 
to sclerostin was found to be impaired [38-40]. Furthermore, just like in patients 
with VBD and SCL, the bone thickening is most obvious at the long bones and the 
mandible, favouring a shared pathogenesis with SCL and VBD [41]. 
In this paper, we describe the genetic analysis of a patient with SCL and her 
relatives resulting in the identification of the first missense mutation in the SOST 
gene. This mutation results in the exchange of a cysteine residue of the cystine-knot 
motif of sclerostin for a non-cysteine amino acid, a defect that leads to a complete 
loss of function of sclerostin due to retention of the mutated protein in the ER. 
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Materials and methods 
Mutation analysis 
We analysed both exons of the SOST gene as well as exon 2, 3 and 4 of the 
LRP5 gene that comprise the first ß-propeller domain of the LRP5 protein, in 
which all mutations causing craniotubular hyperostoses cluster. In a first step, 
amplification was performed by GoTaq DNA polymerase-mediated PCR (Promega 
Corporation, Madison, Wisconsin, USA). Primers used to generate fragments 
containing the exons and its exon-intron boundaries of the SOST gene were: 
forward primer (FW) 5’-AGAATTCTCTCCTCCACCC-3’ and reverse primer 
(R) 5’-GTGCTACTGGAAGGTGGC-3’ for exon 1 and FW 5’-CCCCTGCCCT 
GGGTTGC-3’ and R 5’-CTTTCCACCAGCTCTAGAGC-3’ for exon 2. For LRP5, 
exon 2 was amplified using FW 5’-AACTTCCTGACAACGCCTTAGG-3’ and R 
5’-TGCCATTGAGGTTGGCCACC-3’, exon 3 using FW 5’-CGATGGGTGAGA 
TTTTAGGG-3’ and R 5’-TGACGCTGTTCCAAGTTCTG-3’, and exon 4 with FW 
5’-GGGTCAGCAGCAATGACTGTCGG-3’ and R 5’-CCAGAGCATGGGCTT 
CTGCAGG-3’. Amplified fragments were verified by agarose gel electrophoresis and 
compared with the Generuler 100 bp Plus DNA Ladder (Fermentas International Inc, 
Ontario, Canada). Primers and unincorporated deoxyribonucleotide triphosphates 
(dNTPs) were removed using exonuclease I (New England Biolabs, Inc, Ipswich, 
Massachusetts, USA) and calf intestine alkaline phosphatase (CIAP, Roche Applied 
Science, Hoffmann–La Roche AG, Basel, Switzerland). Sequencing was carried 
out directly on purified fragments with the ABI 310 Genetic Analyser (Applied 
Biosystems, Foster City, California, USA), using ABI Prism BigDye Terminator 
Cycle Sequencing Ready Reaction Kit, version 1.1 (Applied Biosystems, Foster City, 
California, USA). The BigDye XTerminator Purification Kit was used as purification 
method for DNA sequencing to remove unincorporated BigDye terminators. 
Expression constructs and in vitro mutagenesis 
Alignment of the human sclerostin protein sequence (GenBank RefSeq 
NM_025237.2) and its homologue in mouse (GenBank RefSeq NM_024449.5) 
showed that c.493T>C (p.Cys165Arg) in mouse corresponds with c.499T>C 
(p.Cys167Arg) in human (nucleotide numbering refers to the cDNA RefSeq 
87
4
First missense mutation in the SOST gene
using the A of the ATG translation initiation codon as nucleotide +1). Using the 
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California), we 
introduced this mutation in a pcDNA3.1 plasmid that produces a secreted form of 
the WT mouse sclerostin with an HA tag at the amino terminus (WT mSost-HA). 
This construct contains the following elements (5’ to 3’): NheI site, IgG kappa light 
chain signal peptide sequence (QTHILLWVLLLWVQGSTGD), HA tag sequence 
(YPYDVPDYA), two linker peptide residues (GA), EcoRI site, mSost lacking 
endogenous signal peptide, termination codon, and XhoI site. Following primers were 
used for in vitro mutagenesis: FW 5’CCTCGTGCAAGCGCAAGCGCC- 3’ and R 
5’-GGTGAGGCGCTTGCGCTTGCA-3’. The complete insert sequence was verified 
for the presence of the mutation and for the absence of PCR introduced errors, using 
FW 5’ACCGAGTTGGTGTGCTCC- 3’ and R 5’-GCACAGCAGCTGCACCC-3’ as 
primers for direct sequencing on plasmid DNA. Although the mouse Sost gene has 
high similarity with the human SOST gene in the affected region, a human SOST 
construct was also used and the p.Cys167Arg mutation was introduced by site-
directed mutagenesis at Genscript, Piscataway, USA. 
The expression construct mouse Wnt1-V5 was kindly provided by Bart Williams 
(Van Andel Research Institute, USA) and Mesdc2 by Bernadette Holdener (State 
University of New York, USA). Both untagged full-length human WT-LRP5 and 
truncated human WT-LRP5 lacking the transmembrane and cytoplasmic domains 
but with a c-myc epitope at the carboxy-terminus were obtained from Matthew 
Warman (Howard Hughes Medical Institute, Orthopaedic Research Laboratories, 
USA). Bert Vogelstein (The Johns Hopkins University School of Medicine, USA) 
provided the Topflash Wnt reporter construct (pGL3-OT) while the BAT-luc Wnt 
reporter construct was provided by Stefano Piccolo (University of Padua School 
of Medicine, Italy). The Renilla luciferase constructs pRL-TK and pRL-SV40 were 
purchased from Promega Corporation. 
Red fluorescent protein (RFP) fusion proteins for WT and MT mouse Sost were 
generated using the above described WT and MT mSost-HA as a template. PCR 
amplification was performed to disrupt the termination codon and the complete 
region of interest was subcloned into a pTurboFP635-N vector (Evrogen JSC, 
Moscow, Russia) to obtain WT and MT mSost-RFP, respectively. A vector encoding 




The human embryonic kidney (HEK) cell line 293T obtained from Danny Huylebroeck 
(University of Leuven, Leuven, Belgium), was grown in DMEM (Gibco- Invitrogen 
Ltd, Paisley, UK) supplemented with FBS (10% v/v). Twenty-four hours prior to 
transfection, HEK293T cells were plated at 4 x 105 cells/well in 6-well plates (Greiner 
Bio-One, Kremsmünster, Austria). Cells were transiently transfected with either WT 
or MT mSost-HA or empty pcDNA3.1 vector (500 ng/well) using FuGENE 6 (Roche 
Applied Science), according to the manufacturer’s instructions. Twenty-four hours 
after transfection, the culture medium was changed to 1 ml serum-free DMEM 
and 48 h after transfection, conditioned medium (CM) was collected and cells were 
lysed with 500 µl radioimmune precipitation (RIPA) buffer per well (50 mM Tris-
HCl pH 8.0; 150 mM NaCl; 1% NP-40; 0.5% Na-deoxycholate; 0.1% SDS; complete 
protease inhibitor cocktail tablet (Roche Applied Science); benzonase endonuclease 
(Merck, Darmstadt, Germany)). Total protein in cell lysates was quantified using a 
bicinchoninic acid (BCA) assay (Pierce, Illinois, USA) with the purpose of loading 
equal protein amounts on SDS-PAGE. CM and cell lysates were diluted in 5x SDS-
PAGE loading buffer and subjected to reducing SDS-PAGE. After transfer to a PVDF 
membrane, sclerostin-HA was detected using a rabbit polyclonal HA antibody 
(1:2000; BD Biosciences, San Diego, CA). Equal protein loading for lysate fractions 
was verified with a mouse ß-actin antibody (1:5000; Sigma-Aldrich, St. Louis, MO). 
Secondary incubation was performed using a goat anti-rabbit IgG-HRP (1:10000; 
Biorad) and a sheep anti-mouse IgG-HRP (1:5000; Amersham Biosciences), 
respectively, for 2 h at room temperature. Chemiluminescence detection was carried 
out using the Enhanced Chemiluminescence (ECL) Western Blotting Substrate 
(Pierce) according to the manufacturer’s instructions. 
Electrochemiluminescence assay by Meso-Scale Discovery
HEK293T cells and Saos-2 human sarcoma cells (ATCC) were grown in DMEM 
supplemented with FBS (10% v/v). Twenty-four hours prior to transfection, HEK293T 
and Saos-2 cells were plated at 1.3 x 105 and 4.5 x 104 cells/well in 24-well plates 
(Greiner Bio-One), respectively. Cells were transfected with WT and MT constructs 
of both mouse and human Sost/SOST or a control plasmid (empty pcDNA3.1). After 
24h, medium was replaced and after further incubation for 24 h, CM was collected 
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and cells were lysed with 250 µl Meso-Scale Discovery (MSD, Gaithersburg, MD, 
USA) lysis buffer per well (20 mM Tris-HCl pH 7.5; 150 mM NaCl; 1 mM EDTA; 1 mM 
EGTA; 1% Triton X-100; complete protease inhibitor cocktail tablet (Roche Applied 
Science); 10 mM NaF) or total RNA was isolated for RT-PCR analysis. Sclerostin 
levels in CM and cell lysates were determined using the 96-well MULTI-ARRAY® 
human sclerostin assay (MSD) according to the manufacturer’s instructions and 
corrected for SOST mRNA expression as determined by RT-PCR analysis. 
Co-localisation studies using confocal live cell imaging 
HEK293T and Saos-2 cells were grown in DMEM supplemented with FBS (10% 
v/v). Twenty-four hours prior to transfection, cells were plated at low-density 
(0.5 x 105   cells/well) in 24-well plates (Greiner Bio-One). Both cell types were 
transfected with WT or MT mSost-RFP plasmid DNA, or with the ter-mSost-RFP 
as an empty control (200  ng). FuGENE 6 (Roche Applied Science) was used for 
transfection; FuGENE 6 reagent: DNA ratio was slightly higher for Saos-2 cells (4:1) 
than for HEK293T cells (6:1). Twenty-four hours after transfection, medium was 
removed and cells were rinsed with 1x Hanks balanced salt solution (HBSS) (Gibco 
Invitrogen Ltd). In addition, staining with a green fluorescent tracer for live-cell 
ER labeling (ER-Tracker™ Green (glibenclamide BODIPY® FL); Molecular Probes 
Invitrogen Ltd) was performed. Cells were incubated for 20 min at 37°C after adding 
1 µM ER-Tracker™ Green staining solution. Subsequently, the staining solution was 
replaced by probe-free medium and cells were imaged using an inverted microscope 
(Zeiss Axiovert 200; Carl Zeiss, Jena, Germany) attached to a microlensenhanced 
dual spinning disk confocal system (UltraVIEW ERS, PerkinElmer, Seer Green, 
UK), equipped with a three-line (488, 568 and 647 nm) argon–krypton laser. Red 
fluorescent fusion proteins (excitation maximum (ex max): 553  nm; emission 
maximum (em max): 574 nm) were excited by the 568 nm line while the green ER stain 
(ex max: 504 nm; em max: 511 nm) was excited by the 488 nm line. Fluorescence was 
recorded using 527/55 nm and 615/70 nm band pass filters, respectively. Multicolor 
high-resolution time-lapse images (4 images/s) of the living cells were captured over 




Wnt activity reporter assays 
Saos-2 cells were grown in DMEM supplemented with FBS (10% v/v). Twenty-four 
hours prior to transfection, cells were plated at 1.25 x 105 cells/well in 24-well plates 
and at 6.75 x 103 cells/well in 96-well plates (Greiner Bio-One) for stimulation with 
Wnt1-V5 and recombinant Wnt3A (rec Wnt3A), respectively. Cells were transfected 
using FuGENE 6 or FuGENE HD (Roche Applied Science), respectively, according 
to the manufacturer’s instructions. For stimulation with Wnt1-V5 (100 ng/well), 
cells were co-transfected with Mesdc2 (20 ng/well), pGL3-OT reporter (100 ng/
well) and untagged full length WT-LRP5 (20 ng/well) in the presence or absence 
of WT or MT mSost-HA (40 ng/well). For stimulation with rec Wnt3A, cells were 
transfected with untagged full length WTLRP5 (40 ng/well) and BAT-luc (20 ng/
well) and stimulated with 30 ng/ml rec Wnt3A, 24h after the transfection. When 
necessary, empty pcDNA3.1 vector was added to make the total DNA amount equal 
for all transfection experiments. The Renilla luciferase constructs pRL-TK and 
pRL-SV40 were co-transfected to correct for transfection efficiency of Wnt1-V5 and 
rec Wnt3A, respectively. Forty-eight hours after transfection, cells were lysed using 
100 µl passive lysis buffer (Promega Corporation). Firefly and Renilla luciferase 
activity were measured using the dual-luciferase reporter assay system (Promega 
Corporation) according to manufacturer’s instructions. 
Co-immunoprecipitation 
Conditioned media and cell lysates containing WT or MT-sclerostin-HA were 
obtained as described above. In case of LRP5, HEK293T cells were co-transfected 
with truncated human WT-LRP5-myc (1 µg) and, in equal amounts, Mesdc2. 
Proper expression of LRP5-myc protein in CM was evaluated by immunoblotting 
with c-myc antibodies (clone 9E10; Sigma-Aldrich; dilution 1:5000). Rabbit 
polyclonal HA antibody was used to verify the presence of WT and MT sclerostin-
HA in CM or total cell lysates. Equal protein loading for lysate fractions was verified 
using ß-actin antibodies. Based on these results, sclerostin-containing CM or total 
cell lysates were diluted more in the co-immunoprecipitation (co-IP) reactions 
than LRP5-containing CM. Co-IP between sclerostin and LRP5 was carried out 
by mixing CM containing truncated WT-LRP5-myc with CM containing WT-
sclerostin-HA or cell lysates containing MT-sclerostin-HA, respectively. For the co-
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IP reactions, EZ-view™ Red Anti-HA affinity gel (Sigma-Aldrich) was pre-blocked 
for 1h with 3% BSA (Sigma-Aldrich) in 1x TBS buffer (pH7.8) at 4°C using a rotation 
shaker. Hundred µl of CM containing WT-sclerostin-HA or cell lysates containing 
MTsclerostin-HA was mixed with equivalent amounts of secreted LRP5 (total CM 
volume of 250 µl), together with 45 µl of pre-blocked EZ-view™ Red Anti-HA affinity 
gel. The final volume was adjusted to 1 ml with 1x TBS, and incubated for 4h at 4°C 
using a rotation shaker. To remove unbound proteins, the affinity gel was washed at 
4°C in wash buffer (50 mM Tris-HCl pH7.5; 150 mM NaCl; 0.1% Triton-X100) for 5 
min, and then pelleted. Protein complexes were eluted by resuspending the pellets 
in 1x PBS buffer containing 100 µg/ml HA-peptide (Sigma- Aldrich). After 15 min 
incubation at room temperature, supernatants were collected and stored for SDS-
PAGE. To serve as a positive control for binding to the affinity column, IP was also 
performed by adding a comparable volume of CM containing WT-sclerostin-HA, 
or cell lysates containing MT-sclerostin-HA to the preblocked EZ- view™ Red Anti-
HA affinity gel. In the same way, a comparable volume of CM containing truncated 
WT-LRP5myc not expressing the HA-tag, was used as a negative control for IP on 
an anti-HA affinity gel. Following transfer to PVDF, LRP5-myc and sclerostin-HA 
were incubated with anti-c-myc and anti-HA, respectively. Subsequently, LRP5-myc 
and ß-actin proteins were incubated with secondary anti-mouse IgG-HRP for 2h 
at room temperature; sclerostin-HA with a secondary goat anti-rabbit IgG-HRP. 
Chemiluminescence detection was carried as described above. 
Statistical analysis 
Data are expressed as mean values ± SD. Comparisons between two or more 
measurements for a single experiment were performed using a Student’s t-test and 
one-way ANOVA, respectively. For a set of experiments, general linear model (GLM) 
was used. Values of p<0.05 were considered significant. In case of post hoc multiple 
comparisons, Bonferroni was used. All statistical tests were provided by the SPSS 
15.0 software package (SPSS Inc.). 
Modeling of MT sclerostin 
Modeling of the effect of the mutation was based on the NMR structure of mouse 
sclerostin (PDB entry 2KD3). The coordinates comprising the residues Asn59 to 
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Arg167 of mouse sclerostin (corresponding to residues Asn61 to Arg169 of human 
sclerostin) were used for the analysis. After adapting the numbering to human 
sclerostin residue Cys167 was replaced by arginine using the protein modeling tools 
of the software package Quanta2006 (Accelrys Inc, San Diego). Due to the previous 
amino acid Cys167 being involved in a disulfide bond with residue Cys109 and the 
resulting steric clash with the large side chain of the Arg167 introduced, the side 
chain was manually reoriented such that the side chain of Arg167 pointed towards 
the solvent requiring changes in the backbone conformation of the lower part of the 
flexible loop (starting from residue Gly110). The structure was subsequently refined by 
energy minimization runs; only geometrical energy terms without any electrostatic 
contribution were employed. Analysis of the resulting structure of MT sclerostin 
showed comparable statistics for backbone torsion angle distribution and van der 
Waals contacts. To test whether the replacement of Cys167 into Arg167 influences 
the flexibility of the loop, which has been proposed to contain the binding epitope of 
sclerostin for LRP5, molecular dynamics (MD) simulation runs were performed with 
or without NMR distance restraints derived for WT mouse sclerostin. All dynamics 
simulations were done using the software package Quanta2006 and the force field 
CHARMM22 without electrostatic energy terms (Accelsrys Inc, San Diego), the 
non-bonded cut-off for van der Waals interactions was set to 10.5Å, the temperature 
of the bath was kept at 300K to allow for sufficient mobility of the atoms. 
Results 
Clinical description 
A 28-year old Turkish woman from a consanguineous marriage was recognized 
with clinical features suggestive of SCL (Figure 1A) and HBM during investigation 
of a multinodular goitre. She suffered from recurrent facial nerve palsies at the ages 
of 9, 14 and 15 years, complained of severe headaches, and had bilateral mixed-type 
hearing loss and right visual loss. Her height was 190 cm, weight 76 kg and head 
circumference 66.5 cm. The skull and jaw were enlarged, and she had proptosis and 
high arched palate. No syndactyly or other hand malformations were observed. 
Skull radiographs showed thickening of the calvarium (Figure 1B-C), an enlarged 
mandible and a highly increased BMD (T-score: spine +10.6, femoral neck +9.6). 
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Endocrinological investigations revealed no abnormalities except for thyroid 
function compatible with subclinical hyperthyroidism. Her 35-year-old brother 
showed a similar phenotype with a rather uniform sclerosis of the skull, a thickened 
calvarium and an enlarged mandible, which can be noticed from the radiographs 
(Figure 1D-E). This patient also was of tall stature (190 cm), had a large head (head 
circumference: 66 cm) and a highly increased BMD (T-score: spine +9.8, femoral 
neck +7.3). Similar to his sister, he had no syndactyly or other hand malformations. 
Information on the presence of additional clinical symptoms was lacking. Other 
family members were phenotypically normal. 
Mutation analysis 
Because mutations in LRP5 and SOST are known to be causal for craniotubular 
hyperostoses, we evidently included both genes in the mutation screening of the 
patient. Direct sequencing of the LRP5 gene revealed no mutations in the coding 






Figure 1. A) Lateral view of the female patient’s face showing a marked mandibular prognathism. B) Plain 
radiograph of the skull (lateral view) showing uniform sclerosis of the calvaria, skull base and facial bones 
(particularly the mandible). C) Axial CT-scan of the brain showing marked thickening of the cranial vault. D) 
Lateral view of the face of the female’s brother, who also shows a marked mandibular prognathism. E) Plain 
radiograph of the skull (lateral view) of the brother, showing uniform sclerosis of the skull and the mandible.
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c.499T>C (p.Cys167Arg) mutation in exon 2 of the SOST gene (nucleotide numbering 
refers to the cDNA RefSeq using the A of the ATG translation initiation codon as 
nucleotide +1) (data not shown). To investigate whether the mutation segregated 
with the disease, additional family members were recruited and sequenced. This 
resulted in the identification of the same homozygous missense mutation in an 
affected brother. Both unaffected parents and an unaffected sibling were found 
to be heterozygous carriers. Eighty unrelated healthy control individuals (160 
chromosomes) from Turkish origin were checked for the presence of this mutation 
and all turned out to be negative.
Decreased intracellular and extracellular levels of MT 
sclerostin 
Since sclerostin is a secreted protein, we initially tested the intra- and extracellular 
presence of the mutated protein by transient transfection of HEK293T cells with 
WT and MT mouse Sost-HA plasmids. Transfection with a negative control plasmid 
(empty pcDNA3.1) was also included. All transfection efficiencies were similar as 
measured by ß-galactosidase activity (data not shown). By immunoblotting, both 
WT and MT sclerostin were detected in the cell lysates, indicating that the MT 
protein was formed and recognized by the HA antibody. Moreover, the increased 
presence of MT sclerostin in the cell lysate suggested an upregulation of expression 
of the functionally inactive MT sclerostin. In CM, only WT sclerostin was present 
(Supplementary Figure 1A). 
To further investigate the effect of the mutation on intra- and extracellular 
levels of sclerostin, a quantitative electrochemiluminescence assay was used to 
measure the concentration of WT and MT mouse sclerostin in HEK293T cells 
(Supplementary Figure 1B-C) and Saos-2 cells (data not shown). In addition, human 
SOST plasmids with or without the mutation were tested in both cell lines. After 
correction for SOST mRNA, both the intra- and extracellular levels of mouse and 
human MT sclerostin were lower than those of WT sclerostin. The levels of human 
sclerostin were consistently higher than those of mouse sclerostin, which may be due 
to differences in expression efficiency of the plasmids and/or the sensitivity of the 
assay to mouse and human sclerostin. 
95
4
First missense mutation in the SOST gene
Figure 2. Retention of MT sclerostin in the ER. A-B. HEK293T (A) and Saos-2 cells (B) were transiently transfected 
with WT SOST-RFP plasmid to study the subcellular localization of WT mouse sclerostin (red channel). ER stai-
ning was performed using a green fluorescent ER tracker (green channel). Living cells were viewed using an Ultra-
VIEW dual spinning disk confocal system. Arrows indicate the presence of WT sclerostin in variably sized granular 
cytoplasmic structures, preferentially in areas close to the cell membrane. The ER networks typically showed the 
highest density around the nucleus. Merging of the red and green channels clearly revealed that both labels are not 
co-localized. The latter was most obvious in the many cytoplasmic processes of Saos-2 cells. C-D. Similar to Figure 4 
A-B, but now HEK293T (C) and Saos-2 cells (D) were transfected with MT SOST-RFP. The orange/yellow color in 
the merged channel images revealed a major co-localization of MT SOST protein with the ER tracker in both cell 







Retention of MT sclerostin in the ER 
As no previous intracellular localization studies had been reported for sclerostin, we 
hypothesized that, similar to other newly synthesized secreted proteins, it should be 
produced in the ER from where it is further targeted into the secretory pathway via 
the Golgi apparatus and cytoplasmic secretory granules. Mutations in proteins often 
lead to misfolding and subsequent retention in the ER [42]. To study the effect of the 
mutation on the subcellular localization of sclerostin in HEK293T and Saos-2 cells, 
we generated RFP fusion proteins for both WT and MT sclerostin, and the ER was 
visualized using a green fluorescent ER tracker. By confocal live-cell imaging, we 
found that the presence of WT sclerostin was concentrated in granular cytoplasmic 
structures, indicative of secretory granules (Figure 2A-B). The granular staining was 
most prominent in areas close to the cell membrane and hardly co-localized with 
the green fluorescent ER tracker, for which the staining was seen as a rather uniform 
network around the nucleus. The staining pattern of the MT sclerostin-RFP fusion 
protein was more diffuse and appeared to predominantly co-localize with the ER 
tracker (Figure 2C-D). 
Decreased antagonistic activity of MT sclerostin 
The effect of the mutation on the antagonistic capacity of sclerostin on Wnt signaling 
was tested in Saos-2 cells. Cells were transfected with a Wnt reporter construct and 
stimulated with either a Wnt1 expression plasmid or rec Wnt3a. Transfection of 
Wnt1 alone resulted in a 2-fold enhancement of Wnt signaling (Figure 3A). However, 
when the Wnt1 plasmid was co-transfected with an LRP5 expression plasmid, a 13-
fold increase in Wnt signaling was observed. Wild type mSost plasmid significantly 
inhibited Wnt1-stimulated Wnt signaling to almost 50% of its original level 
(p= 0,007), whereas the MT mSost plasmid could only induce a non-significant 20% 
reduction. Stimulation with rec Wnt3a resulted in an almost 20-fold increase in Wnt 
signaling (Figure 3B). Both mouse and human WT Sost/SOST plasmids significantly 
inhibited Wnt signaling, and the human SOST plasmid seemed to be more potent. 
Both MT Sost/SOST plasmids did not inhibit rec Wnt3a-induced signaling. 
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Figure 3. Decreased level of Wnt signal transduction both in the presence of human and mouse MT sclerostin. 
A) Saos-2 cells were transiently transfected with pGL3-OT, pRL-TK, Mesdc2, untagged full length WT-LRP5 in 
the presence or absence of Wnt1-V5. The antagonistic activity on Wnt signaling was evaluated by co-transfecting 
either WT or MT mSOST. Data were generated in three independent experiments, each performed in triplicate. 
Bars represent mean values ± SD. * p<0.05 cells transfected with WT mSOST compared to cells transfected without 
WT mSOST. B) Saos-2 cells were transfected with untagged full length WT-LRP5 and BAT-luc with or without 
mouse and human WT or MT SOST expression vectors and stimulated with rec Wnt3a 24h after transfection 
(n=8). Bars represent mean values ± SD. * p<0.05 cells transfected with mouse or human WT SOST compared 
to cells transfected without mouse or human WT SOST. All data were corrected for differences in transfection 





Impaired binding of MT sclerostin to LRP5 
Co-IP experiments were performed to evaluate the effect of the mutation on the 
ability of sclerostin to interact with LRP5. HEK293 cells were transfected with 
constructs either expressing truncated LRP5-myc (encoding only the extracellular 
part of the protein), WT-sclerostin-HA, or MT-sclerostin-HA. Figure 4A illustrates 
that truncated LRP5-myc and WT-sclerostin-HA were expressed in the CM, while 
MT-sclerostin-HA was found exclusively in the cell lysate (Figure 4A). Subsequently, 
CM of the truncated LRP5-myc transfected cells was mixed with either CM of WT-
sclerostin-HA transfected cells or cell lysates of MT-sclerostin-HA transfected cells to 
determine binding between the extracellular part of LPR5 and WT- en MT-sclerostin. 
From the immune complexes, HA-tagged WT- and MT-sclerostin were precipitated 
using EZ-view™ Red Anti-HA affinity gel and immunoblotted with c-myc antibodies 
to demonstrate co-IP of truncated LRP5-myc with WT- or MT-sclerostin-HA. 
Truncated LRP5-myc was detected in precipitates that contained WT-sclerostin-
HA, but not in precipitates that contained MT-sclerostin-HA, suggesting that the 
mutation in sclerostin resulted in a reduced affinity for LRP5 (Figure 4B). The 
immune complexes were also immunoblotted with anti-HA to demonstrate the 
presence of either WT- or MTsclerostin-HA in all samples (Figure 4B). 
Figure 4. Impaired binding of MT sclerostin to LRP5. A) Total cell lysates and CM from HEK293T cells transfected 
with WT or MT SOST were analyzed for the expression of HA-tagged sclerostin by immunoblotting using HA 
antibodies. Expression of LRP5-myc protein in CM was evaluated by immunoblotting with cmyc antibodies. A 
negative control (empty pcDNA3.1) was included in both immunoblotting experiments. Equal protein loading 
was confirmed by immunoblotting of total cell lysates for ß-actin. B) Mixtures of CM containing truncated WT-
LRP5-myc and either CM containing WT-sclerostin-HA (lane 4) or cell lysates containing MT-sclerostin-HA 
(lane 5) were immunoprecipitated using EZ-view™ Red Anti-HA affinity gels. Cells that were transfected only with 
LRP5myc (lane 1) or WT and MT SOST-HA expression vectors (lane 2-3) were used as controls. Immunodetection 
of HA-immunoprecipitated protein was performed with both anti-HA and anti-myc. From lane 4 and 5 it is clear 




First missense mutation in the SOST gene
Discussion 
The clinical and radiological features of patients with SCL are thought to be due to 
complete absence of sclerostin resulting from loss-of-function mutations in the SOST 
gene. These include both nonsense mutations and splice site mutations [20-22]. In 
this study, we found for the first time a missense mutation in the SOST gene causing 
a cysteine to arginine amino acid substitution at position 167. The pathogenicity of 
this genetic variant was demonstrated by the cosegregation of the mutation with 
the disease in the, albeit small, Turkish family and the absence of the variant in 160 
chromosomes of 80 control subjects of a matched ethnic background. 
The nature of the mutation is strongly indicative for a pathogenic mutation, 
since the amino acid substitution results in the loss of a cysteine residue. Alignment of 
homologous cDNA and protein sequences using CLUSTALW (http://www.ebi.ac.uk/
Tools/clustalw2/index.html) showed that the affected cysteine is highly conserved in 
multiple species (data not shown). Moreover, this cysteine is the last of six cysteines 
forming the characteristic cystine-knot motif (residues 80-167) [43]. Furthermore, 
the cysteine to arginine substitution implies a change from an uncharged polar 
amino acid into a basic amino acid. We tested the putative consequences of this 
substitution in several software programs, such as Polyphen and SIFT [44, 45]. 
These programs sort intolerant from tolerant amino acid substitutions, principally 
on the basis of sequence-homology. Polyphen also includes a search for structural 
parameters to predict whether an amino acid substitution in a protein has a possible 
phenotypic effect. According to both programs, the mutation is damaging with a 
high probability. 
Cysteine residues are characterized by thiol-groups that can form disulfide 
bonds, covalent crosslinks between cysteine side chains that play an important role 
in the rate and efficiency of protein folding and most importantly in the stability 
of folded proteins. Some disulfide bonds have been shown to be indispensable for 
efficient secretion by promoting the production of more compact folded intermediates 
[46]. Removal of disulfides by site-directed mutagenesis has been demonstrated to be 
sufficient to cause misfolding, aggregation and impaired secretion of several proteins 
[47-53]. 
With regard to the p.Cys167Arg mutation in the SOST gene, we used NMR 
structure analysis of mouse sclerostin to predict the possible influence on the 
100
Chapter 4
sclerostin fold. Due to the architecture of the cystine-knot motif three peptide loops 
emanate from the cystine-knot, two of which run in the same direction (and form 
the so-called Finger 1 and 2), whereas the third emanates into the opposite direction. 
Finger 1 and 2 of the WT sclerostin are well defined forming two two-stranded 
anti-parallel ß-sheets, whereas the third loop is highly flexible and disordered 
(Supplementary Figure 2A) [54, 55]. A zoom into the cystine-knot motif showed 
that it is rather loosely packed, with amino acid residues between the cysteine 
residues pointing towards the solvent, indicating that the cystine-knot of sclerostin 
exhibits partly elevated flexibility (Supplementary  Figure 2B). Simulations in silico 
suggested that mutating cysteine 167 (equivalent to cysteine 142 of the mature 
protein) to arginine not only disrupts the outer disulfide bond present in the cystine-
knot motif (Supplementary Figure 2C) but also requires conformational changes 
of the lower loop segment due to the increased spatial requirements of the larger 
arginine side chain. This will lead to global misfolding due to a decreased stability 
of the cystine-knot motif and the presence of an accessible reactive thiol-group 
at the protein surface as one cysteine residue remains unpaired. Even if a global 
misfolding does not occur, the large space requirements of the arginine side chain 
will lead to a further disorder of the loop segment, which has been proposed to be 
important for the activity of sclerostin by mapping the binding site of a neutralizing 
antibody to the tip of the loop segment [54]. Molecular dynamics simulation indeed 
showed a local unfolding of the remaining cysteine network, as the side chain of 
arginine introduced at position 167 (for mature sclerostin residue numbering is not 
accounting for the 25 residue signal peptide: Cys167 corresponds to Cys142) points 
towards the interior of the former cystine-knot requiring an opening of the ring in 
order to avoid steric clashes between the bulky side chain of the introduced arginine 
and surrounding residues like Cys109, Gly107 and Ser106. This rearrangement is 
complemented by conformational changes in the amino terminus, as the former 
packing has to be relieved to create enough space for Arg167. In addition, loss of the 
disulfide bond between Cys109 and Cys167 (now Arg167) enhances conformational 
variability in the loop segment since the few hydrophobic interactions between the 
antiparallel peptide segments of the loop are further weakened. 
This in silico modeling suggests that loss of this crucial cysteine may indeed 
result in impaired folding and hence be responsible for retention of the mutant 
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protein in the ER. This is normally followed by degradation through delivery to 
the 26S proteasome in the cytoplasm or by lysosomal degradation by autophagy. 
The latter mechanism is especially used for misfolded proteins that aggregate 
in the secretory pathway or in the cytosol [56, 57]. Using subcellular localization 
experiments, we were able to show that MT sclerostin indeed does not exit the ER, 
explaining the decreased extracellular levels of MT sclerostin compared to WT found 
by immunoblotting and electrochemiluminescence. In addition, in reporter assays 
MT sclerostin was found to have strongly decreased antagonistic activity on Wnt 
signaling. Using co-IP experiments, we demonstrated that also the binding affinity 
of MT sclerostin for LRP5, which is required for its antagonist activity, is decreased. 
In vivo, these effects resulted in a complete loss of function of sclerostin reflected by a 
phenotype that is highly similar to that of previously reported patients with SCL. In 
the same way, loss-of-function mutations derived from folding problems in a variety 
of proteins with different activities, lead to retention of mutated proteins in the ER 
and their consequent degradation. This mechanism lies at the basis of a large number 
of ER-derived diseases, reviewed by Aridor et al [58]. In addition to this loss-of-
function, increased levels of ER stress, known as unfolded protein response (UPR) 
(i.e. induction of inflammatory responses or cellular apoptosis), due to inability of 
the ER to efficiently dispose of the mutant protein, can contribute substantially to 
disease pathogenesis [58, 59]. It has been reported that strongly secretory cells (and 
maybe also the osteocyte) are extremely susceptible to this UPR, which often results 
in a pathogenic outcome [59]. Since we did not perform experiments to further 
investigate this disease mechanism, our data can not exclude the possibility that this 
mechanism additionally contributes to the phenotype in this family. 
In conclusion, the present work describes here the first missense mutation in 
the SOST gene encoding sclerostin in a patient with SCL. This missense mutation 
involves one of the cysteine residues of the cystine-knot motif of sclerostin. The 
mutation has a devastating effect on the biological function of sclerostin by reducing 
extracellular sclerostin levels as well as the binding capacity of sclerostin to LRP5 
and, thereby, its antagonistic activity on canonical Wnt signaling. It is possible that 
ER stress and UPR, as a consequence of the inability of the ER to efficiently dispose 
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Supplementary Figure 1. Decreased intra- and extracellular levels of MT sclerostin. A) Total cell lysates and 
CM from HEK293T cells transfected with WT or MT SOST or empty vector were analyzed for the expression 
of HA-tagged sclerostin by immunoblotting using an HA antibody. Equal protein loading was confirmed 
by immunoblotting of total cell lysates for ß-actin. One representative experiment of three independent 
immunoblotting experiments is depicted. B) Quantitative expression analysis of sclerostin in cell lysates of 
HEK293T cells transfected with WT and MT constructs of both mouse and human SOST or an empty control 
vector using the MULTI-ARRAY® Human sclerostin assay (MSD). Sclerostin levels were corrected for SOST 






Supplementary Figure 2. Effect of the mutating cysteine 167 to arginine on the NMR structure of sclerostin. A) 
Ribbon representation of the NMR structure ensemble of mouse sclerostin (residues Lys73 to Arg169 is shown, 
residue numbering includes the 25 residue signal peptide, PDB entry 2KD3). The secondary structure elements 
are indicated in yellow (ß-strand), red (a-helix) and green (coil). The overlay of the 15 NMR structures of the 
ensemble shows that finger 1 and 2 are well defined, whereas the loop is highly flexible and disordered. B) Detail 
of the cystine-knot of sclerostin. The cystine-knot is rather loosely packed, with amino acid residues between the 
cysteine residues pointing towards the solvent, indicating that the cystine-knot of sclerostin is flexible in part. 
The cysteine residue, which is mutated in the patient, is colored in magenta, numbering is according to full-length 
sclerostin protein starting with residue 1. C) Same region displayed for MT mouse sclerostin variant. Mutating 










Regulation of SOST mRNA 
expression through 






Regulation of SOST mRNA expression through inhibition of GSK3ß
Abstract
Sclerostin is an important inhibitor of bone formation. When expression of this 
protein is reduced or completely absent, as in patients with Van Buchem disease and 
sclerosteosis, bone mass is dramatically increased. Sclerostin inhibits Wnt signalling 
and can also inhibit downstream effects of BMP such as alkaline phosphatase (ALP) 
activity and matrix mineralisation in vitro. The regulation of sclerostin or SOST, 
the gene encoding sclerostin, is not completely clear. Therefore, we investigated a 
possible feedback mechanism of Wnt signalling on the expression of SOST. Human 
osteosarcoma SaOS-2 cells were treated with different concentrations of Wnt3a 
or a specific GSK3β inhibitor (GIN). Subsequent qRT-PCR analysis showed that 
SOST expression was dose-dependently decreased with increasing Wnt signalling. 
GSK3β inhibition independent of Wnts and Frizzled receptors by GIN strongly 
stimulated Wnt reporter activity and inhibited SOST expression. Several Wnt 
signalling inhibitors, acting either on the binding of Wnt to its receptor, preventing 
the disruption of the Axin/APC/GSK3β complex in the cytoplasm or preventing 
β-catenin binding to the TCF/LEF transcription complex in the nucleus, were 
examined in combination with Wnt3a stimulation or GSK3β inhibition. None of 
these inhibitors could restore SOST expression after GSK3β inhibition. We therefore 
conclude that GSK3β influences SOST expression by a mechanism that is not 




Sclerostin is an important regulator of bone formation. Mutations in the SOST 
gene or the surrounding regulatory regions lead to sclerostin deficiency and bone 
overgrowth in sclerosteosis and Van Buchem disease respectively [1-3]. Sclerostin 
is exclusively expressed in osteocytes in the mineralized matrix and is a marker for 
differentiation of osteoblasts into osteocytes [4]. It has been shown previously that 
sclerostin inhibits canonical Wnt signaling by binding to the LRP5/6 co-receptor 
and thereby preventing the interaction between WNTs and their receptor [4]. WNTs 
are a family of secreted proteins that regulate many developmental processes, for 
example body axis formation, chondrogenesis and limb development [5, 6] and has 
been proven important in bone formation [7]. In the absence of Wnt activation, 
β-catenin is phosphorylated by glycogen synthase kinase 3 β (GSK3β) in a complex 
with axin and adenomatous polyposis coli (APC) and is subsequently degraded. 
When WNTs bind to the Frizzled receptor and LRP5/6 co-receptor, axin is recruited 
to the membrane and the destruction complex is disrupted. Consequently, the 
phosphorylating action of GSK3β is prohibited and β-catenin accumulates in the 
cytoplasm, translocates into the nucleus and activates the transcription of the Wnt 
target genes by binding to the TCF/LEF transcription complex (Figure 1) [8, 9].
Sclerostin is one of several known Wnt signaling inhibitors (Figure 1). Dickkopf-1 
(DKK1) and sclerostin inhibit canonical Wnt signaling in a similar manner by 
binding to the LRP5/6 co-receptor [10, 11]. Apart from endogenous inhibitors, 
many synthetic inhibitors have been developed to inhibit different aspects of the 
Wnt signaling pathway. One of these synthetic molecules is XAV939, a tankyrase 
inhibitor. Tankyrase marks axin for degradation, leading to disruption of the axin/
APC/GSK3β complex. Thus, inhibition of tankyrase leads to accumulation of axin, 
breakdown of β-catenin and inhibition of the Wnt pathway [12]. PNU74654 binds 
to β-catenin, preventing it from binding to the TCF/LEF transcription complex [13].
Even though knowledge on the role of sclerostin in bone biology is ever 
increasing, little is known about the regulation of its expression. Several factors 
have been shown to downregulate SOST, such as PTH [14-16] and mechanical 
loading [17, 18]. Bone Morphogenetic Proteins (BMPs) are known to stimulate 
SOST transcription, and this may in turn inhibit the canonical Wnt pathway [19, 
20]. 1,25-Dihydroxyvitamin  D3 alone or in combination with retinoic acid also 
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increases SOST expression [19, 21]. In addition, several transcription factor binding 
motifs in the SOST promoter have been identified [21], and the ECR5 element has a 
clear function in regulation of SOST expression, as evidenced by patients with Van 
Buchem disease in whom this region is deleted [22]. In this study, we investigated 
a possible feedback mechanism of the Wnt signaling pathway on the expression of 
SOST. 
Materials and Methods
Cells, materials and reagents
The human osteosarcoma cell line SaOS-2 (ATCC, Manassas, VA, USA) and rat 

























Figure 1. Wnt signaling pathway with the different Wnt signaling inhibitors described in this manuscript. 
Dickkopf 1 (DKK1) is an extracellular inhibitor that works in the same way as sclerostin by binding to the LRP5/6 
co-receptor and preventing the interaction with WNTs and the Frizzled receptor. XAV939 is a tankyrase inhibitor. 
Tankyrase marks Axin for degradation, leading to disruption of the Axin/APC/GSK3β complex. Inhibition of 
tankyrase therefore leads to accumulation of Axin, breakdown of β-catenin and inhibition of the canonical Wnt 
signaling pathway. PNU74654 binds to β-catenin itself and thereby prevents interaction with the transcription 
complex and transcription of the Wnt target genes.
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Kremsmünster, Austria) with 4,5 g/L Glutamax Dulbecco’s Modified Eagle Medium 
(Gibco, Carlsbad, CA, USA) supplemented with 10% Fetal Calf Serum (FCS; Greiner 
Bio-One), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco). Recombinant 
BMP4, Wnt3a and DKK1 were purchased from R&D Systems (Minneapolis, MN, 
USA). The specific GSK3β inhibitor 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-
tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-dione (further referred to 
as GIN) was kindly provided by Dr. Rawadi (Prostrakan, France) and previously 
described by Engler et al. and Miclea et al. [23, 24]. The Wnt signaling inhibitors 
XAV939 and PNU74654 were purchased at Sigma (St. Louis, MO, USA). The 
Wnt-responsive luciferase reporter BAT-luc [24, 25] and BMP responsive element 
luciferase reporter BRE-luc [26] have been described previously. 
Luciferase experiments
SaOS-2 cells were seeded in 96-well plates (Greiner Bio-One) at a density of 
22,500 cells/cm2 and cultured overnight to 70-80% confluence. The cells were trans-
fected with BAT-luc or BRE-luc reporter construct and a pGL4-CAG renilla luciferase 
construct using FuGene HD transfection reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. After 24 hours treatment with the 
indicated reagents, luciferase activity was determined using the Dual-Glo Luciferase 
assay system (Promega, Fitchburg, WI, USA) with a SpectraMax L luminometer 
(Molecular Devices, Sunnyvale, CA, USA). Relative luminescence was calculated as 
firefly luciferase/renilla luciferase and expressed as fold change versus control.
Quantitative RT-PCR and primers
Total RNA was isolated from SaOS-2 and UMR106 cells using TriPure Isolation 
Reagent (Roche, Penzberg, Germany) after 24 hours treatment with indicated reagents. 
cDNA was synthesized using M-MLV reverse transcriptase (Promega) according to 
the manufacturer’s instructions. Real-time quantitative PCR was performed using 
the Quantitect SYBRgreen PCR kit (Qiagen, Venlo, the Netherlands) with an iQ5 
PCR cycler (BioRad, Hercules, CA, USA). Primers (Eurogentec, Seraing, Belgium) 
(Table 1) were designed for SOST, and β2 microglobulin was used as an internal 
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Table 1. Primer sequences
Gene Species Forward Reverse
SOST Human 5’-tgctggtacacacagccttc-3’ 5’-gtcacgtagcgggtgaagtg-3’
β2-microglobulin Human 5’-tgctgtctccatgtttgatgtatct-3’ 5’-tctctgctccccacctctaagt-3’
SOST Rat 5’-gagtacccagagcctcctca-3’ 5’-agcacaccaactcggtgac-3’
β2-microglobulin Rat 5’-ccgtcgtgcttgccattcagaaaact-3’ 5’-tgaggtgggtggaactgagacacg-3’
Statistical analysis
Values represent means ± SD. Differences were tested by One-way Analysis of 
Variance (ANOVA) followed by Tukey’s post hoc test using Graphpad Prism 5 
software (La Jolla, CA, USA). Results were considered significant at p < 0.05.
Results
To examine the effect of Wnt signaling on SOST expression, human SaOS-2 cells 
were incubated with different concentrations of Wnt3a and the GSK3β inhibitor 
GIN. There was a dose-dependent increase of luciferase activity of the Wnt reporter 
BAT-luc after Wnt3a stimulation (Figure 2A). SOST expression decreased dose-
dependently after stimulation with Wnt3a (Figure 2B). GIN was more potent than 
Wnt3a in inducing BAT-luc activation, showing an induction of more than 400 fold 
compared to the control (Figure 2C). Inhibition of GSK3β with GIN resulted in a 
marked and dose-dependent decrease in SOST expression (Figure 2D). Interestingly, 
at a concentration of 3 x 10-9M, GIN had no effect on BAT-luc activity, while SOST 
expression was decreased. The effect of GIN was also investigated in UMR106 cells 
(data not shown). A marked decrease (74%) in SOST expression was seen, indicating 
that the effect is not cell-specific. 
Subsequently, we tested the hypothesis that the observed downregulation of 
SOST expression observed after stimulation of the Wnt signaling pathway was a 
direct effect of Wnt/β-catenin signaling. Therefore three inhibitors of the Wnt 
signaling pathway were tested for their ability to counteract the effect of GIN on SOST 
expression. As expected, the extracellular inhibitor DKK1 could not inhibit Wnt 
signaling after stimulation with GIN (Figure 3A). While XAV939 and PNU74654 
significantly inhibited BAT-luc reporter activity, neither of these inhibitors was able 




Wnt/β-catenin or canonical Wnt signaling regulates many developmental processes, 
for example body axis formation, chondrogenesis and limb development [5, 6]. In 
bone, canonical Wnt signaling regulates the expression of several transcription 
factors that are essential to osteoblast differentiation such as Runx2 and Osterix [28, 
29]. The signaling pathway is mediated by GSK3β, a serine/threonine kinase that 
phosphorylates β-catenin to mark it for degradation. Inhibition of GSK3β leads to 
accumulation of β-catenin, which is translocated to the nucleus and activates target 
gene transcription. 
In the current study it was shown that inhibition of GSK3β via the Wnt pathway 






Figure 2. Wnt reporter BAT-luc activity and SOST expression after stimulation with WNT3a or GIN. SaOS-2 cells 
were transfected with the Wnt reporter construct BAT-luc and were stimulated with the indicated concentrations 
for 24 hours. Luciferase (n = 6) and SOST expression (n = 3) were measured. BAT-luc activity increased (A), while 
SOST expression decreased (B) dose-dependently with WNT3a stimulation in SaOS-2 cells. GIN was more potent 
in BAT-luc activation (C) and strongly decreased SOST expression in SaOS-2 cells in a dose-dependent manner (D). 
Compared to control: * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 3. Wnt reporter BAT-luc activity and SOST expression after incubation with GIN and different Wnt 
signaling inhibitors. A) Wnt reporter BAT-luc activity in SaOS-2 cells after stimulation with GIN (n = 6). The 
extracellular inhibitor DKK1 could not inhibit GIN-induced BAT-luc activity. Both XAV939 and PNU74654 
significantly inhibited BAT-luc activity. B) RNA from SaOS-2 cells was isolated after 24 hours incubation with 
GIN and inhibitors (n = 3). None of the inhibitors could restore SOST expression to control levels.
Compared to control: ** p < 0.01, *** p < 0.001. Compared to GIN control: ### p < 0.001.
Wnt signaling inhibitor SOST. However, this did not appear to be a direct effect 
as SOST expression was decreased at a concentration of GIN where no increase in 
BAT-luc activity was seen. In addition, the β-catenin binding inhibitor PNU74654 
was unable to restore SOST expression after treatment with GIN. Downregulation 
of SOST therefore appears to be mediated by GSK3β, independent of β-catenin. 
However, even though GIN was thoroughly screened for selectivity against a panel 
of kinases [23], future experiments need to confirm the role of GSK3β. Inhibition 
of GSK3β using other synthetic inhibitors or an siRNA could for example exclude 
cross-reactivity or off-target effects of GIN. In addition, transfection of a construct 
containing a mutated GSK3β that is insensitive to GIN would, in theory, abolish the 
effect of GIN on SOST expression. 
Looking at the regulatory pathway involved in the downregulation of SOST, 
canonical Wnt signaling seems the most plausible option because of its clear 
connection to regulation of bone cells. However, as shown in this study, the effect 
on SOST was not dependent on β-catenin and therefore ruled out canonical Wnt 
signaling. GSK3β is involved in other pathways like insulin and growth factor 
signaling [29], and has been suggested to influence Runx2 and Smad1 activity in 
bone [30, 31]. The transcription factor Runx2 is a good candidate for SOST regulation 
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considering the known binding site for Runx2 in the SOST promoter [21]. Kugimiya 
et al. [32] showed enhanced transcriptional activity of Runx2 in heterozygous 
GSK3β-deficient mice, and a consequent increased bone formation. As sclerostin 
inhibits bone formation this may have been at least partly mediated by a decrease 
in sclerostin, but unfortunately expression of this protein was not measured in the 
GSK3β+/- mice. SOST promoter studies by Yu et al. revealed an inhibitory effect of 
Runx2 on SOST expression [33]. Conversely, decreased SOST expression was found 
by Sevetson et al. when the Runx2 binding site was deleted from the SOST promoter, 
suggesting a stimulatory effect of Runx2 [21]. This difference is difficult to explain, 
especially since the studies by both Sevetson and Yu et al. were, like the current 
study, performed in SaOS-2 cells. 
BMPs also play an important role in the regulation of bone cells. They induce 
osteoblast differentiation and are essential to bone development in embryos [7]. It has 
been shown previously that BMPs upregulate SOST expression [19, 20] via an indirect 
mechanism, not direct effects on the promoter or ECR5 element [33]. Interplay 
between GSK3β and BMP signaling may therefore underlie the downregulation seen 
in the current study. Fuentealba et al. [34] described a mechanism in which MAPK 
and GSK3β phosphorylations prime Smad1 for ubiquitination and degradation. 
With this mechanism GSK3β controls the duration of Smad1 activation [35]. A 
similar mechanism may be true for Smad 6 and 7, which have been shown to inhibit 
SOST promoter activity [33]. 
Regulation of SOST by GSK3β may have interesting clinical applications. 
Inhibition of GSK3β would increase osteoblast differentiation through induction of 
the Wnt/β-catenin pathway, while it reduces expression of the main Wnt inhibitor 
sclerostin. This could support fracture healing or increase bone formation in 
patients with osteoporosis using GSK3β inhibitors already available. It is clear that 
further investigation is necessary as the results presented here may only apply to 
certain differentiation states or cell types. In addition, only SOST mRNA levels were 
measured in this study and these may not be accurately reflecting sclerostin protein 
production and therefore effects in the cell [33]. 
In conclusion, this study showed the existence of a new regulatory pathway 
for expression of SOST, which is mediated by GSK3β but independent of β-catenin. 
Future research will need to identify the other elements in this pathway and the way 
it interacts with other pathways during bone metabolism.  
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Antisense oligonucleotide-mediated modulation of SOST and Rank expression
Abstract
Osteoporosis is characterized by low bone mineral density and a loss of trabecular 
connectivity, leading to bone fragility and increased fracture risk. Sclerostin, the 
product of the SOST gene, is an important negative regulator of bone formation with 
a restricted expression pattern specifically in osteocytes. It is therefore regarded as a 
good target for new anabolic treatments for osteoporosis. Since sclerostin is a natural 
inhibitor of bone formation, inhibition of sclerostin function or downregulation of 
SOST expression will lead to increased bone formation as is seen in patients with 
sclerosteosis and Van Buchem disease. Another interesting target is the receptor 
activator of nuclear factor-κB (RANK), which is the key activator for osteoclast 
differentiation. Blocking RANK or its ligand RANKL will therefore lead to a decrease 
in bone resorption. 
Here we investigated antisense oligonucleotide-(AON) mediated exon skipping 
as a means of modulating expression of these targets and thereby influencing bone 
formation or resorption. 
As SOST is a 2 exon gene, only qRT-PCR analysis could be used to assess 
efficacy of AONs. Several control AONs and AONs targeting SOST were examined 
and results showed widely varying SOST expression after transfection, and several 
AONs even increased expression of SOST. SOST expression was not decreased with 
any of the tested AONs compared to untransfected control cells. Exon skipping of 
Rank exon 6 was shown, with a maximum of 10.5% skip, and minimal skipping 
efficiency of exon 5 and 7. These levels were too low to be expected to have biological 
significance. 
In conclusion, we have not been able to show substantial exon skipping activity 
in either of the targets. Skipping efficiency of Rank may be further optimized to 




Osteoporosis is characterized by low bone mineral density and a loss of trabecular 
connectivity, leading to bone fragility and increased fracture risk [1]. Prevalence is 
highest among post-menopausal women, as the loss of estrogen production causes an 
imbalance in formation and resorption of the bone [2]. The socioeconomic burden 
of osteoporosis is growing in the ageing society due to the morbidity and mortality 
associated with fractures [3]. Most current therapies decrease the risk of fractures by 
reducing bone resorption, but cannot stimulate bone formation (with the exception 
of parathyroid hormone (PTH)) [4]. These therapies, therefore, are not able to rebuild 
the bone that is already lost. In addition, adherence of patients to current therapies 
such as bisphosphonates is poor and therapy is therefore not always effective [5, 6]. 
The discovery of regulatory pathways in bone metabolism has revealed new targets 
for the treatment of osteoporosis. For example, the Wnt/Low-density lipoprotein 
receptor-related protein 5 (LRP5) pathway is important in osteoblast differentiation 
and therefore has a great influence on bone formation, and the system containing 
Receptor Activator of Nuclear factor Kappa-B (RANK), RANK ligand (RANKL) 
and Osteoprotegerin (OPG) is the key regulator of osteoclast formation and bone 
resorption. 
Targeting Wnt signaling
Wnt proteins belong to a family of secreted proteins that regulate many developmental 
processes, for example body axis formation, chondrogenesis and limb development 
[7, 8] and have an important role in the regulation of osteoblast differentiation [9]. 
When Wnts bind to the Frizzled receptor and its co-receptor LRP5/6, this triggers 
the disruption of the complex containing Axin, Adenomatous Polyposis Coli (APC) 
and Glycogen Synthase Kinase 3 beta (GSK3β) that marks β-catenin for degradation. 
Consequently, β-catenin translocates to the nucleus and activates the transcription 
of the Wnt target genes [10, 11]. Sclerostin is an extracellular inhibitor of canonical 
Wnt signaling and inhibits this process by binding to LRP5/6. While it does not 
compete with WNTs for binding, sclerostin prevents the co-receptor’s interaction 
with WNTs and the Frizzled receptor [12]. 
Sclerostin is exclusively expressed in osteocytes in the mineralized matrix and 
is a marker for differentiation of osteoblasts into osteocytes [13]. Mutations in the 
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SOST gene or its surrounding regulatory regions lead to sclerostin deficiency and 
the massive bone overgrowth seen in sclerosteosis and Van Buchem disease [14-19]. 
Due to its restricted expression pattern, sclerostin is considered a good target for 
the development of new therapies for osteoporosis [4, 20]. There is evidence that 
the beneficial effect of PTH, the only therapy currently in the clinic that is capable 
of increasing bone mass, is mediated at least in part by a decrease in sclerostin 
expression [21-23]. Patients with sclerosteosis or Van Buchem disease as well as Sost 
knockout mice have a very high bone mass with a normal structure and good quality 
[24-26]. In addition, heterozygous carriers of the inactivating SOST mutation have no 
skeletal complications while their bone mass is consistently higher than the mean of 
age-matched controls [25], sclerostin levels in serum are lower and bone formation is 
increased [18]. This effect is also seen in heterozygous Sost knockout mice compared 
to wild type littermates [27]. This suggests that inhibition of sclerostin production 
and/or activity can be titrated leading to increased bone mass without unwanted 
side effects. Neutralizing sclerostin antibodies for the treatment of osteoporosis have 
been developed and are currently in phase III clinical trials (AMG 785, NCT01575834 
and NCT01631214 on www.clinicaltrials.gov). 
Targeting the RANK/RANKL/OPG system
The RANK/RANKL/OPG system is one of the key regulators of bone resorption and 
plays a central role in bone metabolism [28]. In this system, the principal regulator 
of osteoclast differentiation is RANK, a membrane-bound cytokine of the tumor 
necrosis factor family. RANK is expressed on haematopoietic progenitor cells and 
the binding of RANK to its ligand (RANKL), which is expressed by osteoblasts, 
induces the NF-κB pathway that leads to osteoclastogenesis and osteoclast survival 
[29, 30]. OPG is also produced by osteoblasts and acts as a soluble decoy receptor 
that competes with RANK for RANKL [31]. This interaction inhibits osteoclast 
differentiation and proliferation, and consequently decreases bone resorption. The 
ratio between RANKL and OPG determines the effect on osteoclasts. RANKL is not 
only essential for osteoclast differentiation and survival, it contributes to activation 
of mature osteoclast function as well [32]. 
The importance of the RANK/RANKL/OPG system was demonstrated by the 
effects of deletion and overexpression of these genes in animal and in vitro models [33]. 
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For example, Rank -/- and Rankl -/- mice have shortened limbs and poorly remodeled 
structures blocking the marrow cavities and show a complete absence of osteoclasts 
[34, 35]. In contrast, Opg -/- mice showed a progressive decrease in Bone mineral 
density (BMD) and excessive osteoclast activity [36, 37]. Further highlighting the 
importance of this system is the fact that mutations in RANK and RANKL were 
discovered in several bone-related diseases such as Paget’s disease, autosomal 
recessive osteopetrosis and familial expansile osteolysis [33, 38-40]. Genome-wide 
association studies into the polymorphisms that have an effect on bone density 
or osteoporosis often find RANK, RANKL or OPG in strong associations [41, 42]. 
Moreover, decreased estrogen production as seen after menopause in females leads 
to an increase in RANKL production by osteoblasts [43, 44]. 
The RANK/RANKL/OPG system is therefore an interesting pathway to target 
in the search for new osteoporosis therapies. Recently, a human monoclonal antibody 
against RANKL (denosumab, Amgen) was approved for treatment of osteoporosis 
and bone destruction by bone metastases or rheumatoid arthritis [45]. Binding to 
RANKL, denosumab inhibits the formation, function and survival of osteoclasts and 
thereby inhibits bone resorption. Clinical trials revealed marked reduction of bone 
turnover markers and a BMD gain at all measured sites after 1 year of treatment. Few 
specific side-effects have been reported even though RANK and RANKL also have 
functions in the immune system and vascular system [46].  
Exon skipping of SOST and Rank
A relatively new method of in vivo protein modification is antisense-mediated exon 
skipping. Antisense oligonucleotides (AONs) can interfere with the splicing process 
of the pre-mRNA and thereby induce skipping of an exon during splicing. Depending 
on the target, exon skipping can be used to restore aberrant splicing when this is 
disturbed by mutations, induce secretion of a membrane-bound protein by skipping 
of the membrane anchor, achieve alternative splicing or inactivation of a protein by 
removal of the active domain or disruption of the reading frame (reviewed in [47, 
48]). Because exon skipping utilizes the natural splicing machinery in the cell and 
does not induce catalytic cleavage of the RNA, effects can be more subtly titrated 
than conventional knockdown with for example siRNA [49]. 
In this manuscript we investigated the use of exon skipping as a new method 
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for the treatment of osteoporosis and targeted both bone formation via inhibition 
of sclerostin, and bone resorption via inactivation of RANK. SOST is a gene that 
consists of only two exons. Exon skipping has, to our knowledge, not been attempted 
on two-exon genes or the final exon of a gene before. Nevertheless, mutations that 
interfere with splicing of this two-exon gene have been found in some patients 
with sclerosteosis [16, 50, 51]. This project was therefore a proof of principle for the 
efficacy of interfering with splicing using AONs on two-exon targets. The RANK 
gene encodes a transmembrane domain on exon 7 and is expressed as a membrane-
bound protein. We aimed to skip exon 7 of RANK which would lead to the removal 
of the transmembrane domain and production of a soluble protein. This soluble 
RANK protein would not be able to transduce differentiation signals to osteoclast 
precursors and thereby inhibit osteoclast formation. In addition, solubilized RANK 
is a protein similar to OPG; it competes with other RANK molecules for RANKL 
and therefore potentially has a dual effect in inhibiting bone resorption. 
Materials and methods
Cells, materials and reagents
The human osteosarcoma cell line SaOS-2 and the murine monocytic cell line 
RAW264.7 (ATCC/LGC Standards, Wesel, Germany) were cultured in cell culture 
flasks (Greiner Bio-One, Kremsmünster, Austria) with 4.5 g/L Glutamax Dulbecco’s 
Modified Eagle Medium (Gibco, Grand Island, NY, USA) supplemented with 10% 
Fetal Calf Serum (Greiner Bio-One), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Gibco). Recombinant BMP4 was purchased from R&D Systems (Minneapolis, MN) 
and puromycin from Invitrogen (Carlsbad, CA, USA). 2’-O-methyl (2OMe) RNA 
phosphorothioate (PS) AONs were designed using the method described by Aartsma-
Rus [52] and produced at Prosensa BV (Leiden, The Netherlands) (sequences in Table 
1 and 2 and Figure 1). Gapmers (AON 9 and 10) were designed to include a middle 
section without 2OMe backbone modification. The PS backbone in this section is 
capable of inducing RNAse H cleavage, while the 2OMe modification increases 




For AON transfection, SaOS-2 cells and RAW264.7 cells were seeded in 24-well 
plates (Greiner Bio-One) at a density of 45,000 cells/well and 1.2-1.5 x 105 cells/well 
respectively. After overnight incubation, cells were washed with Hank’s balanced 
salt solution (HBSS, Gibco) and 1 ml transfection medium containing 2% FCS was 
added to the wells. Transfection complexes were produced in 0.15 M NaCl with 1 µg 
AON per 100 µl NaCl solution. The transfection reagent polyethyleneimine (PEI) 
(Prosensa) was added at an equivalent of 3.65 for SaOS-2 cells and 6.5 for RAW264.7 
cells. The amount of PEI was calculated with a method based on the protocol for 
ExGen500 (Fermentas, Burlington, Canada): µl PEI = (equivalent x µg AON x 3) 
/ 5.47. Upon adding PEI, the transfection mix was vortexed and incubated for 10 
minutes at room temperature. Per well, 100 µl transfection mix was added to the 
Name Chemistry Sequence Target
AON 1 2OMePS GGUCACGUAGCGGGUGAAGU Exon 2
AON 2 2OMePS GCUCGGUGACCGGCUUGGC Exon 2
AON 3 2OMePS UGAAGUGCAGCUCGCGGCA Exon 2
AON 4 2OMePS CACUGGCCGGAGCACACCAG Exon 2
AON 5 2OMePS CGGACACGUCUGUGGAGAGA Intron/exon 
boundary exon 2
AON 6 2OMePS CCAUACCUUUGGUCUCAAAG Intron/exon 
boundary exon 1
AON 7 2OMePS CUGCAUGGUACCAGCCAGA Exon 1
AON 8 2OMePS CUCCAGCUCCGGUGGAGGCU Exon 1
AON 9 RNA/dna gapmer CUGCAtggtaccagCCAGA Exon 1 (as hAON7)
AON 10 RNA/dna gapmer CACUGgccggagcacACCAG Exon 2 (as hAON4)
Table 1. Sequences of AONs targeted to SOST.
Figure 1. Location of AONs targeted to SOST.
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cells and medium was changed after 24 hours of incubation. Transfection efficiency 
was monitored by fluorescence microscopy in each experiment using the fluorescent 
5’fluorescein label attached to control AON A and B. 
(q)RT-PCR and primers
Total RNA was isolated using TriPure Isolation Reagent (Roche Diagnostics GmbH, 
Mannheim, Germany) 48 hours after AON transfection. cDNA was synthesized 
using M-MLV reverse transcriptase (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions. PCR was performed using GoTaq® DNA Polymerase 
(Promega) with a MyCycler PCR cycler (Bio-Rad, Hercules, CA, USA) and real-
time quantitative PCR (qRT-PCR) was performed using the Quantitect SYBRgreen 
PCR kit (Qiagen, Hilden, Germany) with an iQ5 PCR cycler (Bio-Rad). Primers 
(Eurogentec, Seraing, Belgium) were designed for SOST, the house-keeping gene β2 
microglobulin and different exons of Rank (Table 3). SOST qRT-PCR measurements 
were performed in triplicate and analyzed using the 2-ΔΔCt method [55]. For Rank, 
PCR products were analyzed by agarose gel electrophoresis on a 1-2% agarose gel. 
In addition, several samples were selected for further analysis and quantification of 
skipping percentage using an Agilent DNA 1000 chip (Agilent Technologies, Santa 
Clara, CA, USA) according to the manufacturer’s instructions. 
Name Chemistry Sequence Target
PS362 2OMePS ACAGAGAUGAAGAGGAGCAG Exon 7 Transmem-
brane domain
PS363 2OMePS CUUCCUGUAGUAAACGCCGA Exon 7 Transmem-
brane domain
PS419 2OMePS GGCCUCUGUGUCAGAAGAA Exon 7 Transmem-
brane domain
PS420 2OMePS AAGGUUUGCAUUUGUCUGUGG Exon 5 Out-of-frame
PS421 2OMePS GUGCUUCUAGCUUUCCAAGG Exon 6 Out-of-frame
PS422 2OMePS GCAGACCACAUCUGAUUCCG Exon 6 Out-of-frame
PS423 2OMePS GGUGGUCUCCUCAGUGUCAU Exon 6 Out-of-frame
Table 2. Sequences of AONs targeted to Rank.
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Sclerostin measurement in medium
Medium was collected from SaOS-2 cells 48 hours after transfection with AONs. 
Sclerostin concentration was measured with 96-well MULTI-ARRAY® Human 
Sclerostin Assay (Meso Scale Discovery (MSD), Gaithersburg, MD, USA) according 
to manufacturer’s instructions. Briefly, the MULTI-SPOT 96-well plate was blocked 
for 1 hour with blocker buffer. Calibrators and samples were added to the wells and 
incubated for 2 hours. Wells were incubated with detection antibody for 1 hour. 
Plates were read directly after addition of MSD Read buffer on the Sector Imager 
2400 (MSD). 
Statistical analysis
Values represent means ± SD. Differences in experiments with n > 2 were tested by 
One-way Analysis of Variance (ANOVA) followed by Tukey’s post hoc test using 
Graphpad Prism 5 software. Results were considered significant at p < 0.05.
Results SOST
AONs decrease SOST expression compared to control AON
Two AONs were tested for their ability to decrease SOST expression in SaOS-2 
cells. qRT-PCR results of SOST expression after transfection with these AONs were 
compared with samples that were transfected with a non-targeting control AON. 




β2 microglobulin Fw TGCTGTCTCCATGTTTGATGTATCT
β2 microglobulin Rev TCTCTGCTCCCCACCTCTAAGT
RANK exon 4 Fw AGTGTGCACCTGGCTTCG
RANK exon 5 Fw TGCAGCTCAACAAGGATACG
RANK exon 7 Rev ATGAGACTGGGCAGGTAAGC
RANK exon 9 Rev ACCATCTTCTCCTCCCGAGT
Table 3. Sequences of primers used in PCR
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as sclerostin protein concentration in conditioned medium (Figure 2B). However, 
when SOST expression after AON transfection was compared to expression in 
untransfected cells, there was no decrease. In fact, transfection with the control 
AON increased SOST expression (Figure 2C). This was not due to the transfection 
reagent or low serum concentration as these conditions did not change SOST 
expression (data not shown). In subsequent experiments, SOST expression after 
A B
C
Figure 2. The effect of AONs targeted to SOST in SaOS-2 cells. A) SaOS-2 cells were transfected with AON 1 and 2 
or Control AON A (n = 6). RNA was isolated 48 hours after transfection. SOST expression was decreased by about 
90% compared to cells that were transfected with control AON A. B) Sclerostin was measured in medium of cells 
that were transfected with AONs using the Meso Scale Discovery 96-well MULTI-ARRAY® Human Sclerostin 
Assay (n = 6). Measurements confirmed the decrease in sclerostin compared to cells that were transfected with 
control AON A. C) SOST expression of AON treated wells was compared with SOST expression in untransfected 
control cells (n = 3). Control AON A increased SOST expression 48 hours after transfection. There was no 
difference in SOST expression after transfection with AON 1 and 2 compared to untransfected control cells. 
Compared to Control AON A: * p < 0.05; ** p < 0.01; *** p < 0.001; Compared to untransfected control: ### p < 0.001. 
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AON transfection was compared to untransfected control cells that were treated like 
the transfected cells but without addition of transfection reagent or AON. Compared 
to the untransfected control cells, AONs targeted to SOST did not change SOST 
expression (Figure 2C). 
Effects of non-targeting control AONs on SOST expression
To examine the increase of SOST expression after transfection with control AONs, 
we tested 10 different control AONs for their effect on SOST mRNA levels (Table 4). 
These AONs were designed to target the DMD gene and checked for specificity by 
Basic Local Alignment Search Tool (BLAST) to exclude partial overlap with the SOST 
gene. As they were ineffective for their target DMD exons and were not expected to 
have any effect on other targets, these AONs were considered good control AONs. 
However, the effect of the control AONs on SOST expression varied between no effect 
and a 6.5 fold increase compared to the untransfected control (Figure 3). Results 
were consistent between two separate experiments and were therefore considered to 
be AON-specific. The sequences of the AONs that increased SOST expression were 
compared to those that did not, to detect any consensus sequences or motives that 
might explain the differences in effect. However, no similarities were found. 
Effects of SOST-targeted AONs on SOST expression
Since we were not able to show a decrease in SOST expression with the first two AONs 
directed against SOST, another 8 AONs were designed and expression was compared 
to the untransfected control. While the first AONs were targeted to Exonic Splicing 
Enhancer (ESE) sites in the second (and last) exon, several AONs in the second series 
were designed to target ESE sites in the first exon or the intron/exon boundaries. 
In addition, two gapmers were designed to induce RNAse H cleavage of the pre-
mRNA (sequences in Table 1). Like the control AONs, the AONs targeting SOST 
had varying effects on SOST expression (Figure 4). Several AONs increased SOST 
expression (up to 22-fold compared to untransfected cells), while none of the AONs 
decreased SOST expression. In addition, four out of ten of the AONs that were tested 
induced widespread cell death after transfection (indicated by † in Figure 4). As 
before, comparison of the AON sequences did not reveal any consensus sequences 
that could explain the results. 
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Table 4. Sequences of control AONs
Name Chemistry Sequence
Control AON A 2OMePS + FAM-label UUUUUCUGUCUGACAGCUG
Control AON B 2OMePS + FAM-label UGCUGCUGUCUUCUUGCU
Control AON C 2OMePS AUUUUUCCUGUAGAAUACUGG
Control AON D 2OMePS CGCUGCCCAAUGCCAUCCU
Control AON E 2OMePS GUGCUGAGGUUAUACGGUG
Control AON F 2OMePS GUCCCUGUGGGGCUUCAUG
Control AON G 2OMePS GGGCACUUUGUUUGGCG
Control AON H 2OMePS UCCUAUAAGCUGAGAAUCUG
Control AON I 2OMePS GCCUUCUGCAGUCUUCGG
Control AON J 2OMePS GAGAGGUAGAAGGAGAGGA
Figure 3. SOST expression in SaOS-2 cells after transfection with control AONs. 
SaOS-2 cells were transfected with different control AONs (n = 2). These AONs were specifically designed to target 
dystrophin, but were ineffective for this purpose. SOST expression was increased after transfection with several 
control AONs. This expression profile was seen in two separate experiments.
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Increasing SOST expression with BMP4
Very few cell lines express SOST, and those that do (such as the SaOS-2 cells), express 
very low quantities. With low expression, it might be difficult to detect a further 
decrease after transfection with AONs. SOST expression was therefore increased 
by stimulating the cells with BMP4 during AON transfection. As shown in Figure 
5, SOST expression in cells stimulated with BMP4 is indeed increased over 40-fold 
compared to the unstimulated control. However, transfection with AONs targeted 
to SOST did not decrease expression. The control AONs that were chosen for this 
experiment had the same effect as shown in Figure 3: control AON J did not change 
expression, while control AON H markedly increased SOST expression (Figure 5). 
Results RANK
RAW264.7 cells were transfected with different AONs targeted to exon 5, 6 or 7 or 
combinations of AONs targeting one or more exons. In this case, the aim was to 
induce an exon skip that produced a soluble and non-functional protein (exon 7 
skip), or produce a truncated and non-functional protein (exon 5 and 6 skip). PCR 
was performed with primers amplifying exon 4-9, showing skips of all targeted 
exons (Figure 6A). AONs targeting exon 6 resulted in a clearly visible skip product. 
No additional bands were visible on agarose gel, indicating that no double skips 
had occurred after targeting multiple exons. In Figure 6B, PCR results are shown 
that were performed with primers in exon 5 and 7, thus showing only skips of exon 
6. Skipped products were excised and sequenced, proving that indeed exon 6 was 
skipped in all samples targeting exon 6 (data not shown). In addition, several samples 
were selected for analysis on an Agilent DNA 1000 chip for quantification of skip 
percentages. The percent of successful exon 6 skip ranged between 6.7 and 10.5% 
(Figure 6). RT-PCR analysis of samples that were transfected with an AON targeting 
exon 7 confirmed the absence of a skipped product (data not shown).
Skipping exon 5 or 6 of Rank would result in a frameshift and premature 
stopcodon, which may induce a nonsense-mediated decay mechanism. To inhibit 
nonsense-mediated decay, 1 µg/ml puromycin was added after AON transfection for 
4 hours or overnight. PCR was performed with primers amplifying exon 6 (Figure 7). 
No apparent increase in the ratio between skipped and unskipped product was seen 
after addition of puromycin. 
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Figure 4. SOST expression in SaOS-2 cells after transfection with SOST-targeting AONs. 
SaOS-2 cells were transfected with AONs designed to target SOST (n = 2). None of the AONs was able to decrease 
SOST expression compared to the untransfected control, while several AONs increased SOST expression. AONs 
3, 6, 9 and 10 induced cell death after transfection (indicated by †). 
Figure 5. Effect of AON transfection on SOST expression in SaOS-2 cells after stimulation with BMP4. 
Because SOST expression in SaOS-2 cells is low, it might be difficult to detect a decrease after transfection with 
AONs. SOST expression was therefore increased with BMP4 during AON transfection. RNA was isolated 48 
hours after transfection and stimulation (n = 2). SOST expression in cells stimulated with BMP4 is increased 
more than  40-fold compared to the unstimulated control, but transfection with AONs targeted to SOST did 
not decrease expression. As before, control AON J did not change expression, while control AON H increased 
SOST expression approximately 3-fold. *** p < 0.001 vs. untransfected and unstimulated control. # p < 0.05 vs. 
untransfected control + BMP4
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Figure 6. Schematic representation and gel electrophoresis results of Rank PCR products after transfection with 
the AONs and combinations of AONs indicated above the lanes. Targeted exon is also indicated. A) Schematic 
representation of Rank cDNA with primers in exon 4 and 9 or exon 5 and 7 showing product length before and 
after exon skips. B) PCR was performed with primers in exon 4 and 9, showing skips of all targeted exons. Skips 
of exon 5 and 7 were very faint. No additional fragments were found, indicating that multiple skips did not occur. 
Skipped product lengths: exon 5 skip 445 bp, exon 6 skip 444 bp, exon 7 skip 425 bp. C) PCR products are shown 
with primers in exon 5 and 7, showing only exon 6 skips. Several samples were selected and run on an Agilent 
DNA 1000 chip and the skipped product percentage of the total product was calculated by the Agilent 2100 
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Discussion
Osteoporosis is a growing problem in the aging society, and there is a need for better 
therapies. The discovery of important regulatory pathways in bone metabolism has 
revealed interesting new targets for treatment of this disease. Here we investigated 
AONs as a means of modulating expression of two of these targets by exon skipping, a 
technique that is very promising for the treatment of Duchenne muscular dystrophy 
(DMD). We showed that SOST expression was not decreased with any of the tested 
AONs compared to untransfected control cells, and that changes in SOST expression 
after transfection with different targeting and non-targeting AONs varied widely. 
Exon skipping of Rank was achieved but with low efficiency. 
Even with the extensive knowledge of AON design criteria that has been 
accumulated in DMD research [52], none of the 10 AONs that were examined was 
able to decrease SOST expression. In fact, several AONs increased expression. This 
effect was consistently seen in two separate experiments and seemed to be unrelated 
to the target, since several control AONs also increased SOST expression. In the 
described experiments control AONs were used that were targeted to dystrophin, 
but proved ineffective. These AONs were considered to be good controls, as they 
were ineffective for their target and were not expected to have any off-target effects. 
However, we showed that SOST expression was consistently influenced by some of 
these AONs. 
Figure 7. Gel electrophoresis of Rank PCR products after 
transfection with AON PS423 targeting exon 6, and treated 
with 1 µg/ml puromycin for 4 hours or overnight (ON). The 
control AON does not show any skipped product, while samples 
transfected with PS423 display weak bands at the predicted 
height. The ratio of full length versus skipped product does not 
markedly change after addition of puromycin.
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It is not clear what the mechanism behind the increased SOST expression is. 
A component of stress in the cells that was caused by the transfection may induce 
expression of SOST. We have tested several stressors like the transfection reagent 
without AON, oxidative stress, low serum conditions, pH changes and mechanical 
stress, and none increased SOST expression to the levels seen with the AONs (data 
not shown). Also, as the increases in SOST expression were consistent between 
experiments, they seem to be AON- or sequence-specific and are probably caused 
by some other factor than transfection-induced stress. The most likely explanation 
lies in the fact that phosphorothioate AONs bind to serum proteins, in particular 
heparin-binding proteins and albumin [56, 57]. This binding is aspecific but appears 
to be influenced by AON length and sequence [58]. In vivo, binding to proteins 
inhibits excretion through the kidney and thereby increases half-life [59, 60]. While 
the 2OMe modification that was used here in combination with phosphorothioate 
increases stability and sequence specificity of the AON, it does not abrogate protein 
binding. As sclerostin is known to interact with heparin [61], the AONs may bind 
to sclerostin in the growth medium and render it inactive. This could trigger a 
compensation mechanism leading to increased SOST transcription. 
The low level of SOST expression in SaOS-2 cells may make it difficult to 
detect downregulation of this gene and show an effect of the AONs. However, when 
basal SOST expression was increased with BMP4 stimulation no decrease of SOST 
expression could be seen with AONs. The two control AONs that were chosen for the 
subsequent experiment showed the same results before and after BMP4 stimulation; 
control AON H increased expression and control AON J did not change expression. 
This validated that SOST expression could be modulated in the same way with and 
without BMP4 stimulation. In addition, basal expression and BMP-stimulated 
expression can be decreased by other factors such as the Wnt signaling stimulator 
GIN (Chapter 5), indicating that the lack of downregulation by AONs was not a 
technical limitation of the experimental model. 
To our knowledge, exon skipping has not been attempted on a two-exon gene 
before. Unlike exon skipping in larger genes like Rank and DMD where internal 
exons are targeted, it is not possible to demonstrate an exon skip in SOST by fragment 
analysis by gel electrophoresis. Instead, qRT-PCR was performed using intron-
spanning primers to detect a decrease in the full-length RNA. With this method it is 
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more difficult to detect differences in expression due to exon skipping (or in this case 
inhibition of splicing), whereas one would usually detect the appearance of a new 
fragment. This is especially true when the AONs result in a variable expression. It is 
therefore conceivable that some or even all AONs did have an effect on splicing of 
SOST, but that small decreases in expression could not be detected. We can therefore 
not conclude that exon skipping is unattainable in two-exon genes and this needs to 
be investigated in other genes, but the detection method remains challenging. 
While exon skipping of SOST has not been done before, some experience has 
been gained in exon skipping of proteins that are involved in inflammatory diseases 
such as rheumatoid arthritis. Exon skipping of the Tumor necrosis factor alpha 
(TNF-α) receptor resulted in a soluble protein that was able to reduce inflammation in 
mouse models for hepatitis and arthritis [62]. In addition, work is ongoing on several 
other inflammatory mediators such as interleukin-1 receptor accessory protein (IL-
1RAcP), IL-5 receptor and complement factor 5 [63]. Even though RANK is a member 
of the TNF receptor family and therefore shares a similar structure, we were not 
able to achieve the levels of exon skipping in Rank that were shown for the TNF-α 
receptor. Options for the design of AONs targeting exon 7 in Rank were limited as the 
exon does not contain many ESE sites predicted by ESEFinder (http://rulai.cshl.edu/
cgi-bin/tools/ESE3/esefinder.cgi?process=home), and the splice sites contain many 
CCC or GGG motifs that make AONs vulnerable for aggregation. We therefore also 
targeted exon 5 and 6 of Rank. While skipping of exon 7 would produce a soluble 
protein that could have dual actions – inhibiting signal transduction and competing 
with membrane-bound molecules – skipping of exon 5 or 6 would produce a reading 
frame shift and therefore a truncated protein. The maximum of 10.5% skipping 
efficiency in the exon 6 targeted samples was expected to be too low for a biological 
effect, and AONs targeting exon 5 or 7 resulted in even lower percentages. It has 
been reported that proteins undergo nonsense-mediated decay when a premature 
stop codon is introduced [64], which could lead to underestimation of results. 
Still, this does not appear to play a large role in this case as inhibition of nonsense-
mediated decay with puromycin did not change results. The observed low skipping 
percentages could partly be due to the cell type that was used, as RAW264.7 cells 
are difficult to transfect and result in a maximum of ~50% transfection efficiency 
(data not shown). However, skipping of the IL-1RAcP in these cells was much more 
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efficient than RANK (data not shown), excluding the cells as the main cause for the 
observed low skipping efficiency. Nevertheless, skipping efficiency may be optimized 
by designing and testing more AONs or further optimizing transfection. 
In conclusion, exon skipping of SOST or Rank was unsuccessful with the 
AONs here described. It has been shown that the sclerosteosis phenotype in some 
patients is caused by mutations in the 3’ splice site of the first exon of SOST and these 
mutations inactivate sclerostin [16, 50, 51]. Even though this proves interference in 
the process of splicing a two-exon gene is possible, an AON targeting this region 
(AON6) did not decrease SOST expression in our experiments. We were therefore 
not able to provide a proof-of-principle for splicing modulation of two-exon genes 
using AONs, but because of the limits to our detection method, it is too early to 
exclude this possibility. Exon skipping of Rank was not efficient enough to anticipate 
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Abstract
Alizarin Red S staining is the standard method to indicate and quantify matrix 
mineralization during differentiation of osteoblast cultures. KS483 cells are 
multipotent mouse mesenchymal progenitor cells that can differentiate into 
chondrocytes, adipocytes and osteoblasts and are a well-characterized model for 
the study of bone formation. Matrix mineralization is the last step of differentiation 
of bone cells and is therefore a very important outcome measure in bone research. 
Fluorescently labelled calcium chelating agents, e.g. BoneTag and OsteoSense, are 
currently used for in vivo imaging of bone. The aim of the present study was to 
validate these probes for fast and simple detection and quantification of in vitro 
matrix mineralization by KS483 cells and thus enabling high-throughput screening 
experiments. 
KS483 cells were cultured under osteogenic conditions in the presence of 
compounds that either stimulate or inhibit osteoblast differentiation and thereby 
matrix mineralization. After 21 days of differentiation, fluorescence of stained 
cultures was quantified with a near-infrared imager and compared to Alizarin Red S 
quantification. Fluorescence of both probes closely correlated to Alizarin Red S 
staining in both inhibiting and stimulating conditions. In addition, both compounds 
displayed specificity for mineralized nodules. We therefore conclude that this 
method of quantification of bone mineralization using fluorescent compounds is a 




During osteoblast differentiation collagen is deposited in the extracellular space. 
When Ca2+ and inorganic phosphate accumulate to form hydroxyapatite crystals, 
the matrix mineralizes to form bone [1-3]. In vitro, primary bone cells or bone 
marrow derived cells can be induced to form a mineralized matrix when cultured 
in osteogenic medium [4]. KS483 cells, a murine mesenchymal progenitor cell line, 
can differentiate into chondrocytes, adipocytes and osteoblasts and are a well-
characterized model for bone formation [5, 6]. These cells are used for the study of 
many aspects of bone biology, as well as new drug targets for bone-related diseases 
[7-9].
The quantification of matrix mineralization in cell cultures is one of the most 
important indicators for successful differentiation. Currently, the most common 
method for the quantification of mineralization is the Alizarin Red S staining [10]. 
This staining can be quantified by extraction with hexadecylpyridinium chloride 
and spectrophotometric analysis [3]. 
IRDye® 800CW BoneTag™ and OsteoSense® 800 are fluorescently labelled 
probes with high affinity for bone currently used for in vivo imaging. BoneTag is a 
tetracycline derivate coupled to IRDye 800CW [11], while OsteoSense is based on 
the bisphosphonate pamidronate with an IRDye78 label [12]. Both compounds have 
an emission wavelength of 800 nm, reducing auto-fluorescence both in vivo and in 
vitro [13]. 
We now describe a simple and fast method for the quantification of matrix 
mineralization in cell cultures using BoneTag and OsteoSense. To validate this 
method, results obtained with these compounds were compared to the well-
established method of Alizarin Red S staining in different culture conditions. 
BoneTag and OsteoSense fluorescence correlated with Alizarin Red S staining 
quantifications in cultures after incubation with compounds that either stimulate or 
inhibit osteoblast differentiation and/or matrix mineralization. We therefore show 
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Materials and methods
Cell culture and differentiation
KS483 cells were cultured as described previously [6]. Briefly, cells were cultured 
routinely in α-MEM (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented 
with penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA), Glutamax 
(Gibco) and 10% fetal calf serum (FCS; Greiner Bio-One, Frickenhausen, Germany). 
For differentiation assays, KS483 cells were seeded at a density of 9,200 cells/cm2 
in 12-wells plates (Greiner Bio-One). Every 3-4 days the medium was replaced. At 
confluence (from day 4 of culture onward) 50 µg/ml ascorbic acid (BDH Prolabo, 
VWR International, Radnor, PA, USA) and when nodules appeared (from day 11 
of culture onward) 5 mM glycerol 2-phosphate disodium salt (βGP; Sigma-Aldrich, 
St. Louis, MO, USA) was added to the culture medium. When applicable, bone 
morphogenetic protein 6 (BMP-6; kindly provided by prof. S. Vukicevic, Department 
of Anatomy, School of Medicine, Zagreb, Croatia) was added at day 4 of culture or 
parathyroid hormone related protein (PTHrP; Bachem, Bubendorf, Switzerland) 
was added from day 4 onward. 
Alkaline phosphatase measurements
Medium samples were taken every 3-4 days before medium change. Alkaline 
phosphatase (ALP) activity was measured by adding 200 µl of 120  nM 
p -nitrophenylphosphate (PNPP, Thermo-Scientific, Waltham, MA, USA) in 100 mM 
glycine/1 mM MgCl2/0.1 mM ZnCl2 buffer (pH10.5) and measured for 10 min using 
a VERSAmax Tunable Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) 
at 405 nm. ALP activity was determined as the slope of the kinetic measurement 
(mOD/min). 
Quantification of mineralization by fluorescence
At 24 hours before analysis, the cell cultures were incubated with the calcium 
binding agent IRDye® 800CW BoneTag™ (BoneTag, LI-COR Biosciences, Lincoln, 
NE, USA) or the IRDye78 labeled bisphosphonate pamidronate OsteoSense® 800 
(Perkin Elmer, Waltham, MA, USA), both at a concentration of 2 pmol/ml (1:10,000 
dilution). After incubation the cells were washed with phosphate-buffered saline 
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(PBS) and fixed with 3.7% buffered formaldehyde. The fixed cells were scanned with 
the Odyssey Infrared Imaging System (LI-COR) at a resolution of 42 µm, medium 
quality and intensity 5.0-6.5. Integrated intensity (counts-mm2) of each well was 
calculated by the Odyssey software. 
Quantification of mineralization by Alizarin Red S
Mineralized nodules were fixed with 3.7% buffered formaldehyde, stained with 2% 
Alizarin Red S solution for 2 minutes and washed 3 times with H2O. Pictures were 
taken using a Powershot A650IS Digital Camera (Canon, Ōta, Tokyo, Japan) through 
a light microscope at 5x magnification. For quantification, Alizarin was removed 
from the cell layer by overnight incubation with 10% hexadecylpyridinium chloride 
in 10 mM PO4 buffer (pH 7.5), and measured at 550 nm on a VERSAmax Tunable 
Microplate Reader (Molecular Devices) against a range of Alizarin standards (0.005-
0.8 µg/ml). 
Figure 1. Comparison of Alizarin Red S staining, BoneTag and OsteoSense in KS483 cell cultures during 
differentiation. A) Representative photos of Alizarin Red S staining and BoneTag and OsteoSense fluorescence; 
B) measurements of ALP activity; C) quantification of Alizarin Red S staining; D) quantification of BoneTag 
fluorescence; E) quantification of OsteoSense fluorescence; F) correlation between Alizarin Red S staining 
and BoneTag fluorescence. R2=0.73 p<0.0001; G) correlation between Alizarin Red S staining and OsteoSense 
fluorescence. R2=0.93 p<0.0001. 
* p<0.05, ** p<0.01, *** p<0.001 vs. day 11 or for ALP measurements vs. day 4.
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Statistics
Values represent means ± SD. Differences were tested by two-way (ALP 
measurements) or one-way analysis of variance (ANOVA) followed by Tukey’s post 
hoc test using Graphpad Prism 5 software (La Jolla, CA, USA). Nonlinear regression 
was performed for the correlation between Alizarin Red S staining and fluorescent 
markers. Results were considered significant at p<0.05.
Results
Alizarin Red S staining and BoneTag or OsteoSense 
fluorescence increase over time during differentiation
To validate the quantification of in vitro matrix mineralization using the fluorescent 
compounds BoneTag and OsteoSense, readouts of these compounds were compared 
to the well-established method of Alizarin Red S staining in different culture 
conditions. First, Alizarin Red S staining and fluorescent images were quantified at 
different time points during differentiation. Figure 1A shows representative pictures 
of Alizarin Red S staining, BoneTag and OsteoSense fluorescence at each time point. 
ALP activity was measured in medium as a measure for osteoblast differentiation 
and increased over time (Figure 1B). As shown in Figure 1C-E, signals from all three 
readouts increased in intensity as the matrix becomes more mineralized over time. 
Both BoneTag and OsteoSense displayed slight background fluorescence. However, 
a significant correlation was observed between Alizarin Red S staining and both 
BoneTag (R2 = 0.73 p < 0.0001; Figure 1F) and OsteoSense (R2 = 0.93 p < 0.0001; 
Figure 1G). In addition, both fluorescent readouts appear to be more sensitive for 
small changes in matrix mineralization than Alizarin Red S, as shown by the non-
linear correlation. Indeed, at day 18 of differentiation both BoneTag and OsteoSense 
were able to identify an increase in matrix mineralization, while this was only 
apparent from day 21 with Alizarin Red S staining. 
Correlation between Alizarin staining and fluorescence 
after modulation of differentiation
To validate BoneTag and OsteoSense quantification further, we examined whether 
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Figure 2. Comparison of Alizarin Red S staining, BoneTag and OsteoSense in differentiated KS483 cell cultures 
after stimulation with different concentrations of BMP-6. A) Representative photos of Alizarin Red S staining 
and BoneTag and OsteoSense fluorescence; B) measurements of ALP activity; C) quantification of Alizarin Red S 
staining; D) quantification of BoneTag fluorescence; E) quantification of OsteoSense fluorescence; F) correlation 
between Alizarin Red S staining and BoneTag fluorescence. R2=0.92 p<0.0001; G) correlation between Alizarin 
Red S staining and OsteoSense fluorescence. R2=0.75 p<0.0001. 
ALP: *** p<0.001 vs. day 4. Alizarin, Bonetag and Osteosense: ** p<0.01 and *** p<0.001 vs. control.
the correlation between Alizarin Red S staining and BoneTag or OsteoSense 
fluorescence is still present after modulation of osteoblast differentiation. Therefore, 
KS483 cell cultures were were stimulated with BMP-6 and inhibited with PTHrP 
[14]. BMP-6 stimulated ALP activity and increased Alizarin Red S staining and 
fluorescence dose-dependently (Figure 2A E). PTHrP dose-dependently decreased 
ALP activity and both Alizarin Red S staining and fluorescence (Figure 3A-E). 
Correlation between both BoneTag and OsteoSense and Alizarin Red S staining was 
significant with R2 = 0.92 and 0.75 (p < 0.0001), respectively, for cultures stimulated 
with BMP-6 (Figure 2F-G) and R2= 0.84 and 0.92 (p < 0.0001), respectively, for 
cultures with PTHrP (Figure 3F-G).
Specificity of staining for mineralized nodules
Next, we examined the specificity of BoneTag or OsteoSense binding to mineralized 
matrix by culturing KS483 cells without βGP. Without phosphate, the nodules 
did not mineralize as shown by the absence of staining in samples without βGP 
(Figure 4A). ALP activity after stimulation with BMP-6 but without βGP is slightly 
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Figure 3. Comparison of Alizarin Red S staining, BoneTag and OsteoSense in differentiated KS483 cell cultures 
after inhibition with different concentrations of PTHrP. A) Representative photos of Alizarin Red S staining and 
BoneTag and OsteoSense fluorescence; B) measurements of ALP activity; C) quantification of Alizarin Red S 
staining; D) quantification of BoneTag fluorescence; E) quantification of OsteoSense fluorescence. F) correlation 
between Alizarin Red S staining and BoneTag fluorescence. R2=0.84 p<0.0001; G) correlation between Alizarin 
Red S staining and OsteoSense fluorescence. R2=0.92 p<0.0001.
*** p<0.001 vs. Control. 
Figure 4. Comparison of Alizarin Red S staining, BoneTag and OsteoSense in KS483 cell cultures differentiated 
in the presence or absence of βGP and/or stimulated with 50  ng/ml BMP-6 at day 4 of differentiation. A) 
Representative photos of Alizarin Red S staining, light microscope images of alizarin stained samples at 100x 
magnification, and BoneTag and OsteoSense fluorescence; B) measurements of ALP activity; C) quantification of 
Alizarin Red S staining; D) quantification of BoneTag fluorescence; E) quantification of OsteoSense fluorescence. 






increased compared to BMP+βGP (Figure 4B). Staining of unmineralized nodules 
was minimal, even after stimulation with BMP-6 (Figure 4A). Quantification of 
staining showed a large difference between conditions +βGP and –βGP in both 
Alizarin and BoneTag-stained samples. OsteoSense showed some background 
staining in samples without βGP, especially in the control condition (Figure 4C-E). 
Fluorescence microscopy of stained nodules revealed the localization of fluorescence 
in the mineralized matrix (Supplementary figure 1). 
Discussion
The Near Infrared fluorescent calcium binding agents BoneTag and OsteoSense are 
currently used for in vivo imaging of bone. To validate these agents for quantification 
of matrix mineralization in cell cultures, we compared the results of quantification 
with these compounds to the well-established method of Alizarin Red S staining 
after modulation of differentiation and matrix mineralization. In stimulating and 
inhibiting conditions both BoneTag and OsteoSense fluorescence correlated with 
the quantification of matrix mineralization by Alizarin Red S staining. In addition, 
similar to Alizarin Red S staining, both fluorescent compounds showed selectivity 
for mineralized nodules.  
Differentiation of osteoblasts and matrix mineralization were increased by 
culturing in the presence of BMP-6. Increased ALP activity with increasing BMP-6 
concentrations is evidence of the stimulation of differentiation of osteoblasts [6, 15]. 
Mineralization of the extracellular matrix increased dose-dependently when the cells 
were stimulated with BMP-6, which is also reflected by an increase in fluorescent 
signal of both BoneTag and OsteoSense. On the other hand, PTHrP decreased ALP 
activity in a dose-dependent manner. Like PTH, PTHrP signals via the PTH receptor 
and the cyclic AMP pathway to inhibit osteoblast differentiation and thereby matrix 
mineralization [14, 16-18]. Our results show a good correlation between Alizarin 
Red S staining and BoneTag or OsteoSense fluorescence after modulation with either 
BMP-6 or PTHrP. While the fluorescent stains were more sensitive to small changes, 
Alizarin Red S staining could be used in highly mineralized samples. 
Specificity for mineralization was tested by culturing KS483 cells in the presence 
or absence of βGP. ALP activity dramatically increased after stimulation with BMP-
6, and then declined after day 11 of culture. However, ALP activity remained high 
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when the cells were cultured without βGP. The difference in staining quantification 
between conditions +βGP and -βGP in both control and BMP-stimulated conditions 
indicated that the staining was able to distinguish between mineralized and 
unmineralized nodules and thus indicates specificity. Like Alizarin Red S, BoneTag 
displayed low background staining in unmineralized nodules, while OsteoSense 
staining seemed to have a higher background and could not distinguish between 
+ and - βGP without BMP-6 stimulation. This indicates that BoneTag has a higher 
specificity to the bone mineral compared to OsteoSense. 
Bisphosphonates are compounds that bind with high affinity to bone and are 
used in the clinic for treatment of osteoporosis because of their ability to inhibit 
bone resorption by osteoclasts [19]. Because of their high affinity, bisphosphonates 
have a long half-life when bound to a mineralized matrix [19, 20]. OsteoSense is 
based on the bisphosphonate pamidronate [12], and care must be taken when using 
this probe in bisphosphonate research, since competition between the administered 
bisphosphonate and OsteoSense staining may occur. This potential problem is not 
expected when using BoneTag, which is a tetracylin-based probe [11]. In addition, it 
is important to note that in our experience OsteoSense is stable for a limited period 
of time (up to 8 weeks), even when stored at -80°C (data not shown), while BoneTag 
storage could be extended to over a year without loss of specificity.
Alizarin Red S is the standard staining for mineralized matrix in bone 
research. It can be dissolved and quantified by spectrophotometry. There are several 
advantages of using BoneTag and OsteoSense compared to Alizarin Red S staining:
1) They are added in the culture medium prior to fixation of the cells, and 
require no additional washing or staining procedures. 
2) Both BoneTag and OsteoSense are available with fluorescence at 800nm 
and 680nm. The long wavelength of these probes makes them ideal for use 
with mineralized matrix as this greatly reduces autofluorescence. 
3) These probes are universal in use for in vivo and in vitro bone research 
as they can also be used for in vivo imaging of bone formation. They are 
commercially available as quality controlled validated batches, reducing 
variability. 
4) They can be quantified with great sensitivity using the dedicated Odyssey 
near-infrared imaging system. 
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5) Because small amounts of dye are needed for staining, the dyes are very 
cost-effective; up to 12,000 samples can be stained with a single vial of 
24 pmol.
Other options for fluorescent detection of in vitro mineralization may be xylenol 
orange or calcein blue. Wang et al. [21] have for example used these substances to 
evaluate mineralized nodule formation in living osteoblastic cultures. However, 
this method was used to count the number of positive nodules, and not to quantify 
mineralization. Furthermore, these fluorescent dyes emit blue or red light, which is 
sensitive to autofluorescence of the mineralized matrix.
In conclusion, BoneTag and OsteoSense are good substitutes with many 
advantages over Alizarin Red S staining. The results of both fluorescent compounds 
provide good correlation with Alizarin Red S staining in a range of different 
experiments stimulating and inhibiting differentiation and mineralization. BoneTag 
is more specific in conditions of low mineralization and can be stored for extended 
periods of time. The long emission wavelength in the near-infrared range reduces 
autofluorescence during detection. For both compounds numerous possibilities exist 
for combination with other fluorescent markers at different wavelengths, such as 
DNA stains. This opens up many possibilities for quantitative and high-throughput 
experiments in bone research. 
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Supplementary figure 1. Mineralized nodule in a differentiated KS483 culture stained with BoneTag (LI-COR) 
and photographed by a Nuance 2.8 camera mounted on a Leica DM IRE2 fluorescence microscope (Leica). 
Magnification 400x. A) Brightfield image, B) Fluorescence image with BoneTag in green (800 nm), C) Composite 










Osteoporosis is a growing problem in the aging society. While several therapies are 
available, none of these are able to persistently increase bone formation and return 
bone mass to a more favorable quantity that is strong enough to resist breaking. 
Research is therefore needed to discover new targets and develop drugs for the 
treatment of osteoporosis in the future. 
Clinical importance
Sclerostin, a natural inhibitor of bone formation that is expressed by osteocytes, was 
discovered in mutation analyses of patients with sclerosteosis [1, 2]. These patients 
present with severe bone overgrowth and a bone mass that can be up to 11 standard 
deviations above normal [3]. Interestingly, the bone of these individuals is of very 
good quality and no affected person has been reported to have suffered a fracture 
[4]. Even heterozygous carriers of mutations in the gene coding for sclerostin (SOST) 
have consistently higher bone mass than control subjects and are relatively resistant to 
fracture, suggesting a gene-dose effect. The restricted expression pattern of sclerostin 
adds to the view of sclerostin as one of the most interesting targets for new treatment 
options for osteoporosis. Knowledge of the mechanism of action and regulation of 
sclerostin expression are essential to optimally benefit from its characteristics in 
future therapies. Chapter 2 therefore gives an overview of the current knowledge on 
sclerostin function, expression and regulation. Even though much is known about 
the expression pattern and effect of sclerostin, the exact mechanism of action and 
pathways by which it is regulated remain to be elucidated. 
A lot can be learned from mutation studies, especially in naturally occurring 
human diseases. In Chapter 3 we found that Dickkopf 1 (DKK1), a protein that 
like sclerostin inhibits Wnt signaling through binding to Low-density lipoprotein 
receptor-related protein 5/6 (LRP5/6), was increased in serum samples from patients 
with sclerosteosis and Van Buchem disease. DKK1 may be increased in an effort to 
compensate for the lack of sclerostin in these patients. However, their increased bone 
mass indicates that the increase in DKK1 expression is insufficient to protect against 
excessive bone formation. While sclerostin is facilitated by LRP4 [5], DKK1 employs 
Kremen as a co-receptor [6, 7]. In addition, sclerostin is expressed almost exclusively 
in osteocytes in mineralized matrix, whereas DKK1 is expressed in many cell types 
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throughout the body and is implicated in tumorigenesis [8]. The proteins seem to 
have different roles during development. SOST knockout mice show increased bone 
mass without gross developmental abnormalities while mice deficient in DKK1 are 
embryonic lethal displaying fore- and hindlimb malformations and lacking anterior 
head structures [9, 10]. Therefore, even though both proteins bind to LRP5/6 they 
have a different mechanism of action, a different expression pattern and may act 
on osteoblasts at different developmental stages. This may explain the finding that 
DKK1 was not able to fully compensate for the lack of sclerostin. 
The populations of patients with sclerosteosis and Van Buchem disease are quite 
isolated in South Africa and a small town in the Netherlands, respectively. After the 
discovery of the causative mutations for sclerosteosis and Van Buchem disease, other 
sclerostin mutations were found in phenotypically identical patients from Brazil, USA 
and Senegal [11, 12]. These mutations include several different nonsense mutations 
leading to a premature stop codon, and a splice site mutation interfering with correct 
splicing of the gene. In Chapter 4 we described a novel missense mutation in two 
siblings from Turkey with classic sclerosteosis characteristics like enlarged skull and 
jaw, facial nerve palsy, hearing loss, headaches and highly increased bone mineral 
density (BMD). This mutation causes a cysteine to arginine amino acid substitution at 
position 167. The affected cysteine residue is the last of six cysteines forming a cystine 
knot and is highly conserved in multiple species. Recent data have emphasized the 
importance of the cystine knot motive for sclerostin function [13, 14]. The structure 
of sclerostin contains two fingers and a loop, emanating from the central cystine 
knot resembling many other cystine knot proteins [15]. This structure is highly 
dependent on the folding of the cystine knot. Because of the important function 
of the cysteine residues in protein folding, the mutation in sclerostin was predicted 
to disrupt the cystine knot motif and require conformational changes of the loop 
segment to accommodate the larger arginine side chain. These changes would lead 
to a global misfolding of the protein and retention in the endoplasmatic reticulum. 
In addition, we showed that the binding affinity of mutated sclerostin for LRP5 was 
decreased and its function was impaired. In the patients, this led to a phenotype 
comparable to that of patients with sclerosteosis. Together, these data highlight the 
importance of sclerostin structure and correct protein folding for its function in 




Modulating sclerostin expression and investigating effects
As sclerostin is a negative regulator of bone formation that acts by inhibiting the 
Wnt signaling pathway, inhibiting the expression of this protein in patients with 
osteoporosis would lead to increased bone formation. By understanding the 
endogenous regulatory mechanisms that control SOST expression, we may eventually 
be able to specifically target and modulate these mechanisms in patients with 
osteoporosis to increase bone formation with minimal side-effects. In Chapter 5 we 
investigated the regulation of SOST by modulating the activity of the Wnt signaling 
pathway. SOST expression appeared to be downregulated by increased Wnt signaling 
activity, and was strongly decreased by the GSK3β inhibitor GIN. However, several 
Wnt signaling inhibitors that work at different stages in the pathway could not 
abrogate the decrease in SOST expression. A compound that blocked the binding 
of β-catenin to the TCF/LEF transcription complex and thereby directly inhibited 
downstream target gene transcription, had no effect on the expression of SOST after 
treatment with GIN. It seems therefore that the decrease in SOST expression is not 
mediated by Wnt/β-catenin signaling, but via a different effect of GSK3β. 
The importance of GSK3β in bone has been shown by inactivation and 
overexpression studies in mice. Global deletions of GSK3β are lethal in late embryonic 
or perinatal stages with various skeletal abnormalities [16-18]. Heterozygous 
deletions result in increased bone mass (both trabecular and cortical), and increased 
bone formation parameters without skeletal malformations [18, 19]. In addition to its 
role in Wnt/β-catenin signaling, GSK3β is also involved in insulin signaling through 
PKB/AKT [20]. While both pathways have been reported to induce bone formation 
[21, 22], GSK3β appears to be differentially regulated through the phosphorylation of 
different amino acids [23]. This may facilitate different downstream actions. Further 
research will need to identify the mechanism that GSK3β employs in the regulation 
of SOST. 
While interfering with endogenous regulation of sclerostin expression is an 
interesting therapeutic option, other methods are being investigated to block the 
effect of the protein. New therapeutic strategies focus on increasing bone formation 
by inhibiting sclerostin with either antibodies or small molecules. Alternatively, 
interfering with transcription using antisense methods has become a common 
method in cell biological experiments, and efforts are being made to develop 
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these methods for use in the clinic. Antisense technology could therefore also be 
interesting in the regulation of sclerostin expression. In Chapter 6 we investigated a 
novel method for the inhibition of SOST expression using antisense oligonucleotides 
(AONs). As described in detail in Chapter 1, AONs interfere with the splicing of a 
gene, leading to exclusion (skipping) of an exon from the mRNA. Depending on 
the exon that is skipped and its reading frame, this produces a truncated protein 
(out-of-frame skip) or a protein with a missing fragment (in-frame skip). As SOST 
contains only two exons, skipping of one of the exons would lead to a nonsense 
mRNA and obstruction of protein production. Examining 20 different AONs (both 
targeting SOST and control) did not reveal decreased SOST expression with any of 
them. In fact, several AONs increased SOST expression. The mechanism behind 
this increase is not clear, but we hypothesize that this might be due to binding of 
the AONs to sclerostin, triggering a compensational mechanism. Investigating the 
mechanism that increases SOST expression further may be of therapeutical interest, 
not to patients with osteoporosis, but instead to those with high bone mass diseases. 
As bone mass is a balance between formation and resorption, therapeutic efforts 
could focus on either or both of these. Most available therapeutics are anti-resorptive 
and prevent further loss of bone mass. A relatively new anti-resorptive drug, 
Denosumab, targets RANKL in the RANK/RANKL/OPG pathway. This pathway is 
critical in the development of osteoclasts, and the anti-RANKL antibody therefore 
leads to a decrease in osteoclast differentiation and resorption. Denosumab showed 
substantial improvements in BMD and fracture risk in postmenopausal women 
with osteoporosis [24, 25]. In Chapter 6 we included exon skipping of Rank for the 
decrease of resorption. Exon skipping of the membrane-binding domain of Rank 
has the added benefit that the resulting protein resembles osteoprotegerin (OPG), 
a decoy receptor that has an inhibitory effect on bone resorption due to reduced 
osteoclast differentiation. Therefore not only will Rank be inactivated, but a protein 
is formed that has an extra inhibitory effect. Unfortunately, while exon skipping was 
shown in several experiments, further research is required to optimize the efficiency. 
Only then can a biological effect be expected. 
Discovering compounds that induce an increase in bone mass and strength in 
patients with osteoporosis would greatly improve current therapeutic options. High-




investigate potential candidates. For osteoblast differentiation, alkaline phosphatase 
(ALP) or Runx2 activity are often used as early differentiation markers. For later 
differentiation stages osteocalcin or sclerostin expression can be measured by RT-
PCR. However, mineralization is the final and probably most fundamental step 
in bone formation and should therefore be the readout of choice. To provide an 
easy and scalable method for quantification of in vitro mineralization, Chapter 7 
describes a new method using fluorescent compounds Bonetag 800 and Osteosense 
800. The results obtained with this method have been compared to the commonly 
used Alizarin Red S staining [26], and were confirmed to correlate with this method. 
In addition, fluorescence was specific for mineralized nodules and even seemed 
to be more sensitive to small changes in mineralization. Other advantages of this 
fluorescent method include a fast analysis, few handling or washing steps, and a 
readily quantifiable result. 
Future perspectives of therapeutic strategies
A number of therapies have been approved for treatment of osteoporosis. Most 
therapies involve a decrease in bone resorption, and in this class bisphosphonates 
are most frequently prescribed. New therapeutic strategies that aim to increase 
bone formation and thereby restore bone mass, mainly focus on sclerostin as a 
target because of the favorable characteristics, such as its restricted expression 
pattern. Neutralizing antibodies against sclerostin have been shown effective in 
prevention of osteoporotic fractures and are in late stage clinical trials ([27] for 
results of the phase II trial; phase III trials NCT01575834 and NCT01631214 on 
www.clinicaltrials.gov), and small molecule inhibitors of sclerostin are in pre-clinical 
stages (www.osteogenex.com). The aim of this thesis was to increase knowledge of this 
interesting target and explore other therapeutic options. We therefore investigated 
the regulation of sclerostin expression in patients and in vitro, and the modulation 
of splicing using AONs. Modified AONs are a promising class of therapeutics, and 
many insights have been gained from the AONs used for exon skipping in patients 
with Duchenne muscular dystrophy (DMD). In DMD, affected muscle cells are often 
damaged and have leaky membranes through which AONs can easily pass [28-30]. 
Bone cells in patients with osteoporosis do not have this advantage. In addition, 
bone cells are already more difficult to reach for any compound since bone tissues 
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have less vasculature than muscle. Coupling AONs to specific peptides may enhance 
cellular uptake and targeting to certain tissues or cells [31]. Local delivery would also 
decrease potential systemic side effects. However, peptides may have effects of their 
own, leading to unexpected results or even toxicity. Indeed, clinical development 
of a peptide-coupled phosphorodiamidate morpholino oligomer (PMO) AON for 
treatment of DMD (AVI-5038) was discontinued after unexpected toxic effects 
were seen when high doses were administered to primates [32]. For osteoporosis, 
the class of bisphosphonates would be a good candidate for targeting of AONs. 
Bisphosphonates bind strongly to the hydroxyapatite in bone, and are therefore 
quickly cleared from the circulation after administration [33]. Even so, this does not 
automatically result in a high uptake of the AON by bone cells, as the AON would 
be bound to the bone matrix. By coupling bisphosphonates to AONs with a cleavable 
link, the AONs could be released locally by enzymatic cleavage, for example during 
the bone resorption process. The bisphosphonates would in this case provide a dual 
effect as they would also retain the antiresorptive action for which they are already 
used in the clinic now.
Current therapies like bisphosphonates treat osteoporosis by arresting bone 
resorption, but do not restore bone mass to a healthy and strong level. Drugs that 
stimulate bone formation would therefore be a valuable addition. This may be achieved 
by inhibiting sclerostin, whether by neutralizing antibodies, small molecules, 
modulation of gene regulation, or antisense technology. This thesis describes the 
development of a new quantification method for in vitro mineralization, which can 
facilitate high-throughput screening of new therapeutic compounds, the exploration 
of a new method of modulating expression of sclerostin, and studies which add to 
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The skeleton has many different functions. It gives structure to the body, provides 
protection to vital organs and the bone marrow, serves as a reservoir for minerals 
and facilitates movement by providing anchor points for muscles. Bone is a living 
tissue that is constantly formed, resorbed and reformed by the bone cells: osteoblasts, 
osteoclasts and osteocytes. During the process of remodeling, osteoclasts resorb the 
bone matrix and new matrix is formed by osteoblasts. Some osteoblasts become 
trapped in the newly formed bone and differentiate into osteocytes. The osteocytes 
are connected to each other and to the cells on the bone surface by long cellular 
processes and are therefore in a perfect position to sense changes in the bone, 
for example loading. The osteocytes secrete factors to signal instructions to the 
osteoblasts and osteoclasts to react to these changes. In addition, osteoblasts and 
osteoclasts also produce signals and can react to some systemic hormones, which 
results in a complicated and not yet fully defined regulatory network that maintains 
the bone tissue. In Chapter 1 some important factors in the regulation of bone 
metabolism are discussed. 
Normally, there is a balance between resorption and formation and a constant 
bone mass. An imbalance can lead to an increase or decrease in bone mass, and 
diseases such as osteoporosis. Osteoporosis is the most common skeletal disease and 
is characterized by low bone mass and loss of internal bone structure. This leads to 
decreased bone strength and increased risk of fracture, particularly in the spine, hip 
and wrist. Elderly women are most at risk because bone resorption is accelerated 
after menopause due to the loss of estrogen production. Treatment for osteoporosis 
usually consists of bisphosphonates that specifically inhibit osteoclasts and therefore 
slow down bone resorption and disease progression. Unfortunately, bisphosphonates 
do not rebuild the bone to a healthy bone mass, and life-long treatment is therefore 
required. Other drugs are available or will probably become available in the coming 
years, but the ideal therapy has not yet been found and further research into the 
mechanisms of bone metabolism and possible therapeutic strategies is necessary. 
Chapter 2 gives an overview of current knowledge on sclerostin. Sclerostin 
is a protein that is produced by osteocytes in mineralized bone matrix and 
inhibits bone formation through inhibiting Wnt signaling. It is produced by the 
SOST gene. Mutations in SOST or the surrounding regulatory regions and loss of 
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sclerostin production lead to increased bone formation. Patients with sclerosteosis 
or Van Buchem disease for example can present with a bone mass that is up to 11 
standard deviations above normal with consequent problems such as facial paralysis 
and hearing loss due to facial nerve entrapment. Interestingly, the bone of these 
individuals is of very good quality and even heterozygous carriers of mutations in 
SOST have consistently higher bone mass than control subjects. This suggests a gene-
dose effect in which a lower sclerostin production is associated with a higher bone 
mass. Since sclerostin is expressed specifically in osteocytes, targeting this protein 
in future therapies is expected to result in few side-effects. In addition, the gene-
dose effect indicates that even small changes in sclerostin production could have a 
positive effect in patients with osteoporosis. Sclerostin is therefore one of the most 
interesting targets for new treatment options for osteoporosis. 
Sclerostin can be measured in serum samples, and many studies have 
investigated serum levels in normal individuals and patients with different diseases. 
In patients with sclerosteosis, who have an inactivating mutation in the SOST gene, 
no sclerostin was found. Van Buchem disease is caused by a mutation in a regulatory 
region downstream of SOST and the disease is usually less severe than sclerosteosis. 
In accordance with this, small amounts of sclerostin were found in patients with Van 
Buchem disease. Dickkopf 1 (DKK1) is a protein that, like sclerostin, inhibits Wnt 
signaling. In Chapter 3 we found that DKK1 was increased in serum samples from 
patients with sclerosteosis and Van Buchem disease. DKK1 may be increased in an 
effort to compensate for the lack of sclerostin in these patients. However, the increase 
seems to be insufficient to protect against excessive bone formation. 
New mutations that result in bone phenotypes can increase knowledge on 
the physiological actions of the involved protein. In Chapter 4 we described a 
novel mutation in sclerostin after analysis of two siblings from Turkey with classic 
sclerosteosis characteristics. This cysteine to arginine mutation affected the last 
cysteine residue of the cystine-knot motif and loss of this residue probably leads to 
impaired folding of the protein and retention in the endoplasmatic reticulum. In 
addition, the mutation resulted in a significantly reduced ability to bind the Wnt 
co-receptor LRP5. Together, this caused a complete loss of sclerostin function and a 
sclerosteosis phenotype. 
By understanding the endogenous regulatory mechanisms that control SOST 
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expression, we may eventually be able to specifically target and modulate these 
mechanisms in patients with osteoporosis to increase bone formation with minimal 
side-effects. In Chapter 5 we investigated the regulation of SOST by modulating 
the activity of the Wnt signaling pathway. SOST appeared to be downregulated by 
increased Wnt signaling activity. It was strongly decreased by GIN, which inhibits 
the downstream glycogen synthase kinase 3 beta (GSK3β) enzyme and thereby 
increases Wnt signaling activity. However, several Wnt signaling inhibitors that 
work at different stages in the pathway could not abrogate the decrease in SOST 
expression. In addition, directly blocking Wnt target gene transcription had no 
effect on the expression of SOST after treatment with GIN. It seems therefore that 
the decrease in SOST expression is not mediated by Wnt/β-catenin signaling, but via 
a different effect of GSK3β. 
While interfering with endogenous regulation of sclerostin expression is an 
interesting therapeutic option, other methods are being investigated to block the 
effect of the protein. In Chapter 6 we investigated a novel method for the inhibition 
of SOST expression using antisense oligonucleotides (AONs). As described in detail 
in Chapter 1, AONs interfere with the splicing of a gene, leading to exclusion 
(skipping) of an exon from the messenger RNA (mRNA). As SOST contains only two 
exons, skipping of one of the exons would lead to a nonsense mRNA and obstruction 
of protein production. Unfortunately, examining 20 different AONs (both targeting 
SOST and control) did not reveal decreased SOST expression with one of them. A 
second target that was investigated in Chapter 6 is Rank, which is essential in the 
differentiation of osteoclasts. Exon skipping of the membrane-binding domain of 
Rank has the added benefit that the resulting protein is a protein that resembles 
osteoprotegerin, a decoy receptor that has an inhibitory effect on bone resorption 
due to reduced osteoclast differentiation. Therefore not only will Rank be inactivated, 
but a protein is formed that has an extra inhibitory effect. While exon skipping was 
shown in several experiments, further research is required to optimize the efficiency. 
Only then can a biological effect be expected.
Discovering compounds that induce an increase in bone mass and strength in 
patients with osteoporosis would greatly improve current therapeutic options. High-
throughput screening methods for relevant parameters are needed to efficiently 
investigate potential candidates. Mineralization is the final and probably most 
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fundamental step in bone formation and should therefore be the readout of choice. 
To provide an easy and scalable method for quantification of in vitro mineralization, 
Chapter 7 describes a new method using fluorescent compounds Bonetag 800 and 
Osteosense 800. The results obtained with this method have been compared to the 
commonly used Alizarin Red S staining, and were confirmed to correlate with this 
method. 
Current therapies like bisphosphonates treat osteoporosis by arresting bone 
resorption, but do not restore bone mass to a healthy and strong level. Drugs that 
stimulate bone formation would therefore be a valuable addition. In Chapter 8 
the results of this thesis are discussed in relation to current knowledge on bone 






Het skelet heeft verschillende functies. Zo geeft het vorm aan het lichaam, beschermt 
het vitale organen en het beenmerg, is een reservoir voor mineralen en geeft een 
aanknopingspunt voor spieren zodat bewegen mogelijk wordt. Het bot is een levend 
weefsel dat voortdurend wordt aangemaakt en afgebroken (geresorbeerd) door 
botcellen: de osteoblasten, osteoclasten en osteocyten. Osteoclasten resorberen 
het bot, waarna osteoblasten nieuwe botmatrix vormen. Sommige osteoblasten 
blijven tijdens het vormen van bot in de matrix zitten, waar ze differentiëren tot 
osteocyten. Osteocyten zijn met elkaar en de cellen op het oppervlak verbonden 
via kanaaltjes, waardoor ze veranderingen in het bot (zoals belasting) goed kunnen 
voelen. Als gevolg hiervan scheiden osteocyten factoren uit waarop de osteoblasten 
en osteoclasten reageren. Deze worden daarnaast ook beïnvloed door sommige 
hormonen. Bij elkaar resulteert dit in een ingewikkeld en nog niet volledig begrepen 
systeem dat het botmetabolisme regelt. In Hoofdstuk 1 wordt een aantal belangrijke 
factoren besproken. 
In gezonde personen is er een balans tussen aanmaak en afbraak van bot, zodat 
de botmassa gelijk blijft. Een verstoring van deze balans kan leiden tot een hogere of 
lagere botmassa, en ziekten zoals osteoporose. Osteoporose is de meest voorkomende 
ziekte van het skelet en wordt gekenmerkt door een lage botmassa en verlies van 
stevigheid en interne structuur. Hierdoor breken mensen met osteoporose sneller 
botten, vooral in de pols, heup en wervels. Oudere vrouwen hebben het hoogste 
risico op osteoporose omdat tijdens de menopauze de productie van oestrogeen 
vermindert en hierdoor de botafbraak snel toeneemt. Behandeling van osteoporose 
gebeurt meestal met bisfosfonaten. Deze medicijnen onderdrukken de botafbraak 
doordat ze specifiek de activiteit van osteoclasten remmen. Hierdoor remmen ze de 
progressie van de ziekte en brengen lichte verbetering, maar bisfosfonaten kunnen 
de botmassa niet terugbrengen naar een gezonde sterkte. Daarom moeten patiënten 
vaak levenslang behandeld worden. Er zijn andere medicijnen op de markt, en enkele 
andere komen hoogstwaarschijnlijk in de komende jaren beschikbaar, maar de 
ideale therapie is nog niet gevonden. Meer kennis over botmetabolisme en mogelijke 
nieuwe therapieën is daarom nodig. 
Hoofdstuk 2 geeft een overzicht van de huidige kennis over sclerostin. 
Sclerostin is een eiwit dat de botvorming remt en gemaakt wordt door osteocyten in 
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gemineraliseerde botmatrix. Dit doet het door het remmen van de Wnt signalering, 
een signaleringsroute die belangrijk is voor botvorming en differentiatie van 
osteoblasten. Het gen dat codeert voor sclerostin is SOST. Mutaties in SOST of in 
de regio’s rond het gen die de expressie reguleren kunnen leiden tot verminderde 
of ontbrekende productie van sclerostin en een verhoogde botmassa. Patiënten met 
sclerosteose of de ziekte van Van Buchem hebben een zeer sterk verhoogde botmassa. 
Zij hebben daardoor problemen zoals verlamming van de gezichtsspieren of doofheid 
door beknelling van de gezichtszenuwen. Dragers van deze ziekten hebben geen 
complicaties, maar wel een verhoogde botmassa vergeleken met controlepersonen. 
Het bot is van goede kwaliteit en structuur, en zowel patiënten als dragers lijken dan 
ook goed bestand tegen botbreuken. Dit wijst op een dosis-afhankelijk effect waarbij 
een lagere productie van sclerostin verband houdt met een hogere botmassa. Omdat 
sclerostin specifiek gemaakt wordt in osteocyten, worden bij medicijnen die zich 
richten op dit eiwit weinig bijwerkingen in andere organen verwacht. Bovendien 
betekent een dosis-afhankelijk effect dat kleine veranderingen in sclerostin productie 
al een positief effect kunnen hebben bij patiënten met osteoporose. Sclerostin is 
daarom een van de meest aantrekkelijke aanknopingspunten voor nieuwe therapieën 
voor osteoporose. 
Sclerostin kan worden gemeten in serum, en er zijn veel studies gedaan naar de 
concentraties in serum van zowel controlepersonen als patiënten met verschillende 
ziekten. Patiënten met sclerosteose hebben een inactiverende mutatie in SOST, en 
in hun serum is dan ook geen sclerostin gevonden. In patiënten met Van Buchem 
ziekte werden kleine hoeveelheden sclerostin gevonden. Van Buchem ziekte wordt 
veroorzaakt door een mutatie in een regulerende regio buiten het coderende deel van 
SOST en de symptomen zijn meestal minder ernstig dan bij sclerosteose. Dickkopf 1 
(DKK1) is een eiwit dat, net als sclerostin, de Wnt signalering remt. In Hoofdstuk 3 
vonden we dat DKK1 in serum monsters van mensen met sclerosteose en Van 
Buchem ziekte verhoogd is. Mogelijk gebeurt dit om te compenseren voor het tekort 
aan sclerostin. De sterk verhoogde botmassa in deze patiënten suggereert echter dat 
de verhoging van DKK1 niet voldoende is om sclerostin te compenseren. 
Nieuwe mutaties die botfenotypes tot gevolg hebben kunnen de kennis van 
de fysiologische werking van het gemuteerde eiwit vergroten. In Hoofdstuk 4 
beschrijven we een nieuwe mutatie in sclerostin na onderzoek van een broer en zus 
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met klassieke sclerosteose kenmerken. Deze mutatie heeft een aminozuurverandering 
tot gevolg waardoor een belangrijk onderdeel van de structuur van sclerostin, de 
cystine-knoop, niet goed gevormd wordt. Het eiwit wordt daardoor vastgehouden 
in het endoplasmatisch reticulum en niet uitgescheiden. Daarnaast laten we zien dat 
het gemuteerde eiwit niet goed kan binden aan de Wnt co-receptor LRP5, en dus zijn 
functie niet goed kan uitoefenen. Samen leiden deze veranderingen tot een totaal 
verlies van de functie van sclerostin en het sclerosteose fenotype. 
Door het ontrafelen van de normale werking van regulatiemechanismen 
die SOST expressie controleren, hopen we uiteindelijk dit gen specifiek te kunnen 
aangrijpen en daardoor in patiënten met osteoporose de botmassa te verhogen met 
minimale bijwerkingen. In Hoofdstuk 5 hebben we de regulatie van SOST onderzocht 
door de activiteit van de Wnt signaleringsroute te variëren. SOST expressie leek te 
worden verlaagd door verhoogde Wnt signalering activiteit, en sterk verlaagd door 
GIN. Dit is een remmer van glycogen synthase kinase 3 beta (GSK3β), en daarmee 
een activator van de Wnt signaleringsroute. Verschillende remmers van de Wnt 
signalering konden echter de verlaging in SOST expressie door GIN niet opheffen. 
Bovendien had het rechtstreeks blokkeren van transcriptie van de Wnt signalerings 
targetgenen geen effect op SOST expressie. De verlaging van SOST expressie lijkt 
daarom niet veroorzaakt door Wnt signalering, maar door een ander effect van 
GSK3β. 
Naast het moduleren van de endogene regulatie van sclerostin expressie worden 
andere methoden onderzocht om het effect van het eiwit te blokkeren. In Hoofdstuk 6 
hebben we een nieuwe methode voor het remmen van SOST expressie onderzocht 
met antisense oligonucleotiden (AONs). Zoals uitgebreid beschreven in Hoofdstuk  1 
verstoren AONs de zogenaamde splicing van een gen. Een gen bestaat uit exonen 
(coderende stukken) en intronen (niet-coderend), en tijdens splicing worden de 
exonen aan elkaar geplakt en de intronen weggegooid, waarbij het messenger RNA 
(mRNA) gevormd wordt. AONs kunnen ervoor zorgen dat een exon niet herkend 
wordt, en dus overgeslagen tijdens het vormen van mRNA (een exon skip). Omdat 
SOST maar twee exonen heeft, betekent het skippen van een van deze exonen dat er 
geen eiwitproductie plaats zal vinden. Van de 20 onderzochte AONs (zowel controle 
als specifiek gemaakt voor SOST) bleek helaas geen enkele de SOST expressie te 
verlagen. Een tweede gen waarop exon skipping in Hoofdstuk 6 onderzocht werd 
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is Rank. Het eiwit dat door dit gen gemaakt wordt is essentieel voor de differentiatie 
van osteoclasten. Exon skipping van het membraangebonden deel van Rank heeft 
als extra voordeel dat een eiwit gevormd wordt dat lijkt op osteoprotegerin (OPG), 
een soort dummy-receptor die de osteoclastdifferentiatie en daardoor de botafbraak 
remt. Hierdoor wordt niet alleen de functie van Rank geïnactiveerd, maar wordt 
gelijktijdig een eiwit gevormd dat een extra positief effect heeft. Hoewel we in enkele 
experimenten exon skipping hebben aangetoond, is verder onderzoek nodig om de 
efficiëntie te optimaliseren. Pas dan kan een biologisch effect verwacht worden. 
Het ontdekken van stoffen die een verhoging van de botmassa en –sterkte 
kunnen veroorzaken in patiënten met osteoporose zou een enorme vooruitgang voor 
de huidige therapie betekenen. Voor het onderzoeken van potentiële kandidaten 
zijn nieuwe screeningsmethoden voor relevante parameters en met een grote 
capaciteit nodig. Mineralisatie is de laatste en waarschijnlijk meest belangrijke stap 
in de botformatie en heeft daarom de voorkeur als uitleesparameter. Hoofdstuk 7 
beschrijft de ontwikkeling van een makkelijke en opschaalbare methode voor 
het kwantificeren van de mineralisatie in in vitro celkweken. Hierbij worden de 
fluorescente stoffen Bonetag 800 en Osteosense 800 gebruikt. De resultaten van 
deze methode zijn vergeleken met de veelgebruikte Alizarine Rood S kleuring en we 
hebben aangetoond dat de nieuwe methode hiermee correleert. 
De huidige medicijnen voor osteoporose zoals bisfosfonaten werken door het 
remmen van de botafbraak, maar kunnen het bot niet herstellen naar een gezond 
niveau. Geneesmiddelen die de botvorming stimuleren zouden een waardevolle 
toevoeging zijn aan de huidige behandelmogelijkheden. In Hoofdstuk 8 worden de 
resultaten van dit proefschrift bediscussieerd in relatie tot de huidige kennis van 
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